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Often the needs of an organism exceed the number of genes in the
genome. Thus, modification of the genes, themselves, or of the gene products is
necessary. This becomes particularly important in cells of the immune system,
which have to combat a virtually infinite array of foreign pathogens. Blymphocytes, the mediators of humoral immunity, have developed extensive
mechanisms of gene diversification collectively known as antibody diversification.
Antibody diversification, a set of processes necessary for an organism to mount a
specific and robust immune response, relies on Activation Induced Cytidine
Deaminase (AID) to initiate two of such processes: Somatic Hypermutation
(SHM) and Class Switch Recombination (CSR). AID-dependent deamination of
cytidine bases within the variable region (SHM) and switch region (CSR) of the
immunoglobulin locus (Ig) results in the modification of the antigen binding
domain and diversity within effector function of the antibody, respectively.
Though the activity of AID is known, the regulation of AID during the different
stages of antibody diversification is less well understood. This question has been
particularly challenging to address because of the difficulty of working with AID,
which becomes insoluble when expressed in non B-cells.
This thesis presents the development of a screen, which searches for
interacting partners for poorly soluble proteins. This screen relies on the

insolubility of the protein of interest and the ability of interacting proteins to
induce solubilization via binding and masking of exposed hydrophobic domains.
After validation of this screen using representative soluble and insoluble
proteins, it was applied to AID and thirty putative AID binding partners were
identified. A handful of these proteins were uncovered in prior interaction
screens, thus underscoring the validity of this new screening approach.
In addition, this thesis presents a comprehensive analysis, utilizing both in
vitro and in vivo approaches, of one of the putative AID cofactors discovered in
the screen, RING Finger Protein 126 (RNF126). In vitro studies revealed that
RNF126 is a bona fide AID binding partner and, in addition, acts as an E3
ubiquitin ligase, modifying AID with the addition of a single ubiquitin moiety.
Further, a conditional knockout model of RNF126 was generated and used to
determine that RNF126 plays a role in vivo in fine-tuning AID activity during SHM
and CSR.
The findings presented here demonstrate the utility of a novel screening
technique to search for interacting partners for insoluble proteins and, through its
use, expands the list of putative AID cofactors. In addition, through a thorough
analysis of a single AID binding partner, this thesis puts forth a novel mode of
regulation of the potent mutating enzyme, paving the way for future research to
uncover the role of mono-ubiquitinated AID during SHM and/or CSR.
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CHAPTER 1: INTRODUCTION
The blueprint of an organism is its genome; that is to say that the genome is
the most fundamental code necessary for life. However, much of the diversity of
life and the diversity of processes within a cell necessitate modifications to this
basic code. Thus the “Central Dogma” that one gene produces one RNA, which
produces one protein, has proven to be too simplistic. Mechanisms of
diversification have been described at each level of the Central Dogma. Protein
structure and function is altered with the use of post-translational modifications
(Prabakaran et al., 2012); the composition of, and thus the information contained
within, RNA is modified through processes such as alternative splicing and RNAediting (Hamilton et al., 2010); and lastly, modifications to the DNA, itself, have
been instrumental in generating diversity on a cell-to-cell basis. While
manipulation, or mutation, of the genome can be detrimental to the organism by
promoting genomic instability, complete fidelity in this regard would abrogate
evolution at the organismal and cellular level. Thus, modification at the DNA level
must be tightly regulated to generate a balance between diversity (or genomic
instability) and genomic stability.
One of the most fundamental questions in biology is that of how an organism,
or more simply, a cell, is able to respond to a virtually infinite and unknown array
of environmental factors given only a limited genome to work with. In many
cases, organisms solve this problem by hard-coding many possible surfacebound receptor proteins into the genome in gene families. In these instances,
1

epigenetic mechanisms are used to regulate mono-allelic expression to ensure
that each cell only expresses one of several possible receptors. Complexity in the
organism’s response, then, is derived from the presence of a population of cells,
each expressing a unique receptor. This sort of biological approach can be seen
in receptors of sensory systems, such as olfactory receptors for smell (Serizawa
et al., 2004) and rhodopsin expression for sight (Johnston and Desplan, 2008;
2010).
In instances where much greater diversity is demanded by selective
pressure, additional possibilities that go beyond the scope of the genome are
necessary. This idea is particularly prevalent in the immune systems of higher
vertebrates, where organisms must combat an unknown and virtually unlimited
set of external pathogens. Thus, this system must be anticipatory, that is, it must
be prepared to mount a response even before this information is known. Despite
the human genome containing approximately 20,000 genes, the two antigenrecognition cell types of the vertebrate adaptive immune system, B and T
Lymphocytes, are able to generate greater than 107 different receptors against
potential pathogens (Market and Papavasiliou, 2003). B Lymphocytes, in
particular, make use of additional diversification mechanisms to generate a
potentially limitless number of receptors, increasing the host’s chance of survival.
An exploration of pathogen-defense mechanisms at different branches of
evolution reveals a progression from hard-coded immune receptors to receptors
with flexibility in their specificity due to various mechanisms of genomic
2

modification.
1.1 The Evolution of Adaptive Immunity
At the heart of immunity is an organism’s ability to differentiate between self
and non-self. Organisms of all taxonomical clades have developed mechanisms
to do just this, but arguably the most complex systems developed can be found
within the adaptive immune systems of vertebrates. The journey to this sort of
complexity began with the onset of Innate Immunity, a system alive and well in
complex vertebrates.
During evolution, innate immune defenses emerged prior to adaptive
immunity and innate immune receptors can be found throughout the animal
kingdom and in plants (Flajnik and Kasahara, 2010; Medzhitov and Janeway,
2000). Innate immune receptors are hard-coded in the genome, such that they
are passed on to subsequent generations. Because of this, only a limited number
of receptors can exist, so as not to overwhelm the genome. Thus, rather than
encoding receptors that are specific for unique pathogens, innate immune
receptors have evolved to recognize patterns, or motifs, that are common to a
number of invading pathogens. For this reason, innate immune receptors are
often referred to as Pattern Recognition Receptors (PRRs). Common pathogenassociated motifs (PAMs) detected by these receptors include lipopolysaccharide
(LPS), peptidoglycan, bacterial DNA, and viral dsRNA (Medzhitov and Janeway,
2000). Despite being limited in number, because all innate immune cells express

3

the same repertoire of PRRs, the innate immune response is both rapid and
robust.
Because of the constant challenge posed by new types of pathogens, as well
as the ability of a single pathogen to evolve to evade immune defenses, even
organisms that contain only innate immune systems are under selective pressure
to diversify their receptors. Similar to how sensory receptors are encoded as
large gene families, many organisms have expanded and diversified gene
families encoding innate immune receptors, thus allowing for the expression of
receptors of varying specificities (Litman et al., 2005b). This is exemplified in the
sea urchin, which contains over 200 Toll-Like Receptors (TLRs) as compared to
between 1 and 20 in other animals (Buckley et al., 2008b; Roach et al., 2005).
Additional mechanisms observed include: combinatorial use of encoded
receptors and gene recombination (Buckley et al., 2008a), inclusion of nucleotide
polymorphisms (Lazzaro et al., 2004) and/or alternative splicing of immune
receptor genes and gene families (Danilova, 2012). For example, the drosophila
immune cells have been shown to express more than 18,000 isoforms of the
immunoglobulin-structured receptor, Dscam, through alternative splicing of
variable exons with constant exons (Watson et al., 2005). As an interesting
aside, even single-celled organisms such as bacteria have developed fairly
sophisticated forms of defense. Bacteria have developed defense mechanisms
that are both general, much like innate receptors, which involves the digestion of
foreign DNA by the recognition of palindromic sequences, as well as a more
4

specific defense mechanism known as CRISPR, which involves RNAi-like
machinery (Fineran and Charpentier, 2012).
Importantly, evolution of innate immune responses occurs at the level of the
organism and on a Darwinian evolution time-scale, improving defense systems
from one generation to the next. In contrast, evolution and adaptation within the
adaptive immune system occurs at the cellular level, within the lifetime of a single
organism. Although it was initially thought that conventional adaptive immunity,
consisting of B and T lymphocytes, appeared only in jawed vertebrates in a sort
of “big bang” mechanism, evidence now exists to suggest that even jawless
vertebrates have evolved an adaptive immune system that displays similar
principles of design (Boehm, 2011; Danilova, 2012; Flajnik and Kasahara, 2010;
Litman et al., 2005a; 2010). The occurrence of convergent evolution within these
two branches of vertebrates suggests that it is more likely that the evolution of
conventional adaptive immunity occurred incrementally, with the stepwise
acquisition of additional diversifying mechanisms. The main commonalities of all
vertebrate adaptive immune systems are the presence of a two-cell system and
the expression of receptors, which have been built from gene segments to
generate diversity. Conventional adaptive immunity in jawed vertebrates relies on
two cell types: B lymphocytes (B cells) and T lymphocytes (T cells). B cells,
which act in the humoral immune response, recognize native antigen, and T
cells, which participate in cell-mediated immunity, recognize antigen in the
context of an antigen presenting cell (APC). Similarly, jawless vertebrates (e.g.
5

hagfish and lamprey) have been found to possess two distinct lymphocyte-like
lineages, which function in humoral and cellular immunity, respectively. This fact
suggests that either an extinct common vertebrate ancestor also possessed
lymphocyte-like cells, which provided the foundation for the evolution of both
forms of adaptive immunity, or that a lymphocyte-precursor cell existed in
invertebrates (Boehm, 2011). Notably, other necessary features of conventional
adaptive immunity can be found in extant invertebrate species. Most interestingly,
the enzymes RAG1/2, which are essential for jawed-vertebrate antibody
diversification, were found in the genome of the sea urchin (Fugmann et al.,
2006).
The receptors of jawless and jawed adaptive immune systems are
structurally unique. Jawless vertebrates express receptors called Variable
Lymphocyte Receptors (VLRs), which are structurally similar to PRRs of the
innate immune system and contain leucine-rich modules. In contrast, B cells and
T cells produce receptors known as the B-cell Receptor (BCR, or antibody) and
the T-cell Receptor (TCR); the structure of both receptors consist of characteristic
immunoglobulin folds. Despite these differences, the receptors derived from both
branches of vertebrates can be highly diversified through the recombination of
gene segments. In both cases, it is believed that multiple and diverse gene
segments evolved from several duplication events paired with transposition
(Boehm, 2011). The mechanistic details of how these gene segments are
recombined are slightly different between jawless and jawed vertebrates,
6

however both likely evolved from the same selective pressure. Jawless
vertebrates rely on gene conversion recombination events, placing one of many
leucine-rich modules into an incomplete VLR locus. Interestingly, this gene
conversion event occurs alongside expression of putative cytosine deaminases,
which show homology to the vertebrate antibody diversification enzyme,
Activation Induced Cytidine Deaminase (AID) (Rogozin et al., 2007).
Most jawed-vertebrates recombine gene segments using recombination
enzymes likely derived from transposon insertion, in a process known as V(D)J
recombination. However, in addition to V(D)J recombination, birds utilize cytidinedeaminase-dependent gene conversion events to further diversify their
antibodies, reminiscent of the system that evolved in jawless vertebrates. Again,
these similarities suggest that complex adaptive immune systems have
developed by co-opting enzymes and mechanisms that existed in ancient
organisms (Litman et al., 2010). An overview of immunity throughout evolution is
presented in Figure 1.1.
Within the branch of jawed vertebrates it is clear that further mechanisms
of diversification evolved, as represented by the fact that B cells have developed
mechanisms of secondary diversification that do not exist in T cells. This is likely
due to the fact that extensive diversification in T cells, which must recognize
antigen in the context of self, may be deleterious due to the loss of recognition of
antigen-presenting molecules. B cells, on the other hand, recognize antigen in its
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native context and thus have much more flexibility in the extent of diversification
allowed.
The ability of B cells to diversify their receptors relies on the adoption of
mechanisms typically associated with genomic instability, such as double-strand
break formation and mutation. While genomic instability is necessary for
evolution, when conducted at the level of a single living organism, introduces the
possibility of diseases, such as cancer and autoimmunity. Very exquisitely, B
cells have been able to harness the power of genomic instability at the
immunoglobulin locus, while still protecting genomic stability elsewhere. The
mechanisms involved in this complex balancing act are discussed, with a focus
on secondary diversification.
1.2 B Lymphocytes and Antibodies
B cells are the mediators of humoral immunity because of their ability to
produce both membrane-bound and secreted antigen receptors, known as
antibodies. B cell development in mammals begins in the fetal liver and continues
in the bone marrow, as a result of differentiation from precursor hematopoietic
stem cells. During this development process, the first stage of antibody
diversification occurs, producing a mature B cell with a single, non-autoreactive,
surface-bound B cell receptor. Once this occurs, the B cell leaves the bone
marrow and enters the periphery where it takes up residence in secondary
lymphoid organs, such as the spleen and other lymph nodes. It is here that the B
cell encounters foreign antigen and is stimulated to undergo secondary
9

diversification and selected for enhanced affinity for antigen. A schematic of B
cell development is presented in Figure 1.2.
Antibodies, themselves, are a complex of approximately 150 kDa,
composed of two heavy chain proteins and two light chain proteins. Each of
these proteins is first assembled from gene segments contained within the heavy
chain immunoglobulin locus (IgH) and either the κ or λ light chain immunoglobulin
locus (Igλ or Igκ), respectively. The N-terminus of both the heavy and light chain
proteins constitutes the antigen-binding site of the antibody (Fab), the specificity
of which can be altered through the variation of amino acid sequence in this
region. This portion of the protein is derived from the variable region of the Ig
genes. The C-terminus, on the other hand, constitutes the constant domain (Fc)
of the antibody and plays no role in antigen-specificity. Rather, the constant
domain of the heavy chain decides the isotype of the antibody, which determines
the functionality of the antibody by dictating the immune response downstream of
antibody-antigen complex formation.
1.3 Antibody Diversification
Over 50 years ago, at a time when the scope of the human genome was
not yet known, scientists recognized that it was unlikely that the diversity of
antibody generated was encoded in the genome. Most notably, F. MacFarlane
Burnet, with no experimental evidence invoked a “randomization” process that
would result in the alteration and variation of the coding of immunoglobulin
molecules (Burnet, 1976). Prior to his proposal, the only biological precedent for
10
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chain. At the pre-B cell stage, VJ rearrangement of the light chain locus occurs.
Once V(D)J recombination has occurred on both heavy chain and light chain
genes, a mature IgM BCR is expressed on an Immature B-cell. Alternative
splicing of the heavy chain locus produces a mature B cell that expresses
surface bound IgM and IgD. This mature B cell leaves the bone marrow and
enters the periphery where it contacts foreign antigen. Binding of antigen to the
mature BCR signals secondary diversification in the germinal centers,
including Somatic Hypermutation and Class Switch Recombination. Igα and Igβ
are transmembrane proteins that associate with the BCR and generate a signal
in response to antigen-BCR complex formation.
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such a process was Lederberg’s studies on mutation in phage adaptation
(LEDERBERG, 1959). The first experimental evidence that such a process
occurs was provided by Weigert and Cohn when they showed that immunization
altered the amino acid sequence of immunoglobulin lambda light chains,
introducing single amino-acid changes (Weigert et al., 1970). Half a decade later,
following the advent of recombinant DNA technology, S. Tonegawa showed that,
in addition to mutation, somatic gene rearrangement occurs to piece together the
immunoglobulin gene from several, variable gene segments (Tonegawa, 1983).
These two discoveries began the movement to provide mechanistic insight to
Burnet’s original hypothesis of randomization (Neuberger, 2008).
Today we have a far better understanding of the mechanisms involved in
immunoglobulin diversification. Initial diversification occurs in an antigenindependent fashion through the genomic rearrangement of one of several gene
segments, termed variable (V), diversity (D) and joining (J), respectively. This
process, known as V(D)J recombination, occurs in both B and T cells.
Encounter of a B cell with antigen initiates secondary diversification
reactions at the Immunoglobulin locus. These reactions, Somatic Hypermutation
(SHM) and Class Switch Recombination (CSR), provide greater variability within
the antigen-binding domain and alter the effector function of the antibody by
changing domains within the C-terminus of the protein complex. Each of the
methods of diversification share many similarities, however there exist distinct
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differences that account for their divergent outcomes. An overview of the three
steps of antibody diversification is presented in Figure 1.3.
1.3.1 Primary Diversification—V(D)J Recombination
Initial diversification occurs in an antigen-independent fashion through the
genomic rearrangement of one of several V, D and J gene segments. Diversity is
attained through the random selection of each gene segment as well as the
variability that arises at the junctions upon DNA ligation and repair. The
beginning steps toward working out the mechanism of V(D)J recombination
began with the discovery of the two essential proteins, Recombinase Activating
Gene 1 and 2 (RAG1 and RAG2). The discovery of these enzymes came from a
series of well-planned, but also incredibly lucky, experiments conducted in the
1980s in the lab of David Baltimore (Schatz and Baltimore, 2004). Using an
artificial V(D)J recombination substrate, it was found that lymphocytes, but not
fibroblasts, were able to induce recombination, suggesting the presence of a
lymphocyte-specific master regulator (Schatz and Baltimore, 1988). Through
transfection and expression of large tracts of genomic sequence in fibroblasts,
they were able to rescue V(D)J recombination, leading to the discovery of RAG1
(Schatz et al., 1989). However, it took many more years to discover RAG2, which
is co-expressed with RAG1 and necessary for its function (Oettinger et al., 1990).
Since the discovery of the RAG proteins, many of the basic mechanistic
details of V(D)J recombination have been worked out. The heavy chain
immunoglobulin is composed of V, D and J gene segments, which must be
13
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Figure 1.3 An Overview of Antibody Diversification. A) V(D)J Recombination
is a deletional recombination event between one of many variable, diversity, and
joining segments to create the variable region of the immunoglobulin gene. This
is catalyzed by the RAG1/2 recombinase complex and occurs in an
antigen-independent fashion. B) Somatic Hypermutation results in the
accumulation of point mutations in the recombined variable region. AID initiates
this process through the deamination of cytidine to uridine, followed by removal
of the uracil base by Uracil DNA Glycosylase (UNG) and repair by several Base
Excision Repair (BER) and MisMatch Repair (MMR) enzymes. * denotes the
mutated variable region. C) Class Switch Recombination results in the exchange
of the default constant region, μ (IgM), for one of many downstream regions. AID
initiates this process through deamination of bases in the switch region
(yellow circle) upstream of each constant region, resulting in the formation of
double strand breaks and repair by non-homologous end joining
pathways (NHEJ/A-EJ).
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recombined, while the light chain gene recombines only V and J segments.
Humans have 65 possible V segments, 27 possible D segments, and 6 possible
J segments which can be recombined to produce the heavy chain Ig gene
(Market and Papavasiliou, 2003), accounting for much of the diversity in antibody
produced. Each of these coding segments is flanked by the presence of very
specific sequences known as recombination signal sequences (RSS), which
guide recombination. RSS sequences are composed of a stretch of seven highly
conserved, palindromic nucleotides (heptamer), and a stretch of nine conserved
nucleotides (nonamer) separated by a stretch of either 12 or 23 nucleotides,
referred to as 12RSSs and 23RSSs, respectively. The correct recombination of V
to D (and not V to V or V to J), as well as D to J (and not D to D or J to J) is
helped in part by the fact that 12RSS and 23RSS sequences can only recombine
with one another and not themselves, otherwise referred to as the “12/23 rule.” V
segments are flanked by only 23RSSs, D segments by only 12RSSs and J
segments by only 23RSSs. Thus, this excludes the possibility of eliminating the D
segment from the full IgH gene (Schatz and Swanson, 2011).
The mechanism of V(D)J recombination can be broken down into two
main components: (1) DNA break formation and (2) DNA Repair. The 12 and
23RSSs are brought into close proximity by binding of the RAG proteins, which
then induce DNA nicks within each of the RSS’s. A trans-esterification reaction
between the strands of DNA occurs, resolving the nick by producing a hairpin at
the coding end, and leaving the break on the signal sequence end blunt. The
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signal sequences will be resolved into a circular piece of DNA (sj), while the
hairpins between the coding segments are nicked, and the DNA breaks repaired
utilizing proteins from the non-homologous end joining pathway (NHEJ).
Additional nucleotides are added before break repair occurs by the nontemplated DNA polymerase, TdT, thus providing additional junctional diversity
(reviewed in (Alt et al., 2013; Schatz and Swanson, 2011)).
Many more details of this reaction, ranging from epigenetic modifications
of the locus (Matheson and Corcoran, 2012), the structure of the RAG1 protein
interaction with DNA (Yin et al., 2009), the role RAG2 plays in the recognition of
specific histone modifications (Matthews et al., 2007), as well as a number of
other findings, have been elucidated. These mechanistic details go beyond the
scope of this thesis, but many reviews can be referenced for up-to-date findings
(Alt et al., 2013; Nishana and Raghavan, 2012; Schatz and Swanson, 2011).
The importance of all of these findings in the context of this thesis, though, is in
the recognition of (1) the adaptation of a transposon-like element in evolution to
take advantage of genomic instability to produce antibody diversity, and (2) the
complexity of the mechanisms developed in order to reign in this genomic
instability and protect the genome from extensive damage. Similar themes will be
seen in a discussion of the mechanistic details of secondary diversification in B
cells.
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1.3.2 Secondary Diversification – Somatic Hypermutation and Class-Switch
Recombination
Encounter of a mature B cell with antigen initiates secondary
diversification reactions at the Ig loci, collectively referred to as the germinal
center response. These reactions, Somatic Hypermutation (SHM) and Class
Switch Recombination (CSR) share many basic mechanisms but function very
differently with respect to antibody diversity. SHM generates greater diversity
within the V(D)J-rearranged antigen-binding domain of the antibody and CSR
produces antibodies with the capacity to recruit several different types of
downstream immune effectors, thus governing the type of immune response.
SHM is coupled with a process of selection such that B cells with antibodies that
gain affinity toward antigen are selected for survival and B cells with antibodies
that have lost affinity toward antigen (or gained affinity for self-derived peptides)
are selected for apoptosis. Thus, over time, a population of B cells with increased
affinity for antigen is produced. This process is better known as Affinity
Maturation.
Because the processes of SHM and CSR seem to have exceedingly
different outcomes—it was an astonishing development 10 years ago when AID
was identified as a key player in both reactions. In fact, the cytidine deaminase,
which enzymatically converts a cytidine base to a uridine (C to U) through a
deamination reaction, is essential to initiate both processes. The mechanism of
this deamination reaction is depicted in Figure 1.4.
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Figure 1.4 Proposed AID-mediated cytidine deamination mechanism.
A proposed mechanism based on bacterial cytidine deaminase enzymes that
show homology to AID. A glutamic acid residue (E58), as well as Zn-coordinating
residues (H56, C87, C90) play a role in the mechanism.
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1.3.2.1 Somatic Hypermutation
During SHM, point mutations accumulate in the rearranged variable region
of both the Ig heavy (IgH) and Ig light (Igλ or Igκ) genes. Because this region of
the Ig gene makes up the antigen-binding domain of the protein complex, it is
these mutations that dictate the change in affinity of the antibody for antigen.
There are many characteristic patterns that can be described in terms of the
location and types of mutations that occur during SHM. First, mutations begin
approximately 50-100 nucleotides downstream of the IgVariable promoter region
and extend another 1,000 – 2,000 nucleotides (Lebecque and Gearhart, 1990;
Rada and Milstein, 2001). This suggests that the 5’ boundary of SHM is the
promoter, inferring a connection between mutation and transcription of the locus.
In fact, many groups have observed that mutation frequency is intimately linked
with the level of transcription through the region (Longerich et al., 2005).
Movement of the promoter in front of non-mutated regions induces mutation
(Peters and Storb, 1996), deletion of the promoter drastically reduces mutation
(Fukita et al., 1998), and regulation of transcriptional activity by use of the Tet
operator results in mutation frequencies that are well-correlated with the level of
transcription (Bachl et al., 2001).
It is likely that the role of transcription during SHM is highly nuanced. On
one level, transcription is necessary to open the DNA duplex, revealing a ssDNA
substrate for AID deamination. However, more recent findings suggest that the
RNA molecules, themselves, or processing of the RNA play an important role.
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First, in addition to sense transcription, anti-sense transcription occurs through
the variable coding exons (Perlot et al., 2008). The function of these anti-sense
transcripts is still unknown. Further, the RNA Exosome, an RNA processing and
degradation complex, has been shown to enhance AID deamination on both the
template and non-template strands of DNA—a phenomenon seen in vivo
(Milstein et al., 1998), but not in vitro (Basu et al., 2011). Whether the Exosome
degrades the nascent sense transcript, revealing the template strand of DNA, or
whether it is involved in the processing of other ncRNAs (either sense or
antisense), remains to be seen. However, these findings emphasize the fact that
the role of transcription during SHM likely goes beyond the initial unwinding of the
locus.
Despite the ability of AID to deaminate only base C, mutations can be
found occurring at all four nucleotides. At C:G base pairs, transition mutations are
predominant over transversion mutations, implicating direct replication over the
mismatched U:G as a repair mechanism. C:G mutations occur in a strand nonspecific manner, whereas A:T mutations show a strand bias (Mayorov et al.,
2005a). And lastly, though this is not always the case, often deaminated cytidine
bases are found in the context of the sequence WRCY, or its complement,
RGYW (W = A/T, R = A/G, Y = C/T) (Rogozin and Kolchanov, 1992). These
observed characteristics have been instrumental in elucidating the factors and
mechanisms involved in the resolution of AID-mediated deamination events to
produce point mutations at the variable region of the Ig locus.
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Two main repair pathways have been implicated in the SHM reaction: the
Base Excision Repair pathway (BER) and the Mismatch Repair pathway (MMR).
An overview of these pathways and their involvement in SHM is presented in
Figure 1.5. While these pathways are normally used for faithful and error-free
repair, they have been co-opted to introduce mutations through the recruitment of
error-prone repair proteins.
The BER pathway functions mainly at the deaminated C. Uracil
Deglycosylase (UNG) recognizes the mismatched U:G basepair and excises the
U to generate an abasic site (Li et al., 2012; Rada et al., 2002b). The
endonuclease, APE1, and the Mre11-Rad50-Nbs1 (MRN) complex have been
implicated in nicking the DNA to generate a single-strand break (SSB) (Larson et
al., 2005; Masani et al., 2013; Yabuki et al., 2005). The formation of the SSB
provides DNA polymerases access to the DNA. During error-free repair, the high
fidelity polymerase, pol β, is recruited; however, during SHM, error-prone
polymerases are recruited. The deoxycytidyl transferase, Rev1, which forms a
complex with the DNA polymerase ζ, specifically incorporates cytidine bases
opposite uridine bases or abasic sites. Rev1 has specifically been found to play a
role in SHM, particularly in the generation of transversion mutations at the
deaminated C base (Jansen et al., 2006; Simpson and Sale, 2003). A similar loss
of C and G transversions is seen in mice, which lack the ability to ubiquitinate the
polymerase processivity factor, PCNA. Mice that contain either a lysine-toarginine mutation at lysine 164 or that lack the E3 ubiquitin ligase, Rad18, which
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Figure 1.5. Mechanisms of AID-mediated mutation during SHM. Initial AID
deamination events are processed by various repair pathways to result in the
accumulation of point mutations in the variable region of the Ig locus. Direct
replication over a U:G mistmatch results in a transition mutation. The
involvement of Base Excision Repair enzymes results in all possible mutations
at the deaminated C. Uracil Deglycosylase (UNG) excises the mismatched U,
resulting in an abasic site. The endonuclease, APE1, generates a SSB.
The DNA-encircling processivity factor, PCNA, recruits the Rev1-containing
error prone polymerase complex to generate mutations at the deaminated C.
The involvement of Mismatch Repair enzymes results in the mutation of
A:T base pairs in proximity to the deaminated C. Recognition of the mismatch by
the Msh2/6 complex and resection of DNA by the exonuclease, Exo1, results in
a ssDNA gap. This gap is filled in by the error prone polymerase, pol η, which is
again recruited by PCNA. This results in all possible mutations at A:T basepairs.
Mutations at C:G base pairs tend to be strand unbiased, suggesting that AID
accesses both the non-template and template strands of DNA equally.
However, mutations at the A:T base pairs are strand biased and show
greater mutation of A bases on the non-template strand. This is likely due to the
lack of access of error prone repair proteins to the template strand.
The star represents an abasic site.
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ubiquitinates PCNA, have altered SHM mutation patterns (Arakawa et al., 2006;
Bachl et al., 2006; Langerak et al., 2009; Roa et al., 2008). Thus, ubiquitinated
PCNA plays a role in dictating whether the BER repair pathway will be error-free
or error-prone.
In a parallel, non-competitive fashion, the MMR pathway serves the
purpose of generating mutations at basepairs adjacent to the deaminated C. The
complex of Msh2-Msh6 recognizes the U:G mismatch and, through a currently
unknown mechanism, a SSB is generated (Krijger et al., 2009; Li et al., 2006;
Martomo et al., 2004; Roa et al., 2010). During MMR, this SSB allows the
exonuclease, ExoI, to enter the DNA and resect the DNA neighboring to the
mismatched basepair (Bardwell et al., 2004), creating a single-stranded gap. Just
as was seen for the BER mechanism, either error-free or error-prone
polymerases can be recruited to fill in the gap. Again, ubiquitinated PCNA
recruits the error-prone polymerase, pol η, which erroneously polymerizes
frequently opposite of templated T and A bases (Delbos et al., 2005; Zeng et al.,
2001; 2004). Thus, this accounts for the formation of mutations at A:T basepairs
that are not directly the result of AID deamination. In fact, mice that lack both
Msh2 and pol η produce a mutation pattern that completely lacks mutations at
A:T basepairs (Delbos et al., 2007).
The combined effort of (1) direct replication over the U:G mismatch, (2) the
error-prone BER pathway and (3) the error-prone MMR pathway can account for
all mutations observed during SHM. However, many mechanistic details, such
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as how error-prone repair is targeted and restricted to the Ig locus, remain
unknown. In fact, experiments using ung-/- mice suggest that there is a direct
competition between error-free and error-prone repair during SHM. The mutation
pattern seen in ung-/- mice, which cannot excise the mismatched U base, shows
a loss of transversion mutations and an increase in transition mutations at C:G
basepairs. This suggests that, in the absence of UNG, transition mutations are
generated through replication over the mismatched base pair; however, when
UNG is present and the U excised, error-free BER occurs to faithfully correct at
least some of the deaminated C bases (Rada et al., 2002b). Another perplexing
observation is that mutations at C:G basepairs are strand-unbiased whereas
mutations at A:T basepairs are strand biased. This suggests that, while AIDmediated deamination is targeted to both strands, the subsequent repair
processes are not. In fact, both pol η and the Msh2-Msh6 complex appear to be
biased toward the non-template strand, thus accounting for the bias at A:T
basepairs, but not C:G basepairs (Mayorov et al., 2005a; Unniraman and Schatz,
2007). How this specific targeting occurs is unclear. It is possible that the nontranscribed strand, which is not associated with the nascent pre-mRNA, is more
exposed to these protein complexes. However other mechanisms, such as the
involvement of the RNA Exosome, may be at play here.
Just as was seen during the discussion of V(D)J recombination,
mechanisms that promote genomic instability are co-opted to generate diversity
at the Ig loci. During SHM, the introduction of point mutations occurs at the
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variable regions of the IgH and IgL genes. Introduction of mutations outside of
the Ig loci, though, would be detrimental to the organism. It has been shown in
mice deficient in UNG and Msh2 that AID-mediated mutation can be detected
outside of the Ig locus, however not throughout the entire genome. Thus, it
appears that at least two levels of regulation occur—one that targets AID to a
subset of the genome, and the second, which targets error-free versus errorprone repair enzymes (Liu et al., 2008). Thus, a complex set of mechanisms,
which are now only being revealed, has evolved to allow genomic instability to
exist along side genomic stability within a single cell—quite an amazing
accomplishment.
1.3.2.2 Class Switch Recombination
Class-Switch Recombination (CSR) is a very unique form of antibody
diversification because rather than altering the antigen-binding capabilities of the
receptor, it alters the function of the receptor within the immune response. The
IgM isotype is the most ancient form of antibody and defines the B cell lineage.
Its presence emerged in evolution beginning in cartilaginous fish and can be
found in all jawed vertebrates. While primitive vertebrates appear to have a small
variety of other isotypes of antibodies, it was not until the emergence of
amphibians that CSR evolved, allowing single cells to switch between different
isotypes and thus different effector functions as needed (Flajnik and Kasahara,
2010). Besides IgM and IgD (which is a spliced isoform of the antibody),
mammals have three main isotypes of antibody (with additional subsets): IgG,
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which is involved in high affinity memory responses and makes up the bulk of the
antibody response to pathogens, IgE, which functions mainly in the inflammatory
and allergy responses, and IgA, which is found at mucosal surfaces (Flajnik and
Kasahara, 2010). The C-terminal region of the Ig heavy chain gene and protein
defines each of these isotypes.
Just like SHM, CSR is initiated by, and absolutely dependent upon, AIDmediated deamination of deoxycytidine residues in the Ig locus. However, rather
than occurring in the variable region, deamination occurs in highly repetitive
“switch” regions (S) upstream of each of the constant region gene segments
(Figure 1.3). For example, Sµ lies upstream of Cµ, which encodes the constant
region for IgM and Sγ1 lies upstream of Cγ1, which encodes the constant region
for IgG1. S regions range in size from 1-12 kilobases and contain a highly G-rich
non-template strand sequence (Chaudhuri and Alt, 2004; Dunnick et al., 1993).
Though mutations do accumulate within the S regions, the purpose of AIDmediated deamination during CSR is to generate DSBs within two switch regions
(Sµ and a downstream S region), which can then be recombined. This functions
to delete the IgM constant region and replace it with a downstream constant
region of a different isotype. The excised DNA is ligated to form a circular piece
of DNA (Iwasato et al., 1990) (Figure 1.3). Thus, while the initiating step is the
same between SHM and CSR, the outcomes are quite different. This difference is
largely due to how the cell resolves the mutations generated.
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Similar to SHM, CSR requires transcription through the locus. Specifically,
transcription initiates at intervening (I) exons upstream of each of the switch
regions and continues through each of the constant region exons producing a
non-coding, “sterile”, transcript known as the germline transcript (GLT).
Transcription occurs constitutively at the µ locus and in a stimulus- and switchdependent fashion at each of the other constant loci (Lee et al., 2001; Stavnezer,
1996; Stavnezer-Nordgren and Sirlin, 1986). Transcription from I promoters is
regulated by the distal 3’IgH regulatory region (RR), as deletions in this region
result in decreased transcription and defective CSR (Pinaud et al., 2001; 2011;
Vincent-Fabert et al., 2010). Again, transcription has been proposed to open the
locus, revealing a ssDNA substrate for AID activity. Because of the highly
repetitive, C/G rich sequence of S regions, transcription through this region is
capable of producing stable RNA:DNA hybrids known as R-loops, exposing the
G-rich non-template strand for AID activity (Chaudhuri et al., 2003; Daniels and
Lieber, 1995; Yu et al., 2003). Experiments have demonstrated that the presence
of a G-rich non-template strand aids CSR (Shinkura et al., 2003), however other
studies suggest that R-loop formation may not be the only mechanism at play
here. Most notably, replacement of the murine G-rich S region with the A/T rich
region from xenopus laevis, which cannot form R loops, was still able to support
CSR (Tashiro et al., 2001; Zarrin et al., 2004). This data suggests that either the
formation of stem-loop structures at palindromic sequences or the presence of
the conserved sequence, 5’-AGCT-3’, is sufficient to target AID.
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In addition to making the locus more accessible to AID, experimental
evidence suggests that the RNA molecule, itself, is participating in the
mechanism of CSR. It is well-established that transcription is not sufficient for
CSR; rather, splicing of the sterile RNA is necessary (Hein et al., 1998; Lorenz et
al., 1995). The association of AID with splice-associated protein factors such as
PTBP2 and CTNNBL1 further suggests the importance of RNA splicing for CSR
(Conticello et al., 2008; Nowak et al., 2011). It remains unclear at present if it is
the act of splicing or the product of splicing, the RNA molecule, which is
important for CSR. However, just as in the variable region, high levels of sense
and antisense transcription occur at the constant regions to produce a number of
non-coding RNAs (Perlot et al., 2008).
Recent work has focused on understanding the potential role of these Igassociated non-coding RNAs in the regulation of CSR. These RNA molecules
could act as a guide RNAs, targeting AID to the correct region of the Ig locus
(unpublished data, Chaudhuri Lab), or even recruit necessary DNA repair factors,
as has been seen in DSB repair mechanisms in other systems (Wei et al., 2012).
The discovery that the RNA exosome is required for efficient CSR further
stresses the importance of RNA and RNA processing for CSR (Basu et al.,
2011).
As a side note, transcription generated at Iµ occurs after recombination,
generating a post-switch transcript, which contains Iµ spliced to the constant
region exons of the switched isotype (Li et al., 1994). While this is currently
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thought to be a by-product of CSR, possible functions for this transcript have
simply not been investigated.
Similar repair pathways used for SHM are implicated in the formation of
double strand breaks (DSB) downstream of AID-mediated deamination at S
regions. Mismatched deoxyuridine bases are excised by UNG to generate an
abasic site, allowing APE1 to generate a SSB (Masani et al., 2013; Rada et al.,
2002b). SSBs sufficiently close to one another on opposite strands are easily
processed into DSBs, generating the substrate for recombination. Thus, in the
core of the S region where there is a high density of 5’-AGCT-3’ deamination
hotspots, AID-mediated deamination and SSB break formation is likely to occur
at high rates (Min et al., 2003). It should be noted that, though UNG is clearly
necessary for CSR, evidence exists to raise questions regarding its specific
function. Reconstitution of ung-/- B cells with a catalytically inactive form of UNG
restores CSR. In addition, inhibition of the activity of UNG with a peptide inhibitor
does not affect CSR levels (Begum et al., 2009). Thus, it is possible that UNG
plays a non-canonical role during CSR, acting as a scaffold for the recruitment of
downstream DSB repair factors. It is also possible that UNG plays a dual role
and, in its absence, the generation of DNA breaks is compensated for by the
presence of the MMR repair pathway proteins.
In collaboration with the BER pathway, the MMR pathway also plays a role
in generating DSBs in S regions during CSR. Recognition of a mismatched
basepair by the Msh2-Msh6 complex leads to the recruitment of Mlh1 and Pms2,
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which in turn recruit Exo1 to resect a patch of DNA neighboring to the original
mismatched basepair. Mice that contain deficiencies in each of these proteins
have severely defective CSR (Bardwell et al., 2004; Ehrenstein and Neuberger,
1999; Ehrenstein et al., 2001; Martin et al., 2003; Martomo et al., 2004; Schrader
et al., 1999; 2007; Stavnezer and Schrader, 2006). The importance of both
pathways for CSR is demonstrated by the complete loss of CSR in Msh2/UNG
double knockout mice (Xue et al., 2006). In these mice, Uracil insertion into DNA
is resolved via replication to produce characteristic C-to-T mutations. It is likely
that in physiological settings, the BER pathway functions within the core of the S
regions where a high density of SSBs form, whereas the MMR pathway is used
to process DNA to generate DSBs from non-proximal SSBs. This likely occurs in
the extremities of the S region where AID-hotspots are less frequent. This model
is supported by two key pieces of data. First, in the absence of Msh2, the Sµ
tandem repeat core region is necessary for CSR to occur; second, CSR events to
the isotype, IgG2b, which contains a switch region least speckled with AIDhotspots, is most affected by the loss of mismatch repair enzymes (Min et al.,
2003; Schrader et al., 1999).
Even though it has been shown that the formation of two DSBs is sufficient
to induce a recombination event by engineering ISce-I restriction sites in place of
switch regions, these recombination events occur at a rate much lower than
wildtype (Zarrin et al., 2007). Thus, it appears that the efficiency of CSR depends
on the formation of an excess of deamination events, mutations, SSBs and DSBs
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within the S regions. In fact, it has been shown that removal of the faithful repair
polymerase, Pol β, actually results in an increase in mutation and DSB formation
at the S regions, resulting in slightly increased levels of CSR (Wu and Stavnezer,
2007). Again, there is a battle between error-free and error-prone repair at the Ig
locus. Some deamination events are correctly repaired; however, because the
number of mutations exceeds the capacity of error-free repair, error-prone repair
gains access and DSBs form.
The last step of CSR requires the resolution of DSBs through long-range
recombination of breaks formed in two S regions. This occurs primarily through
the use of the classical non-homologous-end-joining (C-NHEJ) pathway resulting
in blunt DSB junctions, and through the alternative-end-joining pathway (A-EJ),
which results in break joints with greater homology. Often the use of the A-EJ
pathway is revealed in the absence of a critical NHEJ protein factor.
Initially, the DSB is sensed and marked by a variety of protein factors. The
Mre11-Rad50-Nbs1 (MRN) complex recognizes the presence of DSB and
activates the kinase, ATM (Dinkelmann et al., 2009). However, because the
severity of CSR defect is greater in MRN-deficient mice as compared to ATMdeficient mice, it is likely that the MRN complex plays additional roles
(Dinkelmann et al., 2009; Lumsden et al., 2004). In fact, the MRN complex plays
a role in funneling DSBs into both the NHEJ and A-EJ pathways for repair.
Phosphorylation of ATM initiates the ATM-dependent DNA damage response,
which in turn induces the phosphorylation of a number of proteins essential for
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DSB repair including the histone variant, H2AX (to form phospho-H2AX or γH2AX) and 53BP1. These proteins, together, form foci that span over 100 Kb
around the DSB and are essential for CSR (Reina San-Martin et al., 2003; Ward
et al., 2004).
During C-NHEJ, the complex Ku70/Ku80 binds broken DNA ends and
recruits XRCC4 and Ligase4 (Lig4) to promote end-joining. The kinases, DNAPKcs are also recruited, which activate DNA end processing by the
endonuclease, Artemis. Deficiencies in each of these factors results in defects in
CSR to varying degrees, typically ranging from about 20%-40% of wildtype levels
(Boboila et al., 2010; Han and Yu, 2008; Li et al., 2008; Rivera-Munoz and
Soulas-Sprauel, 2009; Soulas-Sprauel et al., 2007). However, the fact that CSR
is not completely abolished in the absence of necessary NHEJ protein factors
suggests the existence of a parallel pathway. In addition, analysis of break joints
in the absence of the C-NHEJ pathway reveals that a greater level of
microhomology is used in repair.
The A-EJ pathway is less well understood, but involves additional endprocessing of DNA by the MRN complex and the DNA end processing factor,
CtIP. Both factors promote a more microhomology-mediated form of DNA repair
(Lee-Theilen et al., 2011). In addition, the DNA damage sensor, Parp1, has been
implicated in this pathway (Robert et al., 2009); however, the bulk of the factors
involved, including the necessary DNA ligase, remain unknown (Boboila et al.,
2012). It also remains unclear what factors dictate the choice of pathway. It has
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been shown that 53BP1 in complex with its binding partner, Rif1, prevents DNA
end-resection, thereby promoting C-NHEJ over A-EJ (Bothmer et al., 2010; 2011;
Di Virgilio et al., 2013); however, additional mechanisms are likely to be revealed
in the coming years. A summary of the mechanisms used to resolve DSBs during
CSR are presented in Figure 1.6 (adapted from (Xu et al., 2012).
1.4 Activation Induced Cytidine Deaminase (AID)
Much of SHM and CSR can be carried out by ubiquitous DNA repair
factors. In fact, the only known B-cell specific factor is AID. Because of the
potential dangers of AID activity, including off-target mutations and the formation
of deleterious translocations, great interest has focused on how AID is regulated
to specifically induce genomic instability at the Ig locus, protecting the rest of the
genome from harm.
1.4.1 The discovery of AID
The discovery of AID and the elucidation of its mechanism were greatly
facilitated by the formation of the B lymphocyte cell line, CH12F3 in 1996 by the
Honjo laboratory. Derived from the CH12.LX lymphoma cell line, CH12F3s were
selected to undergo class switch recombination exclusively, and at high
frequency, to the isotype IgA upon stimulation with IL-4, TGFβ, and CD40L.
Despite the presence of other B cell lines available at the time, the CH12F3 line
provided a robust inducible system in which to study the mechanics of class
switch recombination (Nakamura et al., 1996).
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Figure 1.6 Overview of CSR Repair Mechanisms. Within two switch regions
(yellow circles, blue/purple lines), AID deamination coupled with DNA processing
by BER and MMR enzymes results in the formation of DSBs. Recognition of
DSBs by the MRN complex (Mre11, Rad50, Nbs1) activates the ATM-dependent
repair pathway, resulting in the phosphorylation of 53BP1 and H2AX. Breaks are
repaired through two pathways: Classical non-homologous end joining
(C-NHEJ) and alternative end-joining (A-EJ). The proteins known to take part in
each pathway are depicted. C-NHEJ results in blunt joints or joints with minimal
microhomology. A-EJ results in break joints with larger stretches of homology.
53BP1 has been shown to prevent excess resection, thus preventing A-EJ.
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Predicting that a specific recombinase was responsible for CSR,
Muramatsu and Honjo applied a PCR-based subtraction method to screen genes
upregulated upon stimulation of CH12F3 cells for CSR. Among the four novel
genes discovered, Activation-Induced-Cytidine-Deaminase (AID) proved to be
interesting because of its (1) germinal center B cell restriction, (2) homology to
the APOBEC family of RNA cytidine deaminases and (3) in vitro deaminase
activity, unique from that of APOBEC1 (Muramatsu et al., 1999).
Confirmation of the necessity of AID in somatic hypermutation and class
switch recombination came with the generation of an aicda-/- animal by
Muramatsu et al. in 2000. Though no gross abnormalities were observed, these
animals suffered a striking inability to undergo CSR (upon stimulation in vitro and
antigenic challenge in vivo), and surprisingly, also SHM (in vivo) (Muramatsu et
al., 2000).
Concurrent with the mouse work conducted in the laboratory of T. Honjo,
Anne Durandy was studying human hyper-IgM syndrome (HIGM) patients who
completely lack class switch recombination and over-produce IgM. At the time,
the known cause of HIGM was X-linked, resulting in a deficiency in CD40
signaling (Reviewed in (Durandy et al., 2004)). However, the Durandy lab also
identified groups of patients with an autosomal form of hyper-IgM syndrome and
using standard human genetics identified AID as the gene responsible for a
subset of these patients (henceforth known as type II, or HIGM2 patients).
Interestingly, these patients also lacked somatically mutated immunoglobulin
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genes (Revy et al., 2000). The Honjo and Durandy papers were published backto-back and together provided incontrovertible evidence that AID plays a central
and initiating role in both CSR and SHM.
1.4.2 AID is a DNA mutator
Initial characterization of AID revealed that it possessed a cytidine
deaminase domain with homology to several unknown genes and also to the
known RNA deaminase, Apolipoprotein-B mRNA editing catalytic polypeptide –1
(APOBEC1) (Muramatsu et al., 1999). Due to the homology of AID to the mRNA
editing enzyme, APOBEC1, it was initially hypothesized that AID also edited
mRNA. In order to account for the involvement of AID in both SHM and CSR, it
was imagined that AID targets either (1) distinct mRNAS, a DNA mutator in the
context of SHM and a region-specific recombinase/nuclease in the context of
CSR, or (2) a single mRNA that functions in both SHM and CSR, facilitated by
task-specific targeting co-factors, similar to ACF, the targeting co-factor for ApoB
editing (Mehta et al., 2000; Muramatsu et al., 2000).
Alternatively, it was proposed that AID may edit DNA directly, providing
substance to earlier theories that postulated the existence of a mutating factor
that is directly targeted to the Ig locus (Neuberger et al., 1998; Peters and Storb,
1996; Wiesendanger et al., 1998). Genetic evidence for this scenario was
provided by a number of studies that demonstrated that ectopic expression of
AID was able to mutate mammalian cells, as well as bacteria and yeast (Martin
and Scharff, 2002; Mayorov et al., 2005b; Petersen-Mahrt et al., 2002;
Yoshikawa et al., 2002). As it is unlikely that AID would edit the same mRNA in
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all of these cells to result in the generation of a novel DNA mutator, the simplest
interpretation of these data is that AID is a DNA mutator, and as such, the first
member of a family of polynucleotide deaminases that acts on host DNA. In
support of these cellular studies, in vitro studies have confirmed that AID exhibits
activity on DNA substrates, but not RNA substrates, despite its ability to bind
both DNA and RNA (Bransteitter et al., 2003; Chaudhuri et al., 2003; Dickerson
et al., 2003; Nonaka et al., 2009) Several studies have raised questions
regarding the DNA editing hypothesis including evidence that AID can edit the
RNA of the hepatitis B virus, catalytically dead mutants of UNG can rescue CSR,
as well as correlative studies suggesting that AID downregulates Topoisomerase
I through an RNA-editing mechanism, leading to DSB formation during CSR
(Begum et al., 2009; Kobayashi et al., 2009; Liang et al., 2013). Despite these
studies, though, the preponderance of evidence suggests that AID directly
targets DNA. Not only has AID been observed to be localized at the Ig locus
using chromatin immunoprecipitation (ChIP), but, through a number of indirect
assays, the existence of uracils in DNA has been shown to occur in an AIDdependent manner (Maul et al., 2011; Pavri et al., 2010). Lastly, a
comprehensive study using RNA-seq of both small RNAs and poly-A+ mRNAs
from stimulated B cells shows no evidence of RNA editing upon stimulation for
CSR (Fritz et al., 2013). Thus, proof for the alternative RNA-deamination model
will require the discovery of an AID-mutated RNA molecule.
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1.4.3 The regulation of AID
Regardless of the controversy concerning the molecular mode of action of
AID, the mutagenic strength of AID and thus its threat to genomic stability is not
disputed. As such, it is expected that AID is tightly regulated at multiple levels
within the cell. In fact, several different modes of regulation have begun to be
uncovered, ranging from transcription of AID through regulation of the AID
protein. The various methods of AID regulation are presented below and
summarized in Figure 1.8 (adapted from (Xu et al., 2012) and (Alt et al., 2013)).
1.4.3.1 Transcriptional control of AID expression
Because of the mutagenic potential of AID, its expression must be tightly
regulated. AID transcript is undetectable in naïve B cells, but greatly up-regulated
in response to stimulation. AID expression is induced by classic CSR stimuli,
such as lipopolysaccharide, CD40-receptor engagement, interleukin-4 (IL-4), and
TGFβ, as well as IgM-CD19-CD21 crosslinking in the context of SHM (Dedeoglu
et al., 2004; Faili et al., 2002; He et al., 2004; Pone et al., 2012; Rawlings et al.,
2012). These stimuli function to up-regulate both the canonical and noncanonical NF-κB pathways, which work together to induce and maintain AID
expression (Xu et al., 2012).
In addition to NF-κB, several activating and inhibitory factors have been
identified that help to regulate proper AID expression. These proteins have been
found to bind in four main cis-regulatory elements throughout the AID locus:
Region I lies directly upstream of the promoter, Region II lies downstream of the
promoter in the first intron, Region III lies 17 kb downstream of the promoter, and
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Region IV lies 9 kb upstream of the promoter (Crouch et al., 2007; Gonda et al.,
2003; Xu et al., 2012; Yadav et al., 2006). The activating factors, including
HOXC4, SMAD3, SMAD4, PAX5, E2A proteins, and BATF bind throughout these
four regions and cooperate with NF-κB at the promoter to enhance transcription
of AID (Betz et al., 2010; Ise et al., 2011; Park et al., 2009; Sayegh et al., 2003;
Tran et al., 2009). To keep these activating forces in check, Region II also
contains binding sites for inhibitory factors, such as MYB and E2F (Tran et al.,
2009). These factors are important for maintaining AID in the off-state in naïve B
cells (Xu et al., 2012).
Expression of AID has been documented in other cell types, though at
much lower levels than in germinal center B cells. These cell types include
oocytes, primordial germ cells (PGCs), ES cells, breast tissue, and prostate
epithelial cells (Fritz and Papavasiliou, 2010; Lin et al., 2009; Morgan et al., 2004;
Pauklin et al., 2009). Because of the danger of AID expression, it has been
suggested that AID has a separate function, particularly in DNA demethylation, in
these cell types. While good evidence exists to suggest that this is the case
during zebrafish development, future studies are necessary to determine if AID
functions during mammalian development (Abdouni et al., 2013; Rai et al., 2008).
In addition, thorough DNA methylation studies have been conducted in murine
splenic B cells and it does not appear that AID plays a role in DNA methylation
status in this context (Fritz et al., 2013).
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In addition, AID expression can be induced in conditions associated with
cellular transformation (Gourzi et al., 2006) and has been implicated in the
generation of translocations common in B cell lymphomas (Klein et al., 2011;
Klein and Dalla-Favera, 2008; Robbiani et al., 2008; 2009).
1.4.3.2 Post-transcriptional control of AID expression
miR-155, a miRNA previously shown to play a role in the proper activation
of B lymphocytes, directly regulates AID levels in response to activating stimuli
(Dorsett et al., 2008; Teng et al., 2008). Disruption of the miR-155 target site in
the 3’ UTR of the AID locus produces an up-regulation of AID protein levels upon
activation of B cells; this results in increased levels of CSR. Furthermore, AID
expression in miR-155 mutant mice was found to be temporally deregulated, as
shown by AID expression in peripheral B cells. This suggests that miR-155 plays
a role in switching off AID expression in post-GC B cells (Teng et al., 2008).
Furthermore, both reports noted that in the absence of miR-155 control
excess AID protein led to mutation of off-target sites. For example, the gene bcl6
was found mutated at a rate three times higher than in WT mice; importantly, the
occurrence of cMyc-IgH translocations, a known side effect of aberrant AID
activity, was increased 15-fold (Dorsett et al., 2008; Teng et al., 2008). Thus, via
the regulation of AID protein levels, miR155 acts as a tumor suppressor by
silencing potentially harmful mutations and translocations.
In addition to miR-155, Teng et al. cloned three other microRNAs that
were regulated during the transition from resting to activated B cell upon CSR
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stimulation. One, miR-181a, was significantly down-regulated during the time
course of the reaction (Teng et al., 2008). At the same time, De Yebenes et al.
undertook a screen for microRNAs that suppressed CSR and found that ectopic
overexpression of miR-181b resulted in a ~50% reduction in the levels of CSR to
IgG1 (de Yébenes et al., 2008). The miR-181 family comprises four distinct
transcripts with identical seed regions (a, b, c and d) so it is likely that both
groups identified the same functional seed region of mir-181 as functionally
down-regulated in the context of CSR	
  and, in addition, as perturbing CSR when
ectopically expressed. Standard luciferase assays with mutant and wild-type
versions of the AID 3’UTR suggest that miR-181b may directly control levels of
AID expression; however, whether this control in the proper cellular context is
direct or indirect remains to be determined.
1.4.3.3 Post-translational control of AID protein
Post-translational modifications of proteins (PTMs) are one of the most
well known mechanisms used to regulate the activity of proteins, as well as
provide diversity to their function. This is one mechanism by which a cell can
overcome the limitations of the genome (Hunter, 2007). Thus far, much of the
focus on PTMs with reference to AID regulation has been in the realm of
phosphorylation, but recently investigation has spread to ubiquitination. What is
known about AID in the context of these two modifications is presented below. In
time, it is likely that there will be a greater understanding of the regulation of AID
in terms of these, and other, powerful PTMs.
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Phosphorylation:
Thus far, AID has been found to be phosphorylated at 5 different residues:
serine 3 (S3), threonine 27 (T27), serine 38 (S38), threonine 140 (T140) and
tyrosine 184 (T184) (Basu et al., 2005; Gazumyan et al., 2011; McBride et al.,
2006; 2008; Pasqualucci et al., 2006).
The first occurrence of AID phosphorylation observed, and that which has
been studied the most, is the phosphorylation of S38. Carried out by the
ubiquitous, cAMP-dependent kinase, PKA, this phosphorylation event has proven
to be necessary for both efficient SHM and CSR (Basu et al., 2005; Cheng et al.,
2009; McBride et al., 2006; Pasqualucci et al., 2006). The finding that S38
phosphorylation is necessary for the interaction of AID with the ssDNA binding
protein, RPA, provided some insight into the importance of this modification
(Basu et al., 2008; Chaudhuri et al., 2004; Rada, 2009; Vuong et al., 2009).
Initially, RPA was proposed to stabilize ssDNA in transcription bubbles to
maintain a substrate for AID; however, this would not be necessary during CSR
due to ability of switch regions to form stable R-loops. Based on this, it would be
expected that loss of S38 phosphorylation would only result in a defect in SHM,
not CSR. More recent work, though, has provided convincing evidence that RPA
plays distinct roles during SHM and CSR. The S38A, phospho-null mutant of AID
is unable to deaminate a transcribed SHM substrate in vitro, while still
maintaining the ability to deaminate a transcribed CSR substrate in vitro (Vuong
et al., 2009). Thus, it appears that RPA does play a role in increasing access of
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ssDNA substrates for AID during SHM, when R-loops do not form, but not during
CSR. The defect in CSR observed upon loss of S38 phosphorylation appears to
occur downstream of AID-mediated deamination. It has been shown that AID can
access the S regions in the absence of RPA, and in fact, that phosphorylation of
AID at the Ig locus is necessary for the recruitment of RPA to the locus (Vuong et
al., 2009). Thus, during CSR, it appears that RPA has been co-opted to play a
role in DSB repair. Recent work has shown that RPA binds ssDNA exposed by 5’
-to- 3’ resection and is predicted to allow for alternative, microhomology-based
end-joining to occur if C-NHEJ fails (Yamane et al., 2013). Whether the
recruitment of RPA plays other roles during CSR, such as the recruitment of
downstream repair factors, remains to be seen.
Similar to S38 phosphorylation, phosphorylation of T140 plays a role in
enhancing both SHM and CSR. Mutation of T140 to generate a phospho-null
mutant of AID results in a decrease in both CSR and SHM. Interestingly, SHM is
affected to a greater extent than CSR, suggesting that phosphorylation of T140
may play a role in governing the interaction of AID with factors that are specific
for each process (McBride et al., 2008; Vuong and Chaudhuri, 2012).
Unlike the other phosphorylation sites discussed, phosphorylation of S3
inhibits AID activity. Mutation of the site to prevent phosphorylation leads to an
increase in CSR, as well as off-target effects of AID activity, such as cMyc-IgH
translocations. This phosphorylation event can be generated in vitro by the
ubiquitous kinase, PKC and removed by the phosphatase, PP2A. In fact,
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inhibition of PP2A results in an increase in AID phosphorylation at this site and a
concomitant decrease in CSR (Gazumyan et al., 2011). The mechanism of how
S3 phosphorylation inhibits activity is not yet known, but may involve the
interaction of AID with proteins that block its activity.
The phosphorylation events on Y184 and T27 do not have any known
function at this point. Both fall within predicted PKA phosphorylation motifs and
both can be phosphorylated in vitro by PKA. While Y184-Phospho AID has been
detected in primary B cells by mass-spectrometry analysis, the T27-phospho
form of AID has not, raising questions about its physiological relevance. In
addition, mutation of the Y184 phosphorylation site does not severely inhibit
CSR, suggesting that this phospho-event may not play a role in CSR (Basu et al.,
2005; Pasqualucci et al., 2006). Additional experiments are necessary to
determine the functionality of these two modifications (Vuong and Chaudhuri,
2012).
Ubiquitination:
Ubiquitin is an approximately 8.5 kDa protein that is covalently attached at
its C-terminus to an amino acid, typically a lysine, on a target protein.
Ubiquitination can occur in many flavors, ranging from mono-ubiquitination, or the
attachment of a single ubiquitin moiety to the target protein, to poly-ubiquitination,
or the attachment of ubiquitin chains to the target protein. Ubiquitin chains are
formed by the covalent attachment of one ubiquitin protein to one of seven lysine
residues on another ubiquitin protein. Each of the different types of chains,
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composed of one or many different ubiquitin linkages, are recognized differently
by ubiquitin-binding proteins and thus can produce very different downstream
events. Lysine-48 (K48) linkages are commonly found in proteins targeted for
degradation by the proteasome, lysine-63 (K63) linkages are commonly found in
cell signaling complexes, and mono-ubiquitination of histones has been shown to
play a role in nucleosome dynamics and the regulation of transcription (Pickart,
2001a; 2001b). Despite these examples, though, it is very likely that each of
these types of ubiquitination can play a variety of roles, depending on the cellular
context. An overview of the enzymes involved in ubiquitination is presented in
Figure 1.7.
Aoufouchi et. al. were the first to observe poly-ubiquitination of nuclear
AID upon treatment of cells with a proteasome inhibitor, MG132 (Aoufouchi et al.,
2008). This provides an explanation for the observation that nuclear AID has a
much shorter half-life than cytoplasmic AID and suggests ubiquitin-mediated
degradation as a mechanism to regulate AID activity in the nucleus (Geisberger
et al., 2009). Cytoplasmic poly-ubiquitination has also been observed upon
inhibition of the chaperone, Hsp90 (Orthwein et al., 2010).
Neither of these papers were able to identify (1) the residue(s) on AID that
were ubiquitinated and (2) the E3 ubiquitin ligase(s) involved in the ubiquitination
event. In addition, while the pattern of ubiquitination observed by Aoufouchi et. al.
can be interpreted as poly-ubiquitination, the lower molecular weight “laddering”
pattern seen is more reminiscent of multiple mono-ubiquitination events
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Figure 1.7 Overview of the ubiquitination cascade. Ubiquitination requires a
cascade of three enzymes: the ubiquitin activating enzyme (E1), the ubiquitin
conjugating enzyme (E2) and the ubiquitin ligase (E3). In an energy-dependent
mechanism, ubiquitin is covalently linked at its C-terminus to a cysteine residue
on the E1 and then transferred to a cysteine on the E2. E3 proteins, which
contain RING domains, act as a bridge between the E2 and the substrate protein
and provide much of the specificity for the substrate. This bridge allows for the
transfer of the ubiquitin from the E2 to a residue (lysine, shown) on the target
protein. A mono-ubiquitination event is shown, however repetition of this same
mechanism is used to produce poly-ubiquitin chains.
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(Aoufouchi et al., 2008). This opens the exciting possibility that AID is both polyubiquitinated for degradation, and mono-ubiquitinated for some other in vivo
function. This thesis presents the identification of a novel E3 ligase that is able to
mono-ubiquitinate AID. It will be very exciting in the future to discern the cellular
roles of each of the different ubiquitination events and also determine whether
one or multiple ubiquitin ligases are used in these processes.
1.4.3.4 Subcellular localization of AID
One means to avoid excess genomic mutation by a potent DNA mutator,
such as AID, is to regulate its cellular localization. Exclusion of excess AID from
the nuclear compartment should relieve mutagenic stress. In fact, it has been
observed that in cells where AID is known to be active in the nucleus, no nuclear
accumulation can be detected (Rada et al., 2002a). Thus, there exist
mechanisms to actively import AID into the nucleus when necessary, export it
from the nucleus to regulate its activity and maintain it in the cytosol to prevent
off-target mutation.
Nuclear export of AID is dependent on the CRM1 export pathway and is
thus sensitive to inhibition by the drug, Leptomycin B (LMB). This export has
been shown to rely on the last ten amino acids of AID (residues 188-198), which
make up the nuclear export sequence (NES, Figure 1.8). Treatment of cells with
LMB, or mutation of key hydrophobic residues within the NES, results in the
accumulation of nuclear AID (Brar et al., 2004; Ito et al., 2004; McBride et al.,
2004). Interestingly, mutation of the C-terminal NES also results in a decrease in
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(red) transcription factors. AID expression is further regulated at the level of
translation via miRNAs, specifically miR-155. AID protein is regulated by the
addition of post-translational modifications. The five known phosphorylation sites
are depicted with a “P” enclosed in a red circle. Ubiquitination has been
observed, but the site of modification is not known. Catalytic residues of AID are
also shown. H56, C87 and C90 participate in the coordination of Zn, and E58
plays a catalytic role in the deamination mechanism. AID subcellular localization
is tightly regulated by an N-terminal nuclear localization signal (NLS) and a
C-terminal Nuclear Export Sequence (NES). Lastly, AID association with
transcriptional machinery plays a role in targeting. Stalling by the factor, Spt5,
RNA processing and degradation by the RNA exosome and binding of DNA by
RPA all play a role in enabling AID access to the DNA in order to induce
mutations. Lastly, genomic loci neighboring the Ig locus in the 3D space of the
nucleus have an increased chance of mutation and translocation. Thus, it is likely
that a subset of the nucleus is targeted by AID; however, the mechanisms
involved here are unknown.
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class-switch recombination while maintaining the ability to mutate (McBride et al.,
2004). Replacement of the physiological NES with a heterologous NES cannot
rescue CSR to wildtype levels, despite restoring export (Geisberger et al., 2009).
Thus, it appears likely that either the C-terminus plays two roles—one that is
export-specific and another that is CSR-specific, or that export is important for
the mechanism of CSR, but is extremely sensitive to the efficiency of AID binding
to exportins. In line with dual roles for the C-terminus, it has been shown that AID
is actively imported into the nucleolus and export from this compartment relies on
the C-terminus of AID. It is possible that movement in and out of the nucleolus is
an important step in CSR, and thus the presence of this export sequence would
be as well (Hu et al., 2012).
Though less well understood, recent findings have begun to uncover the
mechanistic details of AID nuclear import. A nuclear localization signal (NLS)
composed of several non-contiguous basic residues is located at the N-terminus
of AID (Hu et al., 2012; Patenaude et al., 2009a). Proper nuclear import relies on
the proper structural folding of AID, as the first 39 residues of AID are required
(Hu et al., 2012) (Figure 1.8). Interestingly, the same signal is used to localize
AID to the nucleolus, suggesting the importance of this compartment for CSR (Hu
et al., 2012).
Last, it is likely that AID is retained in the cytosol by association with a
cytosolic complex. Residues 158-198 of AID have been shown to be important
for cytosolic retention. Replacement of this region with the analogous region in
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Apobec 2 allows for passive diffusion of AID into the nucleus in the presence of
the export inhibitor, LMB (Patenaude et al., 2009b). In addition, cytosolic AID has
been purified from DT40 chicken B cells and shown to be part of a complex that
sediments on a sucrose gradient with a sedimentation coefficient of 10-11S,
suggesting that the complex is about 350 kDa (Häsler et al., 2011). Within this
complex, AID has been shown to interact with the translation elongation factor,
eEF1A; elimination of this interaction by mutating the residues involved results in
an increase in the nuclear accumulation of AID in the presence of LMB (Häsler et
al., 2011). Future experiments will be necessary to determine other key
components of this cytosolic retention complex.
1.4.3.5 AID protein cofactors
The fact that AID is the only known B cell-specific factor necessary for
SHM and CSR, coupled with the extraordinary specificity of SHM and CSR, has
prompted intense investigation to understand how AID is targeted specifically to
the Ig locus, sparing the rest of the genome. In addition, it still remains unknown
how AID is locally positioned at the Ig locus, targeting the variable region during
SHM and the switch regions during CSR. To this end, several labs have
conducted screens to search for AID-interacting proteins that could be the elusive
AID-targeting factor.
The ubiquitous family of 14-3-3 adaptor proteins were identified to bind the
S region motif 5’-AGCT-3’ with high affinity, thus suggesting them as a potential
targeting factors (Xu et al., 2010). In fact, drug inhibition, knock-out or expression
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of dominant negative forms of various 14-3-3 isoforms resulted in decreased
accumulation of AID at S regions and a concomitant decrease in CSR (Xu et al.,
2010). While these proteins may play a role in CSR recruitment, the 5’-AGCT-3’
motif is not abundant in the variable region, suggesting that a different, and
unknown, mechanism is needed to recruit AID to the Ig locus during SHM. It is
possible, though, that differential targeting of AID during SHM versus CSR is
mediated by its interaction with a different subset of cofactors. However, because
14-3-3 proteins are ubiquitously expressed, it seems unlikely that these proteins,
alone, are sufficient to recruit AID specifically to S regions.
In addition to the recognition of DNA sequences, many chromatin
modifying factors have been identified, which regulate the recruitment of AID
and/or repair factors to the Ig locus. The histone chaperone, FACT complex, has
been shown to play a role in both SHM and CSR, suggesting the importance of
nucleosome dynamics in making the locus accessible for SHM and CSR protein
factors (Aida et al., 2013; Stanlie et al., 2010). Interestingly, FACT deficiency
during CSR does not affect transcription through the locus, but rather cleavage of
the DNA (Stanlie et al., 2010). This suggests that chromatin dynamics are equally
important for DSB formation and repair.
Unlike the FACT complex, many of the identified chromatin remodelers
have specific effects on either SHM or CSR. KAP1, which recognizes H3K9me3,
a histone modification associated with CSR, binds and recruits AID to the Sµ
switch region. Loss of KAP1 results in a decrease in AID recruitment to S
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regions, as well as decrease in CSR. Interestingly SHM is not affected in mice,
which lack KAP1 (Jeevan-Raj et al., 2011). Similarly, the histone chaperone,
Spt6, can interact directly with AID. Knockdown of Spt6 results in a significant
decrease in CSR levels in the CH12 cell line (Okazaki et al., 2011). The
mechanism by which Spt6 acts in this setting remains unknown. In contrast, the
nuclear export factor, GANP, actively remodels chromatin specifically at the
variable regions through its histone acetyl transferase activity. This modification
allows access of AID to the region (Kuwahara et al., 2000; 2004; Maeda et al.,
2010; Singh et al., 2013). Mice deficient in GANP exhibit normal CSR, but
decreased SHM.
Many of the AID-interacting proteins discovered provide a link between
AID activity and the well-known fact that transcription is highly correlated with
SHM and CSR. First, AID has been shown to directly interact with RNA
Polymerase II (RNAPII), thus providing a direct connection between transcription
and mutation (Besmer et al., 2006; Nambu et al., 2003). Further, as already
discussed, the ssDNA binding protein, RPA, is thought to play a role in stabilizing
a ssDNA intermediate during transcription of SHM targets (Chaudhuri et al.,
2004; Vuong et al., 2009). Last, the RNAPII associated stalling-factor, Spt5,
interacts with AID and facilitates its interaction with RNAPII. Spt5 localizes with
RNAPII and AID throughout the genome and sites at which Spt5 accumulate are
predictive of AID-mediated mutation (Pavri et al., 2010). Based on these findings,
it is likely that AID associates with RNAPII and the transcription machinery. As
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RNAPII stalls during its elongation phase, AID disassociates, allowing for
mutation. In line with this model, insertion of a transcription terminator containing
a poly(A) signal downstream of the variable region promoter in DT40 cells
increased AID-mediated mutation. Additional AID RNAPII stalling at the Poly(A)
signal sequence likely accounts for the increase in mutation load (Kodgire et al.,
2013). In an attempt to explain how AID activity is limited to a distance of 2 Kb
from the promoter whereas mRNA transcription is not terminated until much later,
it has been proposed that not all transcription complexes at the Ig locus are
created equal. Non-AID containing RNAPII could be responsible for transcribing
the complete mRNA, whereas AID/Spt5-containing transcription complexes may
be more prone to stalling, releasing AID before transcription has terminated
(Kodgire et al., 2013). This model would predict that several incomplete Ig
transcripts exist in B cells stimulated for CSR and/or SHM. In fact, recent work
from the Basu lab has shown that in the absence of a critical subunit of the RNA
exosome, an accumulation of ncRNAs occurs at AID-targeted loci (Basu et. al.,
unpublished, “Immunity and Tolerance” CSH Meeting, May/June 2013). Thus, it
is possible that the existence of these truncated transcripts is masked in wildtype
cells by the activity of the exosome. Future experiments are needed to piece
apart the genesis and role of these ncRNAs, as well as the validity of this model.
The importance of RNA to SHM and CSR has become increasingly
appreciated. Not only is transcription necessary, but also processing of the
transcripts through splicing is required. As such, AID has been found to interact
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directly with the splicing factors, CTNNBL1 and PTBP2 (Conticello et al., 2008;
Nowak et al., 2011). Knockdown of PTBP2, specifically, results in a decrease in
the accumulation of AID at the Ig locus (Nowak et al., 2011). Thus, it is possible
that either the splicing machinery, or the processed RNA, itself, plays a role in
AID stabilization at the locus. Either way, it is clear that RNA processing,
including splicing and degradation by the Exosome, is intimately linked to AID
activity.
As mentioned, the majority of AID in the cell is not in its active form at the
Ig locus. Thus, it is likely that AID is a member of several different protein
complexes throughout its lifetime. As discussed, cytosolic AID is complexed with
both eEF1A and Hsp90 (Häsler et al., 2011; Orthwein et al., 2010). In addition,
Regγ, a protein associated with ubiquitin-independent protein degradation, binds
nuclear AID and also plays a role in regulating the abundance of AID protein
(Uchimura et al., 2011). With time, more of the components of the cytosolic and
nuclear AID complexes will be revealed, hopefully along with a better
understanding of how the activity of AID is regulated. In addition, it has been
shown once that PTMs on AID can affect protein-protein interactions.
Specifically, phosphorylation of AID on S38 enhances binding to RPA. It will be
interesting in the future to understand if, and how, other PTMs, such as
ubiquitination, play a role in regulating AID complex formation. A list of identified
AID cofactors is presented in Table 1.1.
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Table 1.1 AID protein cofactors. A list of identified AID protein cofactors is
given, along with a brief description of its function.
DNA BINDING
14-3-3 Adaptors Bind AGCT repeats in switch regions
CHROMATIN FACTORS
FACT

Histone chaperone, involved in SHM and CSR

KAP1

Recognizes H3K9me3, involved in recruitment of AID to switch regions, CSR specific

Spt6

Histone chaperone, CSR specific

GANP

Histone acetyl transferase, makes variable regions accessible to AID, SHM specific
TRANSCRIPTION-ASSOCIATED

RNAP II

RNA Polymerase

RPA

ssDNA binding protein, binds phosphorylated AID, involved in both SHM and CSR

Spt5

RNAP stalling factor, enhances binding of AID with RNAPII
RNA-ASSOCIATED

Exosome

Processing and degradation of RNA, increases access of AID to template strand, involved in SHM and CSR

CTNNBL1

Spliceosome-associated factor

PTBP2

Splicing factor, stabalizes AID at Ig locus
CYTOSOLIC

EEF1A

Maintains AID in cytosol

HSP90

Stabilizes AID in cytosol
OTHER

PKA
REG

Phosphorylates AID
Degradation of nuclear AID
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1.4.3.6 AID targeting and off-target mutation
It is clear that transcription and the transcription machinery plays a role in
targeting AID. However, many genes in activated B cells are highly transcribed.
Thus, it still remains unclear why AID activity accumulates at the Ig locus. ChIPSeq studies of AID and Spt5 demonstrate that AID accumulates at many highly
transcribed genes in the genome, suggesting that the specificity of mutation
occurs downstream of initial AID targeting (Pavri et al., 2010; Yamane et al.,
2011). Though it is clear that off-target AID activity occurs, as both mutation and
DSB formation have been detected outside of the Ig locus, these mutations and
translocations form at much lower rates than what is seen at the Ig locus.
(Klein et al., 2011; Liu et al., 2008; Ramiro et al., 2004; Robbiani et al., 2009).
Chromatin Capture studies coupled with deep-sequencing have revealed that
genes which are frequently mutated by AID display proximity to the Ig locus in the
3D space of the nucleus (Rocha et al., 2012). Genes that are actively transcribed
are often spatially localized, thus providing a connection with the earlier studies
connecting AID to highly transcribed genes. However, again, not all transcribed
genes are targets of AID and thus there must be unidentified factors that
introduce greater specificity.
In addition to the trans-factors discussed, many labs have searched for
cis-regulatory modules that recruit AID to the Ig locus. While the promoter is
clearly important for the induction of transcription, the nature of the promoter and
neighboring enhancer regions may play a role in the recruitment of AID. An
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analysis of non-Ig genes that undergo AID-mediated mutation revealed the
presence of three transcription factor binding sites: E-box motifs, binding sites for
YY1 and C/EBP-β (Duke et al., 2013). These factors may work together to recruit
AID, providing a mechanism for the specific recruitment to some transcribed
genes, but not others. Experiments conducted in DT40 B cells have shown that
regions 3’ of the Ig locus participate in the recruitment of AID. Deletion of a 6 Kb
region downstream of the 3’ RR resulted in a loss of gene conversion (GCV) and
mutation, despite high levels of transcription due to the insertion of an SV40
enhancer (Kothapalli et al., 2008). Further, insertion of a region 9.8 Kb
downstream of the start site of the IgL locus in DT40 cells into a non-Ig locus was
sufficient to activate hypermutation, thus suggesting that this region could recruit
AID and/or other necessary factors (Blagodatski et al., 2009). Further
experiments will be needed to work out the specific sequences involved in
recruitment, whether it is AID or some other factor that is recruited here, and how
these cis-regulatory modules work together with the transcriptional machinery
and other trans-factors.
1.5 Statement of Problem
AID is a very potent enzyme with the ability to induce mutation in the
genome of cells in which it resides. When harnessed properly, the capacity of
this enzyme to mutate is able to produce a large and diverse repertoire of
antibody specificities and functionalities to fortify the host’s adaptive immune
system. However, when used improperly, AID has the potential to wreak havoc
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on the health and stability of the host’s genome. This misuse of AID can, and has
been shown to, result in the accumulation of point mutations and the formation of
DNA breaks and aberrant chromosomal translocations at non-immunoglobulin
loci in the genome---genomic abnormalities that leave the host vulnerable to the
formation of cellular cancers. Because of this, the localization and activity of AID
must be meticulously regulated to assure the health of the cell and maintain the
balance of genomic instability within the immunoglobulin loci and genomic
stability elsewhere.
Because of the great potential for harm due to the mis-regulation of AID, it
is likely that several layers of regulatory mechanisms exist to ensure that AIDmediated deamination is targeted specifically. In fact, much of the research within
the realm of AID biology is focused on understanding how AID, itself, as well as
its activity, is monitored by the cell. Many of these modes of regulation have been
discussed and likely involve the interaction of AID with other cellular proteins,
which could either target AID to the immunoglobulin loci, regulate its activity, or
participate in the recruitment of events downstream of AID-mediated
deamination.
The interest in the involvement of AID protein cofactors in antibody
diversification has led many laboratories to search for proteins, which can directly
bind AID. However, this venture has proven to be particularly challenging
because of the propensity for AID to become insoluble when ectopically
expressed. Typically, ectopic expression of AID results in its mis-folding,
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aggregation and presence in insoluble inclusion bodies. This makes it difficult to
purify in order to study the protein in vitro, as well as study its interaction to other
proteins using classical techniques such as the yeast-two hybrid assay (Y2H).
Thus far, a variety of techniques, including immunoprecipitation followed by
mass-spectrometry and RNAi knockdown screens, have been used to identify
putative AID cofactors. These screens have suggested the synchronization of
AID with other broadly important cellular pathways, including RNA splicing
(Conticello et al., 2008), RNA processing and degradation by the RNA exosome
(Basu et al., 2011), transcription (Besmer et al., 2006; Fukita et al., 1998;
Lebecque and Gearhart, 1990; Nambu et al., 2003; Rada and Milstein, 2001;
Storb et al., 2007; Tumas-Brundage and Manser, 1997; Winter et al., 1997), and
RNA polymerase stalling (Pavri et al., 2010); however, a clear picture of the
players involved in the AID reaction and the sequence of events remains, for the
most part, unclear. Thus, the search for potential AID cofactors could still benefit
from the development of better techniques for identifying interacting partners for
insoluble proteins.
This thesis presents the development and validation of a novel screening
approach to identify interacting partners for poorly soluble proteins, as well as the
application of this screen to Activation Induced Cytidine Deaminase (AID). Using
the screen, several novel putative AID cofactors have been identified along with
some previously discovered interacting partners, verifying the robustness of the
screening approach.
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In addition, because of its interesting domain structure and the potential
for interesting regulatory mechanisms on AID, one interacting partner identified in
the screen, RING Finger Protein 126 (RNF126), was studied further. RNF126
was verified to be a bona fide AID binding partner and additionally determined to
act as an E3 ubiquitin ligase, modifying AID with the addition of a single ubiquitin
moiety. While poly-ubiquitination of nuclear AID has been implicated in its
degradation, this discovery marks the first example of mono-ubiquitination of AID.
In addition, this is the first example of the discovery of an AID ubiquitination event
paired with the E3 ubiquitin ligase responsible. In addition to studying the function
of RNF126 in vitro, a conditional knockout model was generated and used to
assay the importance of RNF126 during various stages of antibody
diversification. While it is clear that RNF126 is not essential for antibody
diversification, these studies reveal the potential role of RNF126 in fine-tuning the
activity of AID during CSR and SHM. In addition, these studies demonstrate the
layered intricacies of both diversification mechanisms, suggesting the importance
of analyzing putative AID cofactors in a variety of contexts, as it is very possible
that the importance of a single protein factor might not be detectable in an
otherwise wild-type context.
The findings presented here demonstrate the utility of a novel screening
technique to search for interacting partners for insoluble proteins and, through its
use, expands the list of putative AID cofactors. The discovery that the novel E3
Ubiquitin Ligase, RNF126, interacts with and modifies AID presents a novel
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mode of regulation of the potent mutating enzyme and paves the way for future
research to uncover the role of mono-ubiquitinated AID during SHM and/or CSR.
Lastly, the generation of the RNF126 conditional knockout mouse model not only
will prove invaluable for future studies of this enzyme during antibody
diversification, but also in all other systems where RNF126 is expressed.
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CHAPTER 2: DEVELOPMENT AND VALIDATION OF A NOVEL SCREEN TO
IDENTIFY INTERACTING PARTNERS FOR INSOLUBLE PROTEINS
2.1 Motivation
The cell has evolved complex signaling networks to translate external and
internal cues into the appropriate cellular response to foster the survival of the
cell or of the multicellular organism to which it belongs. As our understanding of
these signaling networks has increased, it has become clear that the involvement
of many proteins, and thus of protein-protein interactions, is necessary to carry
out the process faithfully. Traditionally, protein-protein interactions have been
studied on a case-by-case basis using biochemical, biophysical or genetic
techniques (Phizicky and Fields, 1995). However, with the onset of genome-wide
sequencing came an interest in assigning function to the slew of new and
unknown open-reading frames (ORF). Thus, it became increasingly appealing to
develop high-throughput methods to discover novel protein interaction partners of
functionally characterized genes in order to identify biological roles of proteinprotein interaction networks and to provide useful clues to assign function to
unknown ORFs.
Most of the genome-wide protein-protein-interaction data published to date
has been produced with yeast two-hybrid assays or with in vivo pull-down
approaches. Yeast-two-hybrid assays are often utilized for large scale proteinprotein-interaction screens (Fields and Song, 1989; Ghavidel et al., 2005) and
rely on the modular nature of eukaryotic transcription factors in which one domain
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binds DNA in a sequence specific manner and the other domain acts to activate
transcription. Thus, when one protein of interest is fused to the DNA binding
domain and its interacting partner to the activation domain, proof of interaction
can be determined by the transcription of a reporter gene. On the other hand, in
vivo pull-down approaches toward identifying protein-protein interactions typically
rely on the addition of an affinity tag to the protein of interest, expression in its
native cell and purification of the protein along with its bound cofactors. Mass
spectrometry is then applied to identify the proteins that precipitated along with
the tagged protein of interest. Although these purification methods were first
developed for small scale protein identification experiments, they have been
successfully adapted for use in genome-wide proteomics studies (Alber et al.,
2007a; 2007b; Gavin et al., 2006; Krogan et al., 2006). Both yeast-two-hybrid
and affinity based techniques generate false positives and require independent
confirmation of potential interaction partners.
More importantly, though, proteins that are poorly soluble or insoluble
when ectopically expressed are least amenable to characterization using these
tools. Poor solubility upon ectopic expression of a protein can result from either
improper folding or the exposure of hydrophobic domains that would be masked
when in complex with cofactors. This problem is particularly palpable for those
who study the enzyme, AID. Because of the mutagenic potential of AID, it has
been predicted that key regulatory mechanisms involve the interaction of AID
with protein cofactors, which either regulate through binding or impart a post63

translational modification, another mechanism known to be invaluable for AID
regulation. However, because AID is poorly soluble upon expression in bacterial
cells, it has proven difficult to use traditional techniques to screen for AIDinteracting partners.
2.2 Design of solubility-based interaction screen
To specifically address the problem of cofactor identification for poorly
soluble proteins, such as AID, we have devised a new screening approach that
actually takes advantage of the insolubility of the protein of interest to identify
interacting partners. Often proteins that are insoluble when expressed alone will
form soluble complexes when co-expressed with a native binding partner. In
practice, this technique involves the co-expression and co-folding of two proteins,
an unknown protein expressed from a cDNA library of choice, and a known,
insoluble protein fused to an antibiotic resistance protein. As will be shown in the
following proof-of-principle experiments, fusion of the gene for an insoluble
protein with the gene coding for antibiotic resistance produces a fusion protein
that is also insoluble. Thus, when this fusion gene is expressed, bacteria are only
able to grow under drug selection when the fusion protein is solubilized, but not
when it is in its insoluble form. Solubilization of the protein of interest, and of the
fusion protein, rescues the ability of bacteria to grow under drug selection. For
these experiments the drug resistance gene, Chloramphenicol Acetyl
Transferase (CAT), was used, which confers resistance to the drug,
chloramphenicol.
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2.3 Validation of interaction screen
Prior to applying this technique to AID, it has been validated to establish
that: (1) fusion of soluble and insoluble proteins to CAT yields soluble and
insoluble fusion proteins, respectively, (2) drug resistance can be rescued by
solubilization of a known insoluble protein with its native binding partner, and (3)
positive interaction and subsequent solubilization can be detected even when the
interacting partner constitutes the minority of a population of expressed proteins.
In order to establish that the solubility status of the fusion protein is directly
correlated with that of the fused protein of interest, AID was used as a
representative insoluble protein and the phage effector protein, Cell-Cycle
Inhibitory Factor (CIF) (Hsu et al., 2008), a protein of similar size to AID, as a
representative soluble protein. Bacterial expression of AID with a C-terminal
fusion to CAT rendered cells unable to grow on chloramphenicol plates. In
contrast, C-terminal fusions of CAT to CIF enabled cells to be resistant to even
high doses of chloramphenicol, reaching up to 240 µg/mL (Figure 2.1).
In addition, it was necessary to establish that interaction of a known
cofactor to the fused protein of interest could rescue solubility. In order to test
this, we have used a known heterodimer in which one component is necessary
for the solubilization of the other. It has been previously established that the
tRNA editing enzyme adenosine-deaminase acting on tRNA (ADAT3) is insoluble
unless co-expressed with the other component of the heterodimer, ADAT2
(Rubio et al., 2007). Utilizing an N-terminal fusion of ADAT3 to CAT, it can be
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Figure 2.1. A genetic assay selects for the restoration of solubility of an
insoluble protein. (A) A schematic depicts representative CAT fusion
proteins used. AID and AID-CAT are insoluble and thus produce
chloramphenicol sensitive cells; Cif and Cif-CAT are soluble allowing cells to
be resistant to chloramphenicol; ADAT3 and ADAT3-CAT are insoluble unless
coexpressed with its binding partner, ADAT2. (S=sensitive, R=resistant). (B)
Plasmids carrying the indicated genes were transformed into BL21ai E. coli,
plated on chloramphenicol containing plates under induction conditions.
Resistant colonies were counted. Shown here are colony numbers obtained
on LB plates containing 120 μg/ml chloramphenicol.
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seen that, much like for AID, expression of ADAT3-CAT in bacteria results in
drug sensitivity and the inability of colonies to form on chloramphenicol plates.
Only upon co-expression of ADAT2 with ADAT3-CAT, can bacteria harboring the
ADAT3-CAT fusion protein survive on chloramphenicol plates (Figure 2.1).
Together, these results establish that fusions of CAT render cells resistant to
chloramphenicol as long as the fused protein is soluble. Furthermore, at least for
the case of the heterodimer ADAT2/3, reconstitution of a soluble complex by coexpression of a necessary binding partner rescues the ability of bacteria to be
grown on chloramphenicol plates.
To assure that this screening technique would be able to identify novel
AID interacting partners when expressed amongst a large library of sequences,
we took advantage of proteins known to be able to bind AID. In particular, the Cterminal, RING domain containing, region of the E3 ligase mutant double minute
(mdm2) has been shown to interact with AID by a yeast-two-hybrid screen
(MacDuff et al., 2006). Co-expression of the C-terminal region of mdm2 with the
AID-CAT fusion protein was able to rescue the solubility of the fusion protein and
produce resistance to chloramphenicol when neither expression of AID-CAT
alone nor mdm2 alone could do this (Figure 2.2). Thus, this technique was able
to confirm the interaction, which was first shown using the traditional yeast-twohybrid screen.
In order to demonstrate that an interaction could be efficiently isolated
from a pool of known negatives, we generated a small library of irrelevant
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Figure 2.2 Detection of a positive interaction amongst non-interactors.
(A) A schematic depicts representative CAT fusion proteins. (B) Chloramphenicol
resistant colonies after co-transformation of the indicated expression plasmids
were counted. Co-expression of AID-CAT and the Mdm2 RING domain allowed
for efficient survival on chloramphenicol plates. These interactions were revealed
even when the Mdm2 RING plasmid was diluted 1:20 and 1:200 in a mini-library
of known non-interactors.
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bacterial cDNAs, which consisted of 20 cDNAs encoding known bacterial
virulence factors. Co-transfection of this mini-library with AID-CAT did not render
bacteria able to survive on chloramphenicol plates, demonstrating that, as
expected, none of these twenty proteins are able to bind AID. However, dilution
of the mdm2 RING domain expressing plasmid within the mini-library in a 20:1 or
200:1 ratio followed by transformation and expression in the presence of AIDCAT, recovered chloramphenicol resistant clones (Figure 2.2). Importantly, all of
these clones expressed mdm2 RING domain and AID-CAT, confirming that the
solubilization of AID was due to the interaction with the RING domain of mdm2.
Thus, this screening technique is sensitive enough to isolate positive AID
interactions even when the interacting protein constitutes a minority of the total
population of the library.
2.4 Concluding Remarks
Recent progress has been made in the development of novel techniques
to assay protein-protein interactions on a high-throughput scale with the goal of
filling in the gaps in the interactome left by the use of more classical techniques.
Despite the many benefits of these new methods, though, none are particularly
reliable for the identification of interactions with a protein that is poorly soluble or
insoluble when ectopically expressed. The solubility-based screen developed
here specifically targets this subset of proteins in an attempt to expand the
repertoire of methods used to identify protein-protein interactions.
The set of experiments discussed thus far establish the utility of this technique
when working with poorly behaved proteins. By generating fusion proteins
69

between a protein of interest and a drug-resistance protein, it has been
established that there is a direct link between solubility and drug resistance. That
is, fusion of a soluble protein produces a soluble fusion protein and drug
resistance and fusion of an insoluble protein produces an insoluble fusion protein
and drug sensitivity. In addition, solubilization induced through the interaction of
an binding partner can rescue drug-resistance, providing a direct read-out for
protein-protein interactions, thus rendering this technique useful for highthroughput screening for binding partners of a protein of interest.
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CHAPTER 3: IDENTIFICATION OF RING FINGER PROTEIN 126 AS AN E3
UBIQUITIN LIGASE FOR AID
3.1 Application of Interaction Screen to AID
As a source of potential AID-interacting proteins a full length, normalized
cDNA library was generated from the RAMOS human B cell lymphoma line. This
cell line constitutively expresses AID and hypermutates, suggesting that
necessary AID cofactors are also expressed (Sale and Neuberger, 1998). The
library, which contains approximately 22,000 unique clones, was screened in
triplicate in order to be reasonably confident of near-complete coverage. From
these replicates, a list of 127 candidate interactors was generated, of which 36
were cloned more than once in each of the three experiments. The interaction of
these 36 proteins with AID was further validated by co-expression experiments in
E. coli. Each candidate was tagged with an N-terminal hexa-histidine tag and coexpressed in BL21 DE3 cells along side FLAG-tagged AID. Reciprocal affinity
purification and western blots were conducted for all 36 candidates and 30 out of
36 co-purified with AID, suggesting a 16% false positive rate. An outline of the
screen is presented in Figure 3.1
As validation for this novel screening technique, many of the previously
determined putative AID cofactors were also identified in this screen. These
include components of the RPA complex (Chaudhuri et al., 2004), the splicing
factor, CTNNBL1 (Conticello et al., 2008), Karyopherins (Patenaude and Di Noia,
2010; Patenaude et al., 2009a) , and finally AID itself. The fact that AID-CAT
binds co-expressed AID raises the question of why AID-CAT cannot simply
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Figure 3.1 Detailed Schematic of Screening Process. The Gateway Cloning
System (Invitrogen) was used to recombine an entry vector containing cDNA from
the RAMOS cDNA library with a destination vector containing AID-CAT.
Recombination occurs between “attR” and “attL” sites using the
“LR Recombinase”. Notably, recombination replaces the toxic Ccdb gene with a
cDNA from the library. In addition, because only the destination vector contains
spectinomycin resistance, successful recombination can be selected for on
spectinomycin plates. These plates are grown O/N at 30°C to minimize the
potential toxicity due to trace expression of a toxic cofactor. The colonies from
spectinomycin selection are transferred (using velvet pads) onto new plates
containing spectinomycin, chloramphenicol to select for solubilization of AID-CAT,
and arabinose and IPTG to induce T7 RNAP and AID-CAT/cofactor expression,
respectively. Again, plates are grown O/N at 30°C. Colonies that grow on these
plates represent potential AID-interacting candidates as they were able to
solubilize AID-CAT. These colonies are picked, liquid cultures grown, and DNA
prepared and sequenced to identify the unknown cDNA from the library.
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dimerize and rescue solubility. This is likely related to the trimeric nature of active
CAT, which would necessitate the placement of three AID molecules in the AIDCAT trimer at a significant distance from one another. Thus, multimerization of
the AID moiety would preclude CAT trimerization and thus inhibit survival on
chloramphenicol plates (Leslie et al., 1988).
The majority of the novel factors identified in the screen fall within the
category of mRNA transcription, processing, splicing and export—processes that
have already been shown to be necessary for CSR, though the mechanism
remains unknown. In addition, a significant number of factors have been shown
to be important for DNA repair, again a process necessary for CSR. The
remaining identified cofactors are either unknown or from uncharacterized open
reading frames (ORFs), or factors with known functions but whose involvement in
AID-mediated processes is unclear. A list of all factors identified in triplicate, as
well as their predicted functions, is presented in Table 3.1.
3.2 RING Finger Protein 126 (RNF126)
Because of the potential interesting characteristics of one of the unknown
ORFs identified in the screen, Ring Finger Protein 126 (RNF126), further
experiments were conducted to understand its influence on AID and AIDmediated events. RNF126 is a relatively small protein of approximately 310
amino acids and is well conserved throughout evolution. In fact, there exists a
62% similarity between human and zebrafish forms of the protein. Though
virtually nothing is known about the role of RNF126, three domains exist that are
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Table 3.1 List of identified putative AID-Cofactors. A list of all 36 candidates
that were cloned in triplicate. The name and accession number of each gene are
presented, as well as the number of times each gene appeared in the screen
(# cloned). 30/36 hits were verified to interact by Co-IP
(last column—Y=yes, N=no). In addition, the best description of the function of
the gene found in the literature is presented. For many of the genes, the
functions are not known and descriptions of other aspects of the biology of the
gene are given. AID-interacting factors found by other screens are highlighted.
Factor

Accession #

Description
RNA Processing

Function

#cloned

Co-IP?
Y

hnRNP-M

NP_005959

Splicing? Coating transcript?

Unknown

17

hnRNP-A0

NP_006796

Splicing? Coating transcript?

Unknown

35

Y

DDX21

NP_004719

Nucleolar RNA helicase

Unknown

10

Y

DDX19

NP_001014449

Nucleolar RNA helicase

Unknown

10

Y

LGTN

NP_008824

Unknown

16

Y

CPSF73

NP_057291

PolyA Tail Addition

6

Y
Y

XRN2

NP_036387

Sui1; RNA binding
Cleavage and polyadenylation specificity
factor
5’>3’ exoribonuclease

mRNA term.

6

EEF1A1

NP_001393

Translation initiation factor

Translation

9

Y

RBM39

NP_909122

U2AF homolog; splicing

splicing

14

Y

NIP30

NP_079222

Nucleolus-associated

Unknown

3

N

NOL11

NP_056277

Nucleolus-associated

Unknown

12

N

CTNNBL1

NP_110517

Import? Splicing?

6

Y

Nup93
Importin
Subunit -1

NP_055484

Nucleoporin

Nuclear Pore Complex

12

Y

NP_002256

Importin beta family

Nuclear import

11

Y

7

Y

8

Y

mRNA splicing
Nuclear Import/Export

DNA Repair

RAD51

NP_002866

Rad51 Homolog 1 Isoform 1

RRM2B

NP_001025

Ribonucleoside Reductase

IER5

NP_057629

Novel repair factor?

DNA repair
Deoxyribonucleotide
Synthesis
Unknown

6

Y

FEN1

NP_004102

Flap endonuclease

DNA repair

6

Y

General Cellular Biology
Actin

NP_001605

Gamma actin isoform

cytoskeleton

12

Y

RDH11

NP_057110

oxidoreductase

Nucl. Metabolism

6

N

PGAM1

NP_002620

Glycolysis/metabolism

Nucl. Metabolism

13

Y

IMPDH2

NP_000875

Nucl. Metabolism

35

N

UbcH7
PPP2R1A

NP_055904
NP_055040

Prot degradation
Reg subunit

6
6

Y
Y

AICDA
RPA1

NP_065712
NP_002936

DNA mutation
AID cofactor

8
15

Y
Y

TCP1-eta

NP_001009570

Y

NP_005338

chaperone
Chaperone;HSP70 family
member
Upregulated during
unfolded protein response

23

BiP/HSPA5

IMP dehydrogenase
Protein Modification
Ubiquitin ligase
Protein phosphatase
AID Biology
Cytidine deaminase
Replication protein A
Chaperone Proteins
T-Complex Protein 1
78 kDa glucose-regulated protein
precursor

31

Y

9

Y
Y

homocysteine-responsive endoplasmic reticulumresident ubiquitin-like domain member 2 protein

HERPUD2

NP_071768

C14orf94

NP_060285

Unknown Function
Unknown

Unknown

7

C22orf28

NP_055121

Unknown

Unknown

6

Y

CXorf9
ZNF44
DAZAP2
ZMIZ2
RNF126

NP_061863
NP_057348
NP_055579
NP_113637
NP_919442

Lymphoid sp.; SH2 domain
Zn finger; DNA binding
Zn finger; DNA binding
MIZ-type Zn finger
Ring Domain Containing Protein

Unknown
Unknown
Unknown
Unknown
E3 Ubiquitin Ligase

18
6
5
7
6

N
N
Y
Y
Y
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very suggestive of function: an N-terminal Zinc Domain, a C-terminal RING
Finger Domain and a very C-terminal stretch of serine residues (Figure 3.2). The
C-terminal serine tail contains approximately 12 serines that are conserved from
its emergence in zebrafish to human (Figure 3.2). Few other proteins contain
such a domain and its conservation throughout evolution suggests that it plays an
important role in the mechanism of RNF126. Just upstream of the C-terminal
serine stretch lies a C3H2C3-type RING domain, which has been shown to be
necessary for auto-ubiquitination in in vitro assays (Burger et al., 2006). Lastly,
the N-terminal Zinc domain shows significant homology (69%) to a zinc finger
domain on a related E3 ligase, BCA2, which has been identified as a BZF
domain, a novel ubiquitin binding domain (Amemiya et al., 2008). The
conservation of these domains prompts intense investigation to determine how
each play a role in the physiology of RNF126.
3.3 Identification and validation of RING Finger Protein 126 as an AIDinteractor
As with the other potential interacting candidates, the direct interaction of
RNF126 with AID was validated by exogenous expression in both bacterial and
mammalian systems. First, co-expression of a hexa-histidine tagged RNF126
and a Flag tagged AID followed by affinity purification shows that AID and
RNF126 interact. His-RNF126 was purified on a Ni-NTA column and eluted with
increasing amounts of imidazole. Flag-AID co-eluted with RNF126, but did not
appear in elution fractions that did not contain His-RNF126 (Figure 3.3).
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Figure 3.2 RING Finger Protein 126. Cartoon of RNF126 domain structure.
The position and sequences of the RING domain and Zinc finger domain are
shown. The insert shows that the amino acid composition of the C terminal
serine-rich domain is evolutionarily conserved.
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αFlag (AID)
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37

αHis (RNF126)

Figure 3.3 RNF126 interacts with AID in bacterial cells. AID co-purifies with
RNF126 upon co-expression and purification in E.coli. Flag tagged AID was
co-expressed with His-tagged RNF126. Purification of RNF126 on a Talon cobalt
column and elution with imidazole reveals that AID co-elutes with RNF126.
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In order to better characterize the interaction of RNF126 and AID, the
regions on both AID and RNF126 that were involved in protein-protein binding
were determined. Because AID is a small protein, truncation of the protein often
leads to mis-folding and thus misleading results. To get around this, an approach
developed by Conticello et. al. was used (Conticello et al., 2008). A set of
chimera expression constructs, interspersing regions of the APOBEC family
member, APOBEC2, within AID were used to determine the role individual
domains of AID play in its interaction with RNF126. Co-expression of His-tagged
AID and FLAG-tagged RNF126 in bacterial cells followed by co-affinity
purification experiments revealed that, whereas chimeras A, B and D interacted
well with RNF126, Chimera C did not (Figure 3.4). This region replaces residues
88-116 of AID with the comparable region of APOBEC2, and contains part of the
zinc-coordinating motif (Figure 1.8), as well as the region of AID (aa 106-116)
that has been found to confer specificity for AID hotspots. This region, when
replaced with a comparable region from other APOBEC family members, alters
the mutation preference of AID (Kohli et al., 2009).
To ascertain what regions of RNF126 are necessary for its interaction with
AID, N-terminal truncations of Flag-tagged RNF126 were co-expressed with 6XHis tagged AID. AID was purified on a Ni-NTA column, followed by elution with
increasing concentrations of imidazole. The most severe truncation, containing
only the RING finger domain and the C-terminal serine stretch, was sufficient to
interact with AID (Figure 3.5). This data fits well with the observed interaction of
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200
WT 6xHis AID
A (18-58)
B (48-84)
C (88-116)
D (118-132)

B

WCE
WT A

B

C

150 mM Imidazole Fraction
WT A

D

B

C

D

FLAG-RNF126
His-AID (Chimera)

Figure 3.4 Delineation of interaction domain on AID. To define the regions of
AID that interact with RNF126, a set of chimera expression constructs as in
Conticello et al. were made, interspersing regions of the APOBEC family
member, APOBEC2, within AID. Schematics are shown in the figure: the black
line represents APOBEC2 sequence within the AID sequence, shown in grey; in
addition, white boxes indicate the catalytic residues. Co-expression of
Flag-tagged RNF126 and His-tagged APOBEC2/AID chimeras in bacterial cells
followed by purification on a BD Talon Cobalt column demonstrates that whereas
chimeras A, B and D co-purify with RNF126, Chimera C does not. Chimera C
replaces the region of AID spanning residues 88-116 with the comparable region
of APOBEC2. This suggests that this region of AID is the primary site of
interaction between AID and RNF126. Left panel: anti-FLAG and anti-His blots to
demonstrate equivalent expression in whole cell extract of RNF126 and AID
(and its chimeras with Apobec2), respectively. Right panel: the membrane was
first blotted with anti-FLAG to detect RNF126, followed by incubation with
anti-HIS antibody to detect the AID/APOBEC2 chimera proteins.
Co-purification of RNF126-FLAG and 6xHisAID/APOBEC2 was assessed in the
150mM imidazole fraction.
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100

200

300
FLAG-RNF126 (FullLength:1-304)
FLAG-RNF126-T1 (120-304)
FLAG-RNF126-T2 (170-304)
FLAG-RNF126-T3 (200-304)

FL
FLAG-RNF126

T1 T2 T3
24 kDa
18 kDa

FLAG-RNF126

16 kDa
His-AID

His-AID

Figure 3.5 Delineation of interaction domain on RNF126. Truncations of
RNF126 reveal that the RING domain interacts with AID.
Flag-tagged full-length RNF126 (FL) and various truncations of RNF126
(T1, T2, T3 - schematic shown) were co-expressed with His-tagged full-length
AID (gray box-N terminal Zinc finger of RNF126; white box-the RING domain;
black box-the serine tail domain) . Purification of His-AID on a BD Talon cobalt
column (BD Biosciences) reveals that N-terminal truncations of RNF126 are still
able to interact with AID. In addition, the interaction appears stronger as more
of the N-terminus is deleted, which could result because of increased solubility
of some of the truncation constructs. Importantly, the last truncation (200-end),
which contains the RING domain and the serine tail, can interact strongly with
AID. This suggests that AID can interact with isolated RING domains in general.
Indeed, the RING domain of the E3 ligase, Mdm2, can interact with AID in a
yeast-two hybrid screen as well as in our screen; however AID does
not interact with full-length Mdm2.
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the RING domain of the E3 ligase Mdm2 in a yeast-two hybrid screen. Thus, it is
likely that it is also the RING domain of RNF126 that primarily interacts with AID
(MacDuff et al., 2006).
To assure that these two proteins interact in the context of a mammalian
cell, FLAG-tagged AID and Hemagluttin (HA)-tagged RNF126 were expressed in
the mammalian 293T HEK expression system. Purification of either AID or
RNF126 was completed by precipitation with anti-FLAG or anti HA antibodies.
These studies, again, reveal that AID and RNF16 co-precipitate and thus interact
(Figure 3.6). In addition to demonstrating an interaction, these studies also show
that RNF126 and AID reside within the same cellular compartment.
Because AID is primarily expressed in B cells for the purpose of antibody
diversification (Alt et al., 2013; Delker et al., 2009; Teng and Papavasiliou, 2007;
Vuong and Chaudhuri, 2012; Xu et al., 2012), it was important to determine if
RNF126 is expressed in a physiological setting alongside AID. Utilizing both
quantitative RT-PCR and Western blotting, it is clear that RNF126 is expressed in
primary B cells upon stimulation in vitro to undergo CSR (Figure 3.7 A, B). While,
naïve, unstimulated B cells do express RNF126, there appears to be a slight
increase at both the mRNA and protein level upon stimulation. In addition, the
expression of RNF126 is not dependent on the presence of AID or the formation
of AID-mediated breaks in these cells because a similar expression profile is
shown in aicda-/- B cells (Figure 3.7 B).
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Figure 3.6 RNF126 interacts with AID in mammalian cells. RNF126 interacts
with AID in a HEK 293T mammalian system. Flag-tagged AID and HA-tagged
RNF126 were co-expressed. Affinity purification of either tag resulted in the
purification of the binding partner only when both proteins were expressed.
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Figure 3.7 RNF126 is expressed in primary B cells. (A) Expression of RNF126
is induced in switching B cells after stimulation for class-switch recombination
as assessed by qRT-PCR (normalized to CD19 levels). (B) RNF126 protein
levels increase in murine B cells after stimulation to undergo class switch
recombination in an AID-independent manner. Arrow denotes RNF126 band
(Tubulin: loading control). The values beneath the blot denote a quantification
of RNF126 protein levels, normalized to Tubulin.
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3.4 RNF126 ubiquitinates AID
Because RNF126 contains a RING finger domain, a domain commonly
found in E3 ubiquitin ligases, and RNF126 has already been shown to be able to
auto-ubiquitinate in vitro (Burger et al., 2006), it was plausible that RNF126 could
also modify AID in addition to simply interacting. In order to test this, a HEK 293T
ubiquitination assay was developed. In this assay, AID is expressed with and
without co-expression of RNF126 and/or ubiquitin. Upon addition of RNF126, but
not without, AID is ubiquitinated (Figure 3.8). Interestingly, these experiments
exhibited neither a single slow migrating band, representative of a monoubiquitination event, nor a higher molecular weight smear, representative of polyubiquitination events. The pattern of ubiquitination observed, a ladder of
approximately three to four slower migrating bands, could be representative of
either a small poly-ubiquitin chain addition on one residue of AID, or multiplemono-ubiquitination events on different residues of AID. To determine which of
these scenarios is occurring, two mutants of ubiquitin, a Lysine 48 mutation to
Arginine (K48R) and a Lysine 63 mutation to Arginine (K63R) were co-expressed
with AID and RNF126. Poly-ubiquitin chains generated through linkages at lysine
48 are typically found in proteins targeted for degradation by the proteasome;
conversely, poly-ubiquitin chains generated through linkages at lysine 63 are
commonly found on protein components of signaling modules (Pickart, 2001b).
Although other poly-ubiquitin linkages have been seen, K48 and K63 are the
most common. Expression of both K48R and K63R ubiquitin moieties in the 293T
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Figure 3.8 RNF126 ubiquitinates AID in HEK 293T Cells. AID is ubiquitinated
by RNF126 in HEK 293T cells. Co-expression of hAID with HA-tagged RNF126
and Flag-tagged ubiquitin results in the formation of ubiquitylated AID, even in
the presence of K48R/K63R mutant ubiquitin. RIPA extracts were prepared and
AID immunoprecipitated with an anti-AID antibody. An anti-AID and an anti-FLAG
(ubiquitin) blot are shown. The heavy chain band is marked as “HC.”
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assay resulted in a similar three to four band laddering pattern, suggesting that
this laddering pattern is not poly-ubiquitination (at least not of linkages at K48 or
K63), but rather multiple mono-ubiquitination events (Figure 3.8). It has been
shown that increased concentrations of E3 ligase can convert a monoubiquitination event into multiple mono-ubiquitination events (Li et al., 2003).
Because this assay relies on the overexpression of RNF126 in the 293T system,
it is possible that the laddering pattern observed is due to increased levels of
RNF126 over what would be physiological levels of the protein.
To overcome this problem, an in vitro ubiquitination assay was developed
and optimized using purified recombinant RNF126 and AID, as well as other
necessary components of the ubiquitination cascade. Because UbcH5b was
already identified as a compatible E2 ubiquitin conjugating enzyme for RNF126
(Burger et al., 2006), this E2 enzyme was chosen for these in vitro assays.
Further experiments confirmed that only UbcH5b and Ubch5C, although to a
lesser extent, are able to support in vitro ubiquitination of AID by RNF126;
however, other E2s tested were not (Figure 3.9).
Just as in the 293T ubiquitination assays, ubiquitination of AID occurred in
an RNF126-dependent fashion; furthermore, the addition of ubiquitin is
dependent on all other components of the ubiquitination cascade, including Ube1
(E1), UbcH5b (E2), ubiquitin and energy (ATP) (Figure 3.10 A). While it was
possible to detect a slight laddering of AID upon ubiquitination, the band
representative of the addition of a single ubiquitin moiety to AID appears more
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Figure 3.9 UbcH5b and UbcH5c support ubiquitination of AID. UbcH5b and,
to a lesser extent, the highly related UbcH5c are able to support in vitro
ubiquitination of AID by RNF126. A panel of human E2 enzymes is tested in the
in vitro ubiquitination assay. An anti-AID immunoblot is shown; unmodified and
Ub-AID are marked with asterices. The asterix used to mark UbcH5a,b,c denotes
catalytically inactive forms of the enzyme.
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Figure 3.10 RNF126 mono-ubiquitinates AID in vitro. AID is ubiquitinated by
RNF126 in vitro. Purified components of the ubiquitin reaction are incubated at
37°C. (A) All components are necessary for ubiquitylation to occur (lane 1).The
absence of individual components (lane 2-7) prevents ubiquitylation. (B) RNF126
mono-ubiquitylates AID. Addition of a mutant ubiquitin in which all lysines are
mutated to arginine (K0 Ub) shows that the laddering is representative of
multiple mono-ubiquitylation events. anti-AID immunoblots are shown.
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intense than even higher migrating bands, suggesting one main monoubiquitination event with the possibility of additional ubiquitination events on the
same AID molecule. To confirm this, in vitro ubiquitination assays were
performed using a mutant form of ubiquitin in which all seven lysines are mutated
to arginine (K0). This mutant is unable to form poly-ubiquitin chains. The same
slight laddering pattern of AID ubiquitination was observed using K0 ubiquitin as
compared to wildtype, thus confirming that RNF126 mono-ubiquitinates AID
(Figure 3.10 B).
Because the RING domain of E3 ligases is essential for substrate
ubiquitination and because it has already been established that the RING domain
of RNF126 interacts with AID, it was important to determine if mutation of the
RING Domain resulted in a loss of ubiquitination. A mutant version of RNF126
(RNF126*), which contained mutations at two of the zinc-coordinating cysteines
in the RING domain (C229A/C232A), was tested in the 293T ubiquitination
assay. Unlike wildtype RNF126, RNF126* was unable to ubiquitinate AID,
providing direct evidence for the necessity of the RING domain (Figure 3.11).
Though ubiquitination most commonly occurs on lysine residues,
ubiquitination has also been observed on serine, threonine and cysteine residues
(Cadwell and Coscoy, 2005; Wang et al., 2007). To determine the residue on AID
that is ubiquitinated by RNF126, lysine to arginine mutants of AID were subjected
to the 293T ubiquitination assay. Single lysine to arginine mutants, as well as
grouped lysine to arginine mutants, were still able to be ubiquitinated (Figure 3.12
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Figure 3.11 The RING domain of RNF126 is necessary for AID
ubiquitination. Mutations in the RING domain of RNF126 abrogate the ability
to modify AID. Mutant RNF126 (RNF126*), which contains cysteine to alanine
mutations at the first two zinc-coordinating cysteines in the RING domain of
RNF126 (C229A and C232A ) is catalytically inactive. HA tagged wildtype
RNF126 or RNF126* are co-expressed in 293T cells with Flag-AID.
Wildtype RNF126 is able to induce ubiquitylation of AID (lane 2),
but RNF126* is not (lanes 3). Expression of Flag-AID without exogenous ligase
is shown as a control (lane 1). The top panel shows an αAID western blot of an
αFLAG IP. The bottom three panels show levels of Flag-AID (αAID),
HA-RNF126/RNF126* (αHA) and tubulin (αTubulin) in the input/whole cell
extract. The heavy chain band from the antibody used in the IP is denoted
as “HC.”
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A). However, mutation of all lysines to arginine (AID K0) resulted in a loss of
ubiquitination (Figure 3.12 A), suggesting that a lysine residue is ubiquitinated.
However, reconstitution of aicda-/- B cells with AID K0 could not rescue CSR
(Figure 3.12 B). Thus, it cannot be ruled out that structural changes to the protein
are the cause of the loss of ubiquitination. In addition, mass spectrometric
analysis of in vitro ubiquitinated AID was attempted; however, due to limited
material, full coverage of the protein was not achieved and the ubiquitination site
not identified.
3.5 RNF126 displays specificity toward AID
Thus far it has been established that (1) RNF126 can interact with AID,
and (2) RNF126 can act as an E3 ligase to modify AID. To become more certain
that these events were not non-specific, it was important to establish that
RNF126 possesses specificity for AID as a substrate. To determine this, the
ability of RNF126 to ubiquitinate AID was first compared to two other ligases
expressed in B cells, RNF8 and BCA2.
RNF8 has been shown to play a distinct role in mediating the recruitment
of protein factors necessary for double-strand break repair during class-switch
recombination (Ramachandran et al., 2010). To assess the ability of RNF8 to
modify AID, these factors were co-expressed in the HEK 293T ubiquitination
assay. While co-expression of RNF126 with AID in 293T cells results in the
ubiquitination of AID, co-expression of RNF8 and AID in this setting does not
(Figure 3.13 A, left panel). This finding was confirmed using the in vitro
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Figure 3.12 Lysineless AID is not ubiquitinated by RNF126. (A) Mutant forms
of AID containing clusters of lysine-to-arginine mutations were subjected to the
293T ubiquitination assay. Only mutation of all lysines on AID to arginine (AID K0)
resulted in a loss of RNF126-mediated ubiquitination. An anti-AID IP and
immunoblot are shown. The unmodified AID band, as well as the ubiquitinated
form are shown. Lane 1 contains a “No AID control.” “HC” denotes the heavy
chain of the antibody used for immunoprecipitation. (B) aicda-/- B cells were virally
transduced with either empty vector, wildtype AID or AID K0 and assayed for CSR.
While wildtype AID rescued CSR (middle panel), AID K0 did not (right panel).
Representative FACS plots are shown. Y axis = surface IgG1, X axis = Forward
Scatter.
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Figure 3.13 RNF126 selectively ubiquitinates AID when compared to RNF8.
(A) 293T cells were transfected with Flag-AID, alone or with HA-RNF126 or
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ligases (right panel). Co-expression of RNF126, but not RNF8, results in AID
ubiquitylation. Ubiquitylation of PCNA occurs upon co-expression of RNF8 (lane 3),
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components except the substrate and Lane 2 only excludes the E3 ligase. .
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ubiquitination assay, in which it was clear that mono-ubiquitination of AID
required RNF126 (Figure 3.13 B).
RNF126 shows incredibly high homology to another RING domain
containing E3 ligase, BCA2. BCA2 shows 46% identity to RNF126 in overall
amino acid content and 75% homology within the RING domain, lacking only the
serine tail, which is unique to RNF126 (Burger et al., 2006) (Figure 3.14 A).
Further, it is the RING domain of RNF126 that has been shown to bind AID
(Figure 3.5). Thus, comparison of RNF126 with BCA2 in their ability to
ubiquitinate AID provided a good test for the specificity of RNF126. In addition,
BCA2 is expressed in B cells during CSR, providing physiological relevance
(RNA-Seq data from (Fritz et al., 2013)). Despite the similarities between these
two proteins, co-expression of BCA2 with AID in HEK 293T cells does not lead to
AID ubiquitination (Figure 3.14 B). Again, this provides evidence for the
specificity of the RNF126-AID interaction and modification.
In addition to these studies, which compare RNF126 to other E3 ligases, it
was also important to test the ability of RNF126 to ubiquitinate alternate
substrates. Though it is fairly common for ligases to ubiquitinate multiple
substrates in different cellular contexts (Mailand et al., 2007; Zhang et al., 2008),
it was still interesting to determine if RNF126 could ubiquitinate other proteins
that are involved in CSR/SHM. One such substrate is Proliferating Cell Nuclear
Antigen (PCNA), a homo-trimeric ring that encircles DNA and is necessary for
DNA replication and repair in the context of AID mediated reactions (Langerak et
al., 2009; Roa et al., 2008). Specifically, mono-ubiquitination of PCNA at lysine
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164 (K164) is believed to recruit the error-prone DNA polymerase, Pol η,
resulting in the accumulation of mutations at non-C:G base pairs within the
variable region and switch regions of the immunoglobulin locus (Faili et al.,
2004). Mono-ubiquitination of PCNA has been shown to be carried out by two
different E2/E3 ubiquitin conjugating enzyme/ligase pairs: Rad6/Rad18 (Hibbert
et al., 2011; Hoege et al., 2002) and UbcH5c/RNF8 (Zhang et al., 2008).
However, additional enzymes are thought to allow for residual monoubiquitination even in the absence of these canonical modifying complexes. The
ability of RNF8 and RNF126 containing complexes to ubiquitinate PCNA was
determined in both the 293T ubiquitination assay, as well as the in vitro assay. In
both assays it was clear that RNF8 had activity toward PCNA, but RNF126 was
completely inactive (Figure 3.13 A, B).
Though every possible candidate substrate for RNF126, or conversely,
every possible candidate ubiquitin ligase for AID, was not tested, these
experiments establish that (1) RNF126 shows specificity for AID when presented
with a substrate known to be present at the immunoglobulin locus during CSR
and SHM and (2) that two other ligases, one of which has been demonstrated to
be present at the immunoglobulin locus (RNF8) and one which is expressed in
switching B cells and shows high homology to RNF126 (BCA2) cannot
ubiquitinate AID.
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CHAPTER 4: GENERATION AND CHARACTERIZATION OF AN RNF126
CONDITIONAL KNOCKOUT MOUSE MODEL SYSTEM
4.1 Motivation
A number of screening methods have been undertaken to show that AID
interacts with a variety of cellular proteins, suggesting the involvement of several
universal cellular processes in AID-mediated reactions. However, for many of
these factors mechanistic details are still lacking. Often the AID cofactors
identified are essential cellular proteins. This makes it difficult to generate knockout models due to lethality as well as produces complicated phenotypes because
of the existence of multiple cellular roles for a given factor. Thus, most findings
have relied on shRNA knock-down studies and/or mutation of the empiricallydetermined binding interface. In addition, a variety of model systems have been
utilized for these studies, including DT40 chicken B cells, the murine B cell
lymphoma line, CH12s, and primary B cells in vitro and in vivo. Each of these
contexts studies a slightly different AID-dependent mechanism and thus may
utilize a different set of AID cofactors.
Having already established that the E3 Ubiquitin Ligase, RNF126, is able
to interact with and mono-ubiquitinate AID (Delker et al., 2012), the role of
RNF126 and RNF126-mediated ubiquitination in antibody diversification
remained to be examined. Because of the difficulties associated with analyzing
the importance of putative AID cofactors, the generation of an RNF126
conditional knockout mouse model was undertaken in order to provide the most
thorough analysis of the role of RNF126 during antibody diversification. Through
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the generation of a B-cell specific knockout, the role of RNF126 during SHM,
CSR and affinity maturation could be assessed.
4.2 Generation of an RNF126 conditional knockout mouse model
Because rnf126 is a relatively uncharacterized gene, it was unclear
whether a full knockout would result in embryonic lethality. For this reason,
generation of a conditional knockout mouse model, taking advantage of the Cre
Recombinase system, proved to be the most prudent approach (SchmidtSupprian and Rajewsky, 2007). The rnf126 locus on chromosome 10 was
targeted with a knock-out first construct, which contains a gene-trap cassette
within intron 1, terminating translation after exon 1 when the full construct is
present. Conditional knock-out potential can be restored by taking advantage of
the FRT, or Flipase Recombinase sites, that flank the gene-trap cassette. In the
absence of the gene-trap and drug resistant cassettes within intron 1, deletion of
exons 2-8, and thus generation of a knock-out allele, is made possible by the
presence of two LoxP sites which flank exons 2-8, the bulk of the coding region
of the gene (Figure 4.1). A more thorough presentation of the strategy used to
both generate and genotype the RNF126 conditional knockout mouse is
presented in Figure 4.2
Targeted ES cells were derived from a C57BL/6N background, but with an
agouti coat color, thus enabling detection of high chimerism by mosaic coat color
while preserving the C57BL/6 background even in the F1 progeny. Breedings
between several chimeric mice and C57BL/6 wildtype mice produced one
offspring in which transmission of the targeted construct was detected both by
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Figure 4.1 Schematic of targeting construct and resultant allele. The
endogenous allele, targeting vector, targeted allele and knockout allele are shown.
RNF126 contains 9 exons, of which exons 2-8 are flanked by LoxP sites. In
addition, a gene-trap construct has been inserted within intron 1, which, when
present, prevents translation through the locus thereby creating a knock-out allele.
The gene-trap construct is flanked by FRT recombination sites and was deleted
by breeding mice transgenically expressing the Flipase recombinase
(see Floxed and Flipped allele). B-cell specific conditional knockouts were
obtained by breeding mice containing the Floxed (and Flipped) allele with mice
expressing the recombinase CRE from the mb-1 locus. SspI sites used for
genomic DNA digestion and expected band sizes for the endogenous allele and
targeted allele are shown. In addition, primers used for PCR genotyping the
locus are shown as green and red arrows.
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Figure 4.2 Detailed schematic of RNF126 locus and genotyping primers.
(A) Genotyping of the targeted knock-out first allele. Prior to breeding to mice
expressing Flipase, mice containing the knock-out first allele were genotyped with
the R2-F/Endo-R primer set, yielding a 213bp product that is not produced from
the endogenous allele. (B) Differentiation of the endogenous allele from the Floxed
allele is obtained using the primer set Endo-F/Endo-R. Identification of deletion of
exons 2-8 by CRE-induced recombination is determined using the primer set
Endo-F/RP-R. (C) A table denoting genotyping primer sets used and the expected
amplicon for each RNF126 allele.

100

coat color and southern blotting (Figure 4.3A). Deletion of the gene-trap cassette
was accomplished by crossing mice containing at least one rnf126-targeted allele
with Flipase expressing mice. Subsequently, the Flipase transgene was crossed
out, leaving the final targeted allele (abbreviated “Fl”), which has knock-out
potential when crossed with a Cre-expressing strain (Figure 4.3B). Lastly,
attempts to breed mice containing one or two targeted alleles with intact gene
trap constructs suggest that deficiency in RNF126 results in either insufficiencies
in reproduction and/or embryonic lethality as mice containing targeted alleles
were born at much lower frequencies than expected. Further, deceased pups
found from breedings were enriched for mice containing homozygous targeted
alleles (Figure 4.4).
4.3 Validation of the RNF126 conditional knockout mouse model.
In order to generate a B-cell specific rnf126-/- conditional knock-out, the
established mb1-Cre strain of mice, which contains a humanized Cre gene
knocked into the mb1 locus, was used (Hobeika et al., 2006). The mb1 gene
encodes the Igα subunit of the B cell receptor and is expressed at the pro-B cell
stage of B cell development. Thus, Cre expression is upregulated, and the floxed
gene of interest deleted, in the earliest stage of B cell development.
To validate that the construct functions as it should, experiments were
conducted at the DNA, RNA and protein level to confirm that deletion of rnf126
was occurring in the B cells of mice with the genotype RNF126Fl/Flmb1Cre/+.
Importantly, PCR genotyping of genomic DNA derived from the tail reveals an
intact locus, whereas genotyping of genomic DNA from splenic B cells from the
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same mouse reveals the expected deletion (Figure 4.5A). Thus, despite the
presence of the Cre gene throughout the mouse, expression is limited to the Bcell subset. In some cases it appeared as if Cre expression was leaky and
deletion occurred in a subset of cells derived from tail. When mice that contained
leaky Cre expression were used in experiments, it was noted; however, no
differences were observed between B-cells derived from these mice as
compared to non-leaky Cre expressing mice.
In addition, it has been verified that deletion of exons 2-8 of the rnf126
gene in B cells results in loss of gene expression, which can be shown both at
the level of mRNA (Figure 4.5B) and protein (Figure 4.5C).
4.4 Analysis of RNF126 conditional knockout mice
4.4.1 B Cell Development is unaffected by the loss of RNF126
Because the recombinase Cre was expressed from the mb-1 locus, thus
deleting the rnf126 gene at the Pro-B cell stage (Hobeika et al., 2006), it
remained a possibility that B cell development would be affected by the loss of
RNF126. To assess this, flow cytometry was used to characterize the relative
levels of Pro-, Pre- and Immature B cells in the bone marrow of RNF126Fl/Fl
mb1+/+ and RNF126Fl/Fl mb1Cre/+ mice. RNF126Fl/Fl mb1Cre/+ mice, when compared
to both unrelated C57Bl/6 wildtype mice and RNF126Fl/Fl mb1+/+ mice, had
comparable levels of each B-cell subset and thus displayed no observable defect
in B cell development (Figure 4.6 A), In addition, the proportion of mature
IgM/IgD double positive B cells in the spleen of these mice was assayed and,
again, no defect was observed in the RNF126Fl/Fl mb1Cre/+ mice as compared to
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wildtype mice (Figure 4.6 B). Thus, normal B cell development is maintained in
the absence of RNF126.
4.4.2 Genetic deletion of RNF126 results in a slight reduction of CSR in
vitro
As AID is the key component of antibody diversification and loss of AID
results in complete abrogation of antibody diversification in mature B cells, it was
of great interest to determine if deletion of RNF126 also affected CSR. Thus,
experiments were conducted in order to determine if primary B cells derived from
RNF126Fl/Fl mb1Cre/+ mice displayed compromised levels of CSR. Splenic B cells
derived from RNF126Fl/Fl mb1Cre/+ and RNF126Fl/Fl mb1+/+ mice were stimulated in
vitro with IL-4/αCD-40 to induce a switch from the IgM isotype to that of IgG1.
Levels of CSR were measured by flow-cytometry and reported as the percentage
of B cells, which express surface-bound IgG1. While RNF126-deficient B cells
are able to undergo CSR, they do so at a slightly reduced efficiency, both when
CSR levels are measured at 72hr and 96hr post-stimulation (Figure 4.7). In
response to these stimuli, RNF126-deficient B cells displayed a slight delay in
proliferation, which may account for the subtle defects observed in CSR, as it is
known that CSR is dependent on progression through the cell cycle (Figure 4.8).
4.4.3 Loss of RNF126 results in a subtle defect in Affinity Maturation in
response to NP-CGG
In addition to affecting CSR, mis-regulation of AID can also result in
aberrant SHM and affinity maturation. In fact, it is entirely possible that there
exists a different subset of AID cofactors for each of these processes, thus
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Figure 4.8 RNF126 knockout B cells exhibit a slight delay in cell
proliferation. RNF126Fl/Fl B cells were purified from 1 RNF126Fl/Fl mb1+/+
mouse and RNF126Fl/Fl mb1cre/+ B cells were purified from 2
RNF126FL/Fl mb1Cre/+ mice (labeled 1 and 2). Cells were loaded with CFSE
as described in Materials and Methods and stimulated in vitro with IL-4 and
anti-CD40. FACS plots show switch rates to IgG1 relative to cell division
(CFSE) and histograms overlay CFSE profiles of each genotype. Analysis was
completed at (A) 72hr, (B) 96hr and (C) 120hr post-stimulation.
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contributing to the difference in outcomes. At present, and for unknown reasons,
SHM in B cells cannot be assayed in vitro. Thus, to determine if loss of RNF126
results in a defect in SHM and Affinity Maturation, an in vivo immunization model
was used. The established and well-studied nitro-phenol (NP) immunization
model was chosen.
To assay affinity maturation, or the increase in antibody affinity to a given
antigen as a result of somatic hypermutation and B cell-selection in the germinal
center, animals were immunized with NP16-CGG and serum was collected to
assess titers of NP-specific IgG1 antibodies. Affinity to NP conjugated to BSA in
a ratio of 30 (NP30-BSA) was used as a measure of total NP-specific IgG1
antibodies and in a ratio of 3 (NP3-BSA) as a measure of high affinity NP-specific
antibodies. Affinity maturation was then calculated as the ratio of high affinity to
total NP-specific antibodies (NP3/NP30). As expected, there was an increase in
titers of total and high affinity NP-specific antibodies as time progressed postimmunization; this increase occurred in both the RNF126Fl/Fl mb1+/+ and
RNF126Fl/Fl mb1Cre/+ mice, however a significant defect was observed in the
production of high affinity anti-NP antibodies in RNF126Fl/Fl mb1Cre/+ mice (Figure
4.9, (representative of Cohort 2--refer to Figure 4.11)). In total, 28 mice have
been immunized and peripheral blood collected at day 21 post-immunization.
NP3/NP30 ratios have been measured in these mice and show that loss of
RNF126 results in a subtle, but consistent, defect in affinity maturation (Figure
4.10).
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Figure 4.9 Loss of RNF126 hinders production of high affinity antibodies.
Titers of NP3-binding IgG1 and NP30-binding IgG1 were determined by ELISA
for cohort 2, which contained 4 RNF126FL/FL mb1+/+ and 4
RNF126Fl/Fl mb1Cre/+ mice at D7, D14 and D21 post-immunization.
NP-specific IgG1 levels were normalized to total serum IgG1. Error bars denote
standard deviation. P-values, determined by the unpaired student’s t-test, are
shown.
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Figure 4.10 RNF126-deficient B cells display a defect in affinity maturation.
NP3/NP30 ratios at D21 post-immunization, or a measure of affinity maturation,
are shown for each mouse within each genotype (X-axis) and cohort
(color coordinated). A decrease in affinity maturation occurs in mice with
RNF126-deficient B cells, with a p-value of .0625 (unpaired student’s t-test).
The bars denote the average NP3/NP30 ratio and the standard deviation.
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In addition, Figure 4.11 presents the relative titers of (1) high affinity NPspecific antibodies and (2) total NP-specific antibodies measured at D21 postimmunization in the three cohorts of mice immunized. As can be seen, the overall
immune response in Cohort 3 does not appear to be as robust as Cohort 1 and
2. For completeness, though, this data is still included in the affinity maturation
analysis. It is possible, though, that the inclusion of Cohort 3 has skewed the
significance of difference in affinity maturation between wildtype and RNF126
conditional knock-out mice and should be taken into consideration. Affinity
maturation measurements shown in Figure 4.10 are color-coded based on cohort
number and, as can be seen, a much greater defect is observed in the first two
cohorts.
Thus, while RNF126 does not appear to be essential for either CSR and
affinity maturation, genetic loss of RNF126 does result in subtle defects in both
processes. This suggests that RNF126 plays a role in fine-tuning the reactions.
4.4.4 Loss of RNF126 results in altered mutation patterns during Somatic
Hypermutation
Another benefit to using the NP-immunization model is that NP induces a
characteristic immune response, allowing one to sequence the variable region of
the immunoglobulin gene and assess mutation rates and patterns. Due to high
germline affinity for NP, B cells which have produced a V(D)J rearrangement
containing the V186.2 V region and the JH2 J region are selected for postimmunization. Thus, primers specific for these two regions can be used to
sequence for mutations within the variable region.
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Figure 4.11 Complete presentation of antibody titers in three cohorts of
mice. A total of 28 mice, within 3 cohorts, were immunized with NP-CGG as
described in Materials and Methods. Cohort 1 and 2 each contained 4
RNF126FL/FL mb1+/+ and 4 RNF126Fl/Fl mb1Cre/+, and Cohort 3 contained
6 RNF126FL/FL mb1+/+ and 6 RNF126Fl/Fl mb1Cre/+. Average titers of
NP3-binding IgG1 (left panel, high affinity) and of NP30-binding IgG1
(right panel, total) at day 21 post-immunization in control (black) and
RNF126-deleted mice (gray) for cohorts 1-3 are shown. The asterisk denotes
that the decrease in relative NP3-binding IgG1 levels in the RNF126-deleted
mice of cohort 2 compared to wildtype is statistically significant
(p=.046, determined by unpaired student’s t-test). Error bars denote the standard
deviation.
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To investigate whether RNF126 is necessary for somatic hypermutation in
vivo, two RNF126Fl/Fl mb1+/+ and three RNF126Fl/Fl mb1Cre/+ mice were immunized
intraperitineally with nitro-phenol conjugated to chicken gamma globulin (NP16CGG). Mice were sacrificed 14 days post-immunization, germinal center B cells
FACs-sorted using the cell-surface markers FAS, GL7 and CD19 and genomic
DNA prepared. Somatic mutations were assessed in three regions of the
immunoglobulin heavy chain gene: (1) the rearranged V186.2 variable region, the
dominant form of antibody selected for in response to NP, (2) the un-rearranged
JH4 intronic region downstream of the rearranged variable region, and (3) the
region upstream of the V186.2 variable exon and downstream of the promoter
region (schematic presented in Figure 4.12). Mutations found within each of
these regions can be informative. First, because the V186.2 exonic region
encodes for the majority of the antigen-binding domain of the antibody, mutations
found here are under selection pressure to improve affinity. In contrast, mutations
located downstream of the rearranged variable region in the JH4 intron, which
are not informative of the antibody produced, represent those mutations that are
not under selection pressure. Thus, analysis of these mutations can be more
informative of AID activity and repair pathways utilized because selection has not
occurred to erase the mark of those mutations. Lastly, the third region, termed
the V186.2 Upstream Region, was sequenced to assess the existence of any
alterations in the spatial location of mutations relative to the promoter, where AID
is thought to be loaded along with RNAP II (Peters and Storb, 1996) and induce
mutation upon RNAP II stalling (Pavri et al., 2010). Differences in the pattern of
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mutations found in this region could be informative of the presence of defects in
AID complex formation at the Ig locus. Analysis of SHM in RNF126Fl/Fl mb1+/+ and
RNF126Fl/Fl mb1Cre/+ mice is broken down into the regions described. A summary
of the data obtained from the three regions is shown in Figure 4.12.
A. V186.2 Exon
Because this region codes for the portions of the antibody that come into
direct contact with antigen, mutations here have the most impact on affinity.
Thus, an analysis of mutations in this region should correlate with an analysis of
affinity maturation. A defect in the generation of high affinity antibodies, and thus
affinity maturation, was detected in RNF126Fl/Fl mb1Cre/+ mice (Figure 4.9 and
4.10). Intuitively, then, it would be expected that the loss in affinity maturation is
due to a decrease in mutation within this region. Unexpectedly, this was not what
was found. As a note, for all analyses presented unique mutation frequencies
were calculated. This is a more conservative approach because it not only
excludes PCR duplicates (where the entire sequence is the same), but also
excludes duplicate mutations at the same base in the same mouse. These
duplicates could represent bona fide AID-mutations, but more likely represent a
mutation that was carried through to an additional round of mutagenesis. Thus,
this one mutation appears in multiple sequences derived from clonally divided B
cells. Unique mutation frequencies in the V186.2 exonic region were not
significantly different in RNF126Fl/Fl mb1Cre/+ mice as compared to RNF126Fl/Fl
mb1+/+ mice (Figure 4.12). Thus, loss of RNF126 does not inhibit the introduction
of mutations by AID.
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Figure 4.12 Overview of somatic hypermutation analysis in immunized mice.
(A) Schematic of regions used for mutation analysis. Regions were cloned from
genomic DNA prepared from germinal center B cells from 14-day immunized
mice (rnf126Fl/Fl mb1+/+ and rnf126Fl/Fl mb1Cre/+). Primers used to amplify
each region are shown: US-F/R were used to amplify the 295bp V186.2 upstream
region, which spans from the promoter to Intron 1 of the recombined antibody
gene, Exon-F/R were used to amplify the 351bp V186.2 exonic region, which
makes up the bulk of the antigen binding domain of the translated antibody and
JH4-F/R were used to amplify the 357bp JH4 intronic region, beginning at the
exon/intron junction. (B) Detailed representation of mutation analysis. A table is
used to describe the following information for each genotype and region
sequenced: (1) the total number of sequences analyzed, (2) the number of
mutated sequences as an absolute number and a percent of total sequences,
(3) the number of unique and total mutations, and (4) the unique mutation
frequency and (5) the non-unique mutation frequency, each with its
corresponding p-value, as calculated by the chi-squared test. The number of mice
of each genotype used is stated (N=2 for rnf126Fl/Fl mb1+/+ and N=3 for
rnf126Fl/Flmb1Cre/+).
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This data, though, leaves open the question of why affinity maturation is
defective in RNF126 conditional knockout mice. This inconsistency can be
explained in a few different ways. First, it is known that particular mutations
(Tryptophan 33 to Leucine (W33L)) contribute greatly to NP-affinity. Thus, a
decrease in this mutation could explain defective affinity maturation. In addition, it
has been observed before that the introduction of additional mutations in the
region either by overactive AID or AID that persists post-germinal center can also
be detrimental to affinity (Teng et al., 2008). Analysis of V186.2 sequences from
RNF126Fl/Fl mb1Cre/+ and RNF126Fl/Fl mb1+/+ mice revealed that, while there were
no differences in the prevalence of the W33L mutation, there was a shift toward a
larger number of mutations present per sequence/B-cell in the RNF126
conditional knockout mice (Figure 4.13). In fact, an analysis of the non-unique
mutation frequency reveals that RNF126 conditional knockout mice exhibit a
greater number of mutations than their wildtype counterparts (Figure 4.12).
These additional mutations could account for the loss of affinity for immunogen.
Further experiments will be necessary to determine the mechanism of how
RNF126 limits AID mutation in the context of the V186.2 exon.
B. JH4 Intron
As mentioned, the JH4 intron lies downstream of the rearranged variable
region. Thus, it does not encode for antibody and mutations here can be used to
assess the mutagenic load in the absence of germinal-center selection. Just as
was seen in the V186.2 exonic region, unique mutation frequencies in the JH4
intron from RNF126Fl/Fl mb1Cre/+ and RNF126Fl/Fl mb1+/+ mice were not
118

0.8

Fl/Fl

+/+

RNF126

mb1

RNF126

mb1

Fl/Fl

0.6

Cre/+

0.4
0.2

Ty
r

g
Ar

u
Le

Tr

Ph
e

0.0

p

Fraction of Unique Clones

A

Amino Acid at Position 33

Percent of Unique Clones

B

Fl/Fl

20

RNF126

15

RNF126

Fl/Fl

10

+/+

mb1

Cre/+

mb1

p = .0018**

5
0

1 2 3 4 5 6 7 8 9 1011 1213 14 15 16 17 18 19 20 21

# Mutations (per Sequence)

Figure 4.13 Loss of RNF126 results in altered mutation patterns in the
V186.2 exon. (A) An analysis of the types of mutations at residue 33 (W33)
reveals that there is no significant decrease in the known high-affinity mutation
W33 to L33 in RNF126 conditional knockout mice. The fraction of sequences
mutated to other amino acids is also shown. (B) An analysis of the number of
mutations per clone reveals that sequences derived from RNF126-deficient
B cells contain more mutations than those derived from wildtype B cells. This
difference is significant (p = .0018), as determined by the Mann-Whitney test. In
both analyses, unique sequences were used so as to avoid PCR duplicates.
Wildtype data is presented in black and RNF126 conditional knockout data
presented in red.
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significantly different (Figure 4.12). Again, it is not likely that RNF126 affects the
mutagenic activity of AID. In line with this, there does not appear to be a
significant difference in the number of mutations per sequence in the JH4 region
(Figure 4.14).
Despite the lack of difference in total mutation frequency, it is particularly
evident in this region that the pattern of mutation in RNF126Fl/Fl mb1Cre/+ mice is
different from that of RNF126Fl/Fl mb1+/+ mice. It has been well-established that
mutations at C:G basepairs are not strand biased—that is, cytosine bases on the
template (T) strand are just as likely as cytosine bases on the exposed nontemplate (NT) strand to be targeted by AID and mutated. In contrast, mutations at
A:T basepairs do show a strand bias. Adenine bases on the NT strand are
mutated more frequently than the T strand. This has been explained by the
greater accessibility of the error-prone repair pathways, including Pol η, to the NT
strand.
As expected, analysis of JH4 sequences from RNF126Fl/Fl mb1+/+ mice
exhibited strand bias in A:T mutations, but not C:G mutations (Figure 4.15).
Strikingly, however, an analysis of strand bias in JH4 sequences derived from
RNF126 conditional knockout mice revealed a gain in bias toward the T strand in
mutations at C:G bases and a loss of bias at A:T mutations (Figure 4.15). These
results suggest that, in the absence of RNF126, there is enhanced access for
either AID or error-prone repair proteins to the T strand. In vitro transcription and
deamination studies would be useful to determine if the presence of RNF126
inhibits AID access to the T strand, or if these results are better explained by the
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Figure 4.14 Summary of JH4 mutations. A. Pie charts show the fraction of total
sequences that contain between 0 and 9 mutations for rnf126Fl/Fl mb1+/+ and
rnf126Fl/Fl mb1Cre/+ mice. B. A table depicts the percentage of mutations from
each base in the sequence (vertical) to each possible base (horizontal). Values
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T). Wildtype data is presented on the left and RNF126 conditional knockout data
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and increase (green) in mutation rates in the RNF126 conditional knockout,
respectively.
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Figure 4.15 Loss of RNF126 results in an increase in template strand
mutations in the JH4 intronic region. (A) The fraction of total G/C mutations
that occur at NT-strand G bases (or C bases on T strand, black) and NT-strand
C bases (blue) is presented for wildtype and RNF126 conditional knockout mice.
Dotted lines represent expected number of mutations at G and C respsectively,
assuming that there is no strand bias. As previously shown, wildtype mice exhibit
no strand bias in G/C mutations (p value = .45, chi-squared test); however,
RNF126 condtional knockout mice display a bias toward mutation at the template
strand (G>C, p value = .0026, chi-squared test). (B) A similar analysis is presented
for mutations at A:T basepairs. It has been observed that there is a strand bias
toward greater mutations at A bases on the NT strand as compared to template
strand. Accordingly, wildtype mice in this experiment exhibit the expected strand
bias, with more mutations occurring at A bases rather than T bases on the NT
strand (p value = < .0001, chi-squared test). A/T mutations in RNF126 conditional
knockout mice show a loss of this strand bias, with an increase in A mutations on
the T strand (p value = .0538, chi-squared test). Chi-squared tests are performed
on actual mutation load versus expected mutation load assuming no strand bias.
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differential recruitment of error-prone repair at the T strand. It should be noted
that this alteration in strand-bias is not seen in the other two regions analyzed;
however, this could be explained by the fact that this pattern is lost from the
V186.2 exon due to multiple rounds of selection and cannot be detected in the
V186.2 US region because of the scarcity of mutations.
C. V186.2 Upstream (US) Region
From 116 US sequences from RNF126Fl/Fl mb1+/+ and 163 US sequences
from RNF126Fl/Fl mb1Cre/+ mice, there appeared to be no clear difference in either
the total mutation frequency or the spatial distribution of mutations throughout the
region (Figure 4.12 and 4.16). Thus, it does not appear that loss of RNF126
affects the loading of AID on the transcription complex. In addition, the majority of
sequences from mice of both genotypes contained no mutations, reinforcing the
observation that AID-mediated mutation occurs approximately 100 nucleotides
downstream of the promoter (Figure 4.17).
Further, there appears to be no difference in the spatial distribution of
mutations between RNF126Fl/Fl mb1+/+ and RNF126Fl/Fl mb1Cre/+	
  as assessed
within the V186.2 exon and JH4 intronic region (Figure 4.16), again illustrating
that RNF126 does not contribute to the spatial localization of AID-mediated
mutation during SHM.
4.5 Knockdown of RNF126 results in a significant decrease in CSR
Because the process of generating a knockout mouse model is arduous,
gene knock-down studies, which hijack the cellular RNAi machinery to inhibit
translation of a target gene, are often the first step in studying the role of a
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Figure 4.16 The spatial distribution of mutations is unaffected in RNF126
conditional knockout mice. Using SHMTool (Maccarthy et. al., 2009), plots were
generated depicting the frequency of mutation at each base sequenced within the
three regions analyzed. Each base is represented along the X axis, from 5’ (left)
to 3’ (right). The Y axis depicts the fraction of sequences mutated at each base,
including all mutations (non-unique). RNF126FL/FL mb1+/+ data is presented in
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particular gene. The inefficiencies involved in infecting primary B cells, coupled
with the short time-frame of CSR experiment (3-5 days) make RNA knock-down
studies difficult to conduct in primary B cells. For this reason, the CH12 cell line,
which can be induced to switch from IgM to IgA at high rates, can be used. As
expected, shRNA knock-down of AID in CH12 cells results in an almost complete
loss of CSR (Figure 4.18). Similarly, shRNA knock-down of RNF126 using three
different hairpins that target either the 3’UTR or the coding region of the
transcript show a significant decrease in the level of CSR (Figure 4.18). This
loss in CSR is accompanied by a loss in RNF126 at the protein level (Figure
4.18).
Though there is a slight defect in CSR upon genetic deletion of RNF126
from B cells, it is nowhere near the defect seen in the knock-down studies in
CH12 cells. There are several possible explanations for this. First, shRNA knockdown of target genes is notoriously non-specific, especially in mammalian cells. It
is common that hairpins targeted against one gene result in a change in gene
expression profiles of many genes (Kaelin, 2012). For this reason, multiple
hairpins against RNF126 were tested. Second, CH12 cells are an immortal cell
line that contains many chromosomal abnormalities. Thus, it is possible, but
unlikely, that the mechanism of CSR is different in these cells as compared to
primary B cells. And third, the process of gene knock-down in CH12s, which is
representative of the mature B cell state is different than a genetic knock-out in B
cells at an earlier stage of development. As mentioned, mb-1 Cre is expressed
at the Pro-B cell stage and thus RNF126 is knocked-out at the earliest stage of B
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Figure 4.18 shRNA knockdown of RNF126 in CH12 cells results in decreased
class-switch recombination. (A) Representative FACS plots from one
experiment are shown. Knockdown of AID, as compared to the negative control
(shGFP) results in an almost complete loss of CSR, as measured by IgA+ cells.
In addition, knockdown of RNF126 using three different hairpins results in a
decrease in CSR-levels. (B) A summary of three independent experiments is
shown. CSR levels in the shGFP hairpin expressing line are set to 100. The
percent loss of IgA+ cells is depicted above each bar. Error bars are
representative of the standard deviation. (C) Anti-RNF126 western blot
demonstrates that the hairpins against RNF126 (shRNF126-1,2,3) successfully
result in a loss of RNF126 protein. Arrows denote (1) a nonspecific band (ns),
which can be used as a normalization control, and (2) RNF126.
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cell development; however, CSR, SHM and Affinity Maturation are not assayed
until the B cells have matured and left the bone marrow. The time difference
between knockout and experimentation allows for the possibility of compensation
by a homologous protein. In addition to this possibility, expression of a similar
protein in mature B cells may lead to redundancy, or the ability of multiple
proteins to play one role in the cell. Under physiological settings one protein is
often preferred, however the other can compensate upon loss of the first
(Barbaric et al., 2007). The difference in results obtained through knock-down
and knock-out could support this idea.
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CHAPTER 5: DISCUSSION
5.1 Advantages and disadvantages of the solubility-based interaction
screen
Protein-protein interaction data provides valuable insight into molecular
networks within living cells. Popular methods to obtain protein interaction data in
a high-throughput fashion include affinity purification followed by mass
spectrometric analysis of proteins co-purified with the tagged protein of interest,
and yeast-two-hybrid approaches. These approaches can be best thought of as
complementary to one another, as each has distinct drawbacks that the other
lacks. For instance, affinity based pull-down methods do not provide information
about binary protein-protein-interactions; rather, they describe the assembly of
multiple proteins that are stably associated with the tagged bait protein. In
addition, these techniques also suffer from an inherent inability to detect transient
protein-protein interactions. Overall, affinity based methods tend to be biased
toward the identification of large, stable complexes. On the other hand, yeasttwo-hybrid screens investigate interactions in the yeast nucleus between
overexpressed fusion proteins. It is estimated that over 50% of such interactions
are false positives because they cannot be confirmed by other methods such as
co-immunoprecipitation (Sprinzak et al., 2003). This approach also generally fails
to identify weak or transient interactions that do not sufficiently transactivate the
reporter. Thus, yeast-two-hybrid screens seem biased toward the identification of
strong binary interactions. Recent progress has been made to attempt to fill the
gaps in the interactome left by these more classical techniques. New protein129

protein interaction screens include, but are not limited to, split molecule
complementation, which leads to fluorescence upon interaction (e.g. split GFP
approaches (Cabantous and Waldo, 2006), chemical and photo-crosslinking
followed by specific immunoprecipitation to lock more transient interactions in
place (reviewed in (Lowder et al., 2011)), and the fusion of a bait protein with
molecules that can modify and “mark” neighboring proteins (e.g. biotin ligases
such as BirA (Roux et al., 2012)). Despite the many benefits of these methods,
though, none are particularly reliable for the identification of interactions with a
protein that is poorly soluble or insoluble when ectopically expressed. The
solubility-based screen discussed in this thesis further expands our ability to
probe the interactome by specifically targeting this subset of poorly behaved
proteins.
There are a few disadvantages of this technique. First, similar to other
interaction screens, this assay is unlikely to pick up transient interactions.
Because solubilization and drug resistance are the read-outs of this particular
screen, a stable interaction between the drug-resistance gene containing fusion
protein and the unknown cDNA-derived protein is necessary. In addition, this
screen assays the ability of proteins to bind in a non-physiological cell-type.
While this may reveal interactions that may not have been picked up through
affinity pull-downs, putative interactions must be verified in a more physiological
setting. For example, eukaryotic proteins, which may be physically separated due
to cellular localization would still be able to bind in a bacterial cell. Lastly, the
exposure of hydrophobic domains on proteins often makes them “sticky” and
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more likely to bind non-specifically to exposed hydrophobic domains on other
proteins. Thus, it is possible that if the co-expressed unknown partner is also
poorly behaved, binding and solubilization may observed simply because of the
presence of two exposed hydrophobic domains rather than due to a physiological
interaction. Despite these disadvantages, though, this screen provides a platform
to better understand the interactome of insoluble proteins; putative cofactors
identified in the screen can easily be tested for validity.
5.2 Putative AID cofactors identified by interaction screen
The specific motivation behind the development of this assay was to
identify interaction partners for AID, a potent DNA mutator highly expressed in B
lymphocytes (Muramatsu et al., 1999; 2000) and poorly soluble when expressed
in all systems tested. In mature B cells, AID deaminates cytidines at the
immunoglobulin locus to initiate a cascade of error prone repair that results in
either point mutations (during SHM) or genomic recombination (during CSR),
depending on the location within the Ig locus (Longerich et al., 2006). Although
AID preferentially targets the immunoglobulin locus, loci elsewhere in the
genome have been shown to be targeted at a lower frequency by the detection of
point mutations or genomic translocations (Liu et al., 2008; Oliveira et al., 2012;
Robbiani et al., 2008; 2009). For this reason, it is likely that AID is tightly
regulated. In fact, evidence for regulation at the transcriptional, posttranscriptional and post-translational level has been established (Delker et al.,
2009). In addition, the sub-cellular localization of AID is tightly controlled (Brar et
al., 2004; Ito et al., 2004; McBride et al., 2004).
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Many attempts have been made to identify AID interactors using either
affinity-based purification methods or yeast-two-hybrid approaches; as a result, a
handful of proteins have been implicated in the AID reaction (Chaudhuri et al.,
2004; Conticello et al., 2008; MacDuff et al., 2006). Using the solubility based
interaction screen, a number of previously reported AID co-factors have been
successfully identified, including components of the ssDNA binding complex,
RPA, which are thought to play a role in the recruitment of DNA break repair
machinery to the Ig locus (Chaudhuri et al., 2004; Vuong et al., 2009) and
CTNNBL1, a splicing factor recently identified by a yeast-two-hybrid approach
(Conticello et al., 2008). The importance of splicing of the immunoglobulin gene
CSR has been proposed, but the mechanism remains unclear (Hein et al., 1998).
In the past, mdm2, a RING domain containing protein that targets p53 for
degradation, has been shown to interact with AID (MacDuff et al., 2006);
however, full-length mdm2 was not identified in this novel screen, even though
the C-terminal (RING domain containing) truncation of mdm2 can clearly
solubilize AID as previously demonstrated (Figure 2.2 and (MacDuff et al.,
2006)). This is not surprising because the library used here does not contain
mdm2 truncations and it is only the very C-terminus RING domain of the protein
that was shown to interact in previous yeast-two-hybrid studies (MacDuff et al.,
2006).
The fact that this new screening approach has identified known co-factors
underscores its validity. More importantly, however, the screen has identified
factors not previously known to complex with AID. These include proteins that
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are likely to play important roles in DNA repair, such as Rad51 and FEN1. In
addition, the RRM2 complex was identified, which is responsible for the synthesis
of deoxyribonucleotides during DNA repair (Niida et al., 2010). We have also
identified factors with known roles in RNA processing, such as the
polyadenylation factor and endonuclease, CPFS73. RNA processing at the
immunoglobulin locus has increasingly been recognized as a necessary
precursor to the completion of CSR and, although the mechanism is still not
understood, there likely exists a tight coordination between transcription at the Ig
locus, AID-mediated mutation, and double-strand break repair.
We have also identified a number of ubiquitous factors that are potentially
very important for the subcellular localization of AID by either mediating
cytoplasmic-nuclear trafficking (such as karyopherin (Patenaude and Di Noia,
2010) and Nup93), or by playing a role in retaining AID in the cytoplasm and
excluding it from the nucleus (e.g. TCP1-eta and Bip in analogy to other
chaperones (Orthwein et al., 2010). Finally, a number of factors that are of
completely unknown function have been identified and it will be important to
determine their relevance to CSR and SHM in the future.
5.3 Potential roles for RNF126 and mono-ubiquitinated AID
RING Finger Protein 126, a very interesting AID interacting protein, was
revealed using this screen. In addition to verifying that RNF126 is a bona fide
AID interactor in bacterial and mammalian cells (Figures 3.3, 3.4, 3.5, 3.6), it was
determined that it acts as an E3 ubiquitin ligase in a complex that monoubiquitinates AID (Figures 3.8, 3.10). In addition, other E3 ligases expressed in B
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cells with specific functions in B cell biology do not appear to have such activity,
arguing for selectivity (Figures 3.13, 3.14). Though AID ubiquitination has been
noted previously by Reynaud et al. (Aoufouchi et al., 2008), the type of
ubiquitination observed here (mono-) is quite different than the poly-ubiquitination
observed previously. Thus, it is likely that, like phosphorylation, ubiquitination of
AID is a more general PTM used to regulate AID in a variety of different ways.
A number of roles for RNF126 in the context of AID and antibody
diversification can be hypothesized based on sequence similarities of the
domains of this E3 ligase with homologous domains of known function present in
better characterized proteins. For example, in addition to the RING domain,
which interacts with and modifies AID (Figures 3.5, 3.11), RNF126 contains
several intriguing domains that could be suggestive of function. For instance, its
N-terminal zinc finger domain is homologous to a recently identified ubiquitinbinding domain (Bacopulos et al., 2012) potentially suggestive of regulation. The
co-existence of a ubiquitin ligase and ubiquitin binding domain within the same
protein is reminiscent of the proposed regulation of translesion DNA repair.
Ubiquitination of pol η is thought to result in a closed conformation through the
interaction of the ubiquitin moiety with the ubiquitin binding domain at the Nterminus of the polymerase. As a result, this prevents the interaction of pol η with
PCNA. Thus, ubiquitination can either positively or negatively regulate the
assembly of the repair complex, depending on which substrates are targeted by
ubiquitin (Bienko et al., 2010). Whether this phenomenon occurs in the biology of
RNF126 still needs to be determined.
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Lastly, RNF126 contains a conserved stretch of serines at the very Cterminus (Figure 3.2). Though the function of this domain is unknown at present,
it is homologous to similar stretches of serines found in proteins that have been
shown to act as transcriptional activators at RNAPII-dependent promoters (Bates
and DeLuca, 1998; Kretzschmar et al., 1994; Miau et al., 1997). These include
viral proteins, which bind to general transcription factors in order to hijack the
transcription machinery of the host cell (Bates and DeLuca, 1998), but also
include cellular proteins, such as the transcriptional coactivator, PC4 (Ge and
Roeder, 1994; Ge et al., 1994) and other proteins with roles in transcription (Miau
et al., 1997). Given the multitude of genetic and proteomic data linking AID to
transcription initiation, elucidation of the role of this particular domain of RNF126
in the context of a potential dual interaction with the Ig promoter and AID will be
interesting to pursue.
This thesis presents an analysis of only the RING domain of RNF126 and
its activity in ubiquitination. The role that these other domains play in the biology
of RNF126, itself, as well as in AID biology remains a very interesting avenue of
research to pursue in the future. The generation of the RNF126 conditional
knockout mouse makes it easier to investigate the role of individual domains on
RNF126. Bone marrow reconstitution of RNF126 conditional knockout mice with
mutant forms of the protein (for example, with mutant Zn Finger domains, or
truncations of the serine tail) can be used to determine the role single domains
play in SHM and affinity maturation.

135

The role of RNF126-mediated ubiquitination and of mono-ubiquitinated
AID in antibody diversification can be ascertained from an analysis of the
changes in each step of antibody diversification upon loss of RNF126. Of course,
the role of RNF126, itself, may go beyond ubiquitination of AID and this must be
taken into consideration. Despite this, hypotheses derived from experimental
evidence regarding the role of RNF126 in antibody diversification are presented
below.
5.3.1 In Somatic Hypermutation
The relatively uncharacterized protein, RNF126, has been identified as an
E3 ubiquitin ligase with the ability to mono-ubiquitinate AID (Delker et al., 2012).
Ubiquitination, which was originally thought to only play a role in protein
degradation, has been shown to play a variety of roles in many cellular
processes (Pickart, 2001b), thus suggesting that RNF126 may play an interesting
regulatory role for AID and AID-mediated steps of antibody diversification. It has
already been established that mono-ubiquitination is important for both somatic
hypermutation and class-switch recombination. Mono-ubiquitination of the
polymerase processivity factor, PCNA, on lysine 164 (K164) has been shown to
recruit translesion synthesis polymerases necessary for error prone repair. Mice
that express ubiquitin-null mutants of PCNA (K164R) display reduced classswitch recombination ex vivo and a reduction in mutations at A:T base pairs
during in vivo somatic hypermutation (Roa et al., 2008). In addition, the monoubiquitination of the histones H2A and H2AX by RNF8 is necessary for the
recruitment of RNF168 and subsequent RNF168-mediated poly-ubiquitination.
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Both events are important for the recruitment and stabilization of the repair factor,
53BP1, and faithful DSB repair (Doil et al., 2009; Jackson and Durocher, 2013;
Mailand et al., 2007; Mattiroli et al., 2012; Ramachandran et al., 2010).
Thus, given these examples, it is plausible that mono-ubiquitination of AID
plays a similar role in recruiting necessary repair proteins to the Ig locus. In line
with this hypothesis, loss of RNF126 results in an alteration of the pattern of
mutations observed during SHM. Most notably, in the JH4 region, a greater
mutation load was observed on the template strand in the absence of RNF126.
This suggests that either AID, itself, or error-prone repair factors gained greater
access to the template strand upon loss of RNF126. However, based on studies
conducted in mice lacking both UNG and MSH2, it appears that AID has equal
access to both template and non-template strands (Xue et al., 2006). Thus, it is
more likely that the difference observed is due to access of downstream repair
proteins. The only other instance in which the template strand was observed to
accumulate more mutations was in patients deficient for NBS1, a member of the
MRN complex (Du et al., 2008). In addition, overexpression of NBS1 in the
murine B cell line, RAMOS, increases the strand bias of mutations toward the
non-template strand (Yabuki et al., 2005). Thus, through an unknown
mechanism, NBS1 prevents error-prone repair on the template strand. It is
possible then that RNF126, and possibly ubiquitinated AID, functions in the same
pathway. It is conceivable that, in contrast to ubiquitinated PCNA, which recruits
error-prone repair, mono-ubiquitinated AID results in the recruitment of error-free
repair, thus contributing to the local battle between error-free and error-prone
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repair. It is also conceivable that RNF126 plays a role at the G1-to-S cell cycle
check point. Persistence of U:G mismatches into S-phase, where repair is
thought to be dominated more by error-prone repair (Li et al., 2012), could result
in the observed increase in template strand mutations.
Though the same alteration in strand bias was not observed in the V186.2
exon region, the altered mutation rate observed here also supports this
hypothesis. In the absence of RNF126, an increase in the number of mutations
per B cell clone was observed. As mentioned, this could represent overactive
AID or the presence of AID outside of the germinal center, but could also be
representative of an increase in error-prone repair or the persistence of U:G
mismatches into S-phase. If RNF126 promotes error-free repair, then in its
absence, a greater number of mutations would accumulate during the process of
replication and the generation of new B-cell clones.
It would be very interesting to test these hypotheses directly. Schatz et al.
(Unniraman and Schatz, 2007) have generated transgenic mice, which contain a
SHM substrate containing a tract of A/T bases with either one central C (NT
strand): G (T strand) basepair or one central G (NT strand): C (T strand)
basepair. These mice enabled them to determine that, while AID could efficiently
deaminate the C base on both strands, A/T mutations only accumulated when
the deaminated C lay on the NT strand. Thus, strand bias is determined mainly
by the access of error prone repair proteins (Unniraman and Schatz, 2007).
Utilizing this system, it would be predicted that in the absence of RNF126, A/T
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mutations would accumulate equally well with the deaminated C on the T strand,
as compared to the NT strand.
In addition, if RNF126 is truly involved in the recruitment of error-free
repair, then it likely plays a role outside of the Ig locus to correct for off-target AID
mutation. An analysis of off-target mutation load and translocation frequency in
the RNF126 conditional knockout mouse model would informative on this front.
5.3.2 In Class Switch Recombination
It is much more challenging to discern the role of RNF126 during CSR
because the phenotype in the RNF126 conditional knockout with regard to CSR
is much more subtle. Though there does appear to be a subtle defect in CSR in
the knockout B cells, it is not statistically significant. This is further complicated
by the fact that there is a much greater defect upon knockdown of RNF126 in a B
cell line (discussed more in section 5.4). While it is possible that RNF126
performs the same function in CSR as it does in SHM, it is also important to
remember that this is not necessarily the case. Precedent for this exists for the
binding factor, RPA, which likely stabilizes ssDNA during SHM, but was co-opted
to play a DNA repair role during CSR. Further, the mono-ubiquitinated form of
AID generated by RNF126 may play two separate roles in SHM and CSR. An
analysis of mutations generated in the switch regions during CSR in wildtype and
RNF126 knockout B cells would help determine if the mutation pattern is altered
as was seen during SHM. Further, in vitro deamination assays on transcribed
SHM targets compared to transcribed CSR targets (Switch regions) in the
presence and absence of RNF126 would help to elucidate the presence of an
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inherent difference in the role of RNF126 in regulating AID activity on distinct
substrates.
5.4 The possibility of redundancy and/or compensation in the RNF126
conditional knockout mouse model
Often the in vivo function of unknown genes/proteins is approached
genetically through the generation of knockout mouse models. This approach,
however, can be complicated by the presence of genetic robustness, or the
ability of an organism to sustain either environmental or genetic changes and
maintain normal function. Genetic robustness can occur through two main
pathways—(1) genetic buffering, or the use of alternative pathways to
accomplish the same goal, and (2) functional complementation, where two genes
have redundant functions (Barbaric et al., 2007; Gu, 2003). Studies in S.
cerevisiae and C. elegans have shown that genes that exist as single copies with
no sequence similarity to other genes have a greater likelihood of producing a
phenotype when knocked out or knocked-down with RNAi (Gu, 2003; Gu et al.,
2003; Kamath et al., 2003). Furthermore, several examples of compensation
exist in knockout mouse models. For example, redundant, but not completely
overlapping, functions exist for the genes MyoD and Myf5, which are both
involved in skeletal muscle development. Mice lacking both MyoD and Myf5 do
not develop skeletal muscle and die shortly after birth; however, mice lacking
either of the individual genes have phenotypes ranging from normal to slightly
perturbed (Barbaric et al., 2007; Braun et al., 1992; Rudnicki et al., 1992; 1993).
In fact, upon MyoD inactivation, Myf5 is upregulated, presumably to account for
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the loss of MyoD (Rudnicki et al., 1992). Other examples include knockouts of
individual genes within highly related gene families—for example, knockouts of
single caspase genes result in a variety of phenotypes ranging from prenatal
lethality (caspase 8) to no detectable phenotype (caspase 12) (Barbaric et al.,
2007). Compensation and redundancy have even been predicted to play a role in
masking additional functions for AID. Various studies have suggested that AID
may play a role in DNA demethylation by deaminating a methylated cytosine
residue to generate a T:G mismatch, which is repaired to an unmethylated
cytosine (Fritz and Papavasiliou, 2010); however, the aicda-/- mouse model does
not have any observable defects outside of its canonical role in antibody
diversification. To reconcile this difference, it has been shown that, while aicda-/cells are functional in a reprogramming assay, cells in which AID has been
knocked-down are not. This suggests that compensatory mechanisms that exist
in the context of a knock-out may be overcome by the shorter time-frame of
knock-down experiments, thus drawing a distinction between genetic and “acute”
losses of genes/proteins (Bhutani et al., 2012). It should be noted that more
recent studies addressing the role of AID in reprogramming have found that AIDnull cells less proficiently maintain and stabilize a stem-cell like state 4 weeks
post reprogramming and that many genes at this time point are found to be
hypermethylated as compared to wildtype induced pluripotent stem cells (iPSC).
Thus, this suggests that AID does have an alternate role in DNA demethylation
(Kumar et al., 2013). However, these findings do not invalidate the earlier
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studies, which showed that a knock-down of AID results in a loss of
reprogramming.
Because many knock-out mice without obvious phenotypes are not
published, it is hard to estimate how many null mutants result in no observable
phenotype; however, it has been estimated that approximately 10-15% of knockout mice made do not show a phenotype, likely due to the presence of
redundancy (Barbaric et al., 2007). Thus, it is very likely that the subtle defects in
antibody diversification observed in RNF126 conditional knock-out mice are due
to imperfect compensation by other proteins present in the cell. Similar to the
scenario in which acute loss of AID reveals potential functions not seen with the
knock-out mouse model, knock-down of RNF126 in a murine B cell line results in
a much more significant decrease in CSR levels as compared to that seen in the
conditional knock-out model. It remains to be seen whether these discordant
results are due to a difference in cell type, primary cells versus CH12 cell line, or
whether compensation that has occurred in the mouse system is not present in
the cell line. Because Cre was expressed from the mb-1 locus, RNF126 was
knocked out at the pro-B cell stage; however, antibody diversification was not
assayed until the mature B cell stage, allowing ample time for compensation to
occur, which would preferentially occur if RNF126 normally plays a role during
the development process. Experiments are underway to address this issue. Use
of mice, which ubiquitously express the Cre recombinase fused to a mutant
estrogen receptor (Cre-ERT), can be used to induce deletion of a gene of interest
upon treatment of cells with the estrogen-mimic, tamoxifen (Feil et al., 1997).
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Thus, treatment of splenic B cells in vitro directly prior to CSR stimulation will
eliminate the possibility of compensation during B cell development.
Unfortunately, it is much more difficult to get at the question of redundancy in
mature B cells. The generation of multiple gene knockouts in one mouse, or a
combination of gene knockout with gene knockdown may reveal a stronger
phenotype if redundancy is, in fact, occurring.
In the 293T ubiquitination assay developed, BCA2/RNF115, an E3 ligase
that is highly homologous to RNF126, cannot ubiquitinate AID (Delker et al.,
2012). However, it still remains a possibility that, in the absence of RNF126,
BCA2/RNF115 could acquire the ability to modify AID. In addition, hundreds of
E3 ligases are expressed in activated B cells, allowing for the definite possibility
of compensation. At this point it is still uncertain what E3 ligase is actively
ubiquitinating AID in vivo, though the ability of RNF126 to do so in vitro suggests
its function in vivo. Transcriptome-wide comparisons of gene expression in
wildtype versus RNF126 knockout B cells could provide evidence for the upregulation of alternate E3 ligase enzymes, which would be likely candidates for
compensatory mechanisms; however, it is also possible that redundancy can
occur with an enzyme that is already highly expressed in activated B cells.
Future studies of the role of RNF126 in antibody diversification would
likely benefit from the generation of knock-in mice containing mutant forms of the
RNF126 gene rather than knockout mice. The complete loss of the protein likely
contributes to the onset of compensation and/or redundancy. Thus, the presence
of a mutant form of the protein may inhibit this. Knock-in mice containing RING
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domain mutants could be used to study the role of RNF126-mediated
ubiquitination and mice containing mutations of the Zn Finger or truncations of
the serine tail could be used to determine the roles of these other intriguing
domains.
5.5 A model for the role of RNF126 during Antibody Diversification
The change in the measured levels of CSR and SHM observed in the
RNF126 conditional knockout as compared to wildtype is subtle, at best;
however, the pattern of mutations observed at the Ig locus during SHM is
significantly altered. Thus, it is likely that the system of Antibody Diversification
has evolved several mechanisms that function in parallel to account for the
possible loss of one component. Given the alteration in the pattern of mutations
in the JH4 region, there are several hypotheses that can be generated to explain
the role of RNF126 during SHM. First, it is possible that RNF126 participates in
a complex that prevents access of either AID or downstream repair factors to the
template strand of DNA. Thus, in the absence of RNF126, AID and/or mutagenic
repair factors, such as pol η, would gain greater access to the template strand,
thus accounting for the observed shift in strand bias observed. Second, as
mentioned previously, it is possible that RNF126 actually promotes error-free
repair on the template strand, thus targeting error-prone repair on the nontemplate strand. Thus, in the absence of RNF126, error-prone machinery can
extend to the template strand, resulting in the observed mutation pattern.
Though the benefit of limiting mutagenic repair to one strand of DNA is not
directly clear, it is possible that this type of mechanism could act to limit the
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frequency of DSB formation in the variable region during SHM. As such, this
could be a way to differentiate the repair processes that promote the formation of
point mutations during SHM and the formation of DSBs during CSR. In addition
to these two hypotheses, which both suggest that RNF126 plays a role in
preventing mutation on the template strand, it is also simply possible that
RNF126 is involved in the recruitment of known, canonical repair factors, such as
Pol η. Then, in the absence of RNF126, non-canonical repair enzymes would be
recruited to the Ig locus in an attempt to compensate for the loss of RNF126,
thus producing an altered pattern of mutation. This third model opens the
exciting possibility that, analogous to ubiquitinated PCNA, RNF126-mediated
ubiquitinated AID is necessary for the proper recruitment of repair factors to the
Ig locus. These three models are depicted in Figure 5.1.
In order to test the validity of these three models, further experimentation
will be necessary. It will be useful to cross the RNF126 conditional knockout
mouse to mice containing knockouts of various translesion polymerases, such as
pol η, pol κ, pol ι. If, in the context of a double-knockout, the altered pattern of
mutation is no longer observed, then it can be reasonably assumed that the
targeted polymerase works with RNF126 in generating the pattern of mutation.
Further, chromatin immunoprecipitation (ChIP) experiments for known repair
factors can be conducted in the presence and absence of RNF126 to determine
if the factors recruited to either the variable or switch regions is altered in the
absence of RNF126.
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A. RNF126 Prevents Access of AID and/or Repair Factors to the Template Strand
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Fl/Fl

RNF126

No Strand Bias at C:G (C=G)

**

5’
3’

Fl/Fl

+/+

RNF126

mb1

Strand Bias at A:T (A>>T)

Strand Bias at C:G (G>C)

**

MisMatch Repair
Pol η

Non-Template Strand

5’

Template

3’

5’
RNA

5’
RNA

Cre/+

mb1

Less Strand Bias at A:T (A>T)
MisMatch Repair

?

Non-Template Strand
Template

RPA
** Mutation

Figure 5.1 Potential Models to Explain the Role of RNF126 in Antibody
Diversification. Images depicted represent a scenario for wildtype mice (left), in
which there is no strand bias at G:C basepairs (G=C) and strand bias at A:T
basepairs (A>>T) and RNF126 conditional knockout mice (right), in which there
is strand bias at G:C basepairs (G>C) and less strand bias at A:T basepairs
(A>T). A. RNF126 prevents access of AID and/or repair factors to the
template strand. Thus, in the absence of RNF126, error-prone repair occurs on
both the non-template and template strands. B. RNF126 promotes error-free
repair on the template strand, thus targeting error-prone repair to the
non-template strand. In the absence of RNF126, it is possible that error-prone
repair could extend to the template strand. C. RNF126 recruites canonical
repair factors, such as pol η. Thus, in its absence, non-canonical polymerases
are recruited to compensate for the loss, resulting in the altered pattern of
mutation.
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In addition, though, it will be important to determine if the observed
phenotype in the RNF126 conditional knockout mouse is due to a loss in
RNF126-mediated ubiquitination of AID. Along with experiments to determine
the involvement of known translesion polymerases, in vitro studies can be
conducted to determine if ubiquitinated AID can directly interact with each of the
translesion polymerases, thus providing a link between RNF126 and repair.
Furthermore, when the residue on AID that is targeted by ubiquitination is
determined, mice harboring ubiquitin-null mutants of AID can be generated.
Analogous SHM and CSR assays can then be conducted in the context of a
ubiquitin-null mutant of AID to determine if the same phenotype exists as was
seen in RNF126 conditional knockouts. This would provide reasonable evidence
that the phenotype observed upon loss of RNF126 is due to a loss in RNF126mediated ubiquitination of AID.
Thus far, these hypotheses focus specifically on the role of RNF126
during SHM. A more thorough analysis of the pattern of mutations in the switch
regions during CSR in RNF126 conditional knockout mice will be necessary to
determine if these hypotheses can extend to CSR, as well.
5.6 Functions for RNF126 outside of the immune system
Additional substrates for RNF126 in other cellular contexts have been
identified recently, providing excitement for the utility of the RNF126 conditional
knockout mouse model as a generalized tool to study this E3 ligase throughout
cell types in the mouse. First, RNF126 has been implicated in cancer cell
proliferation by targeting the cell cycle regulator, p21, for ubiquitin-mediated
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degradation (Zhi et al., 2013); second, RNF126 and the homologous E3 ligase,
BCA2/Rabring7/RNF115, have been shown to be involved in the internalization
and endosomal sorting of the epidermal growth factor receptor (EGFR) (Smith et
al., 2013). In addition, expression of RNF126 has been documented in a very
specific portion of the hippocampal region of the mouse brain, suggesting a
potential role for this E3 ligase in memory formation or brain function (Lein et al.,
2007). By generating crosses of the RNF126-floxed mouse with cell-type-specific
CRE expressing mice, the importance of RNF126 can be investigated in each of
these systems.
5.7 Looking forward
The work presented here creates a foundation for future research both in
terms of the novel tools developed, as well as in discoveries made. First, the
solubility-based protein interaction screen developed can be applied to any
insoluble proteins of interest, thus making it a useful tool to study proteins in all
biological pathways. Second, the RNF126 conditional knockout can be bred to
cell-specific CRE expressing mice in order to study the role of RNF126 in many
different cellular contexts. In addition to these tools, though, this work has also
identified a novel mode of regulation of the enzyme, AID. The regulation of AID
likely involves a complex interaction of a variety of cellular factors, including both
protein and RNA. In addition, it has become clear that there must exist a balance
between error-free and error-prone repair downstream of AID-induced
mismatches and how this decision is made remains unknown. The finding here
that RNF126 mono-ubiquitinates AID expands the list of AID regulatory
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mechanisms and provides a foundation for future studies to elucidate the exact
role of this modification during the various stages of antibody diversification.
Ubiquitination is a commonly used mechanism to regulate cellular processes so it
is not unexpected that it is utilized during AID biology; however, as has been
discussed, it will be interesting to determine if ubiquitination of Ig-locus
associated proteins, for example AID versus PCNA, provides a mechanism for
the decision made between different types of repair pathways. The findings
presented here provide the foundation and tools necessary to begin to better
understand the role of ubiquitinated AID in antibody diversification.
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CHAPTER 6: EXPERIMENTAL METHODS
6.1 Pertaining to all in vitro work: CHAPTERS 2 and 3
6.1.1 Mice and Cells
Wildtype and aicda-/- C57BL/6 mice between the ages of 8-12 weeks were used
for in vitro class switch recombination assays. For bacterial expression
experiments BL21DE3 E. coli cells were used. For mammalian expression HEK
293T cells were used.
6.1.2 Antibodies Used
The following antibodies were used for this study: anti-Flag (Sigma M2 clone,
beads and HRP conjugate), anti-HA beads (Sigma EZ View Red HA beads), antiHA (Roche, clone 3F10), anti-HA HRP (Miltenyi, cat# 130-091-972), anti-His HRP
(Santa Cruz, cat# 8036), anti-AID (Cell Signaling, EK25G9 clone), anti-RNF126
(Sigma, cat# HPA043050), anti-H3 (abcam, cat# 1791), anti-PCNA (Santa Cruz,
Clone PC10, cat# 56), anti-Tubulin (Sigma, clone DM1A).
6.1.3 Primers Used
AID-Forward: 5′-atggacagcctcttgatgaaccg-3′
AID Linker-Reverse: 5′gcatccatGAGGGGAAGATGTCCCTGCACATTaagtcccaaagtacgaaatgcgtctcg-3′
Linker CAT-Forward: 5′ggacttAATGTGCAGGGACATCTTCCCCTCatggatgcaaaacaaacgcggcag-3
CAT-Reverse: 5′-ttatttggacgttctacgctgcgtataaatcgcatccatc-3′
RNF126 Q1-F: 5’-GCAGCCCGGACGGTACT-3’
RNF126 Q1-R: 5’-AGCTCCTCAATGAAGCCAGACT-3’
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RNF126 Q2-F: 5’-CCCCCACCGACCAGAAC-3’
RNF126 Q2-R: 5’-ATCGTCGAAGATGCCAAAGG-3’
CD19 QPCR-F: 5’-AGAAGGAAAAGGAAGCGAATGA-3’
CD19 QPCR-R: 5’-GGAGAGCACATTCCCGTACTG-3’
6.1.4 Plasmids Used
A. Screen. The AID-CAT fusion gene was assembled by PCR. The human AID
cDNA and the chloramphenicol transferase (CAT) cDNA were amplified by
standard PCR using the primer pairs AID-Forward/AID-Linker-Reverse and
Linker-CAT-Forward/CAT-Reverse, respectively. This was followed by an
overlap-extension PCR using the AID-Forward and CAT-Reverse primer pair.
AID-CAT was then cloned as an NdeI/XhoI fragment into the second expression
cassette of a pCDF-duet vector (Novagen). The first expression cassette
contained either a fragment of Mdm2 (a gift from Dr. Reuben Harris, University of
Minnesota) or candidate interactors.
The fragment of Mdm2 was also cloned into a pCOLA-duet vector (Novagen) as
a SalI/NotI fragment. Similarly, a number of unrelated virulence factors (cagA,
sopB, sopE, sifA, invB, invC, cdtA. cdtB, yopK, yopJ, yopH and others) were
cloned to generate the mock mini-library of factors that are highly unlikely to
interact with AID.
Finally, the CAT-ADAT3 construct was generated similarly to that of AID-CAT
except that it was an N-terminal fusion. The C terminal fusion (ADAT3-CAT)
sterically hindered the interaction with ADAT2, ADAT3’s only known co-factor.
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The cDNA library was derived by Invitrogen from the RAMOS Burkitt’s lymphoma
cell line, which hypermutates constitutively. To generate the destination vector for
the cDNA library, cDNA encoding the AID-CAT fusion protein and the attR1/attR2
recombination cassette containing the ccdB gene were sequentially cloned into the
second and first cloning site of pCDF-Duet (Novagen) using the restriction enzyme
combinations NdeI/XhoI and NcoI/NotI, respectively. The chloramphenicol
resistance cassette located within the attR cassette was removed by cutting with
SacII/BamHI followed by religation. One Shot® ccdB Survival™-T1R Chemically
Competent Cells (Invitrogen) were used to propagate the destination vector.
B. Bacterial Expression. We used the pCDF-Duet vector (Novagen) to clone Cterminally Flag tagged AID into the second multiple cloning site using NdeI/XhoI.
The first multiple cloning site was used to clone various putative interacting
factors (including RNF126). The same vector was also used to clone RNF126 on
its own, for purification purposes, or fragments of RNF126 together with AID for
domain delineation and interaction purposes.
C. Mammalian Expression. The mammalian expression vector pcDNA3
(Invitrogen) was used for transient expression of hAID, hRNF126 and ubiquitin
(and mutants thereof) in HEK 293T cells. In these constructs AID is either
untagged or FLAG-tagged, as indicated for each experiment. RNF126 is HAtagged. Ubiquitin is either untagged or FLAG-tagged, as indicated for each
experiment. Flag-PCNA, HA-RNF8 and HA-BCA2 were expressed from the
pCMV-Sport6 vector (Invitrogen).
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6.1.5 Screening Protocol
Destination vectors based on pCDF-duet and containing the attR1-ccdBattR2 construct in the first expression cassette and AID-CAT in the second, were
directionally recombined with the cDNA library (22,000 cDNAs, split into 42 pools
containing 800-1000 unique colonies per pool) using the Gateway system
(Invitrogen). Each recombination reaction was then transformed into BL21DE3ai
bacteria (Invitrogen) and plated on spectinomycin plates (50µg/ml) and grown at
30°C to determine transfection efficiency. Spectinomycin plates with the expected
~800 colony number were then replica-plated onto induction plates (using velvet
pads) containing chloramphenicol (60µg/ml). Induction was achieved by addition
of arabinose (0.02%) to the plates (which controls T7 RNAP expression in
BL21DE3ai cells) and by addition of IPTG (0.5mM, which controls T7-driven
expression of both cassettes of the pCDFduet vector, namely, the cDNA clone
and the AID-CAT gene). Induction occurred at 30oC overnight (until colonies
were visible). We cannot estimate toxicity because death due to toxicity is
indistinguishable from death due to lack of solubility and thus lack of
chloramphenicol resistance; both scenarios result in a lack of colonies. This is a
limitation of this assay; however, we did try to minimize minor toxicity by growing
non-induction and induction plates at 30oC overnight. Colonies that survived on
induction plates were picked, grown in liquid culture (again under induction
conditions and at 30oC overnight). DNA from these cultures was then prepped
and sequenced to identify potential interactors.
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We aimed for a number of colonies per spectinomycin plate consistent with
the expected number of clones per pool (800-1000); however, the number of
colonies recovered on induction plates was variable presumably due to the variable
number of potential interactors per pool.
Interactors that were recovered multiple times or a few times, but
reproducibly in each of three independent screens, are shown in Table 3.1 along
with their identity and accession number. Each of these hits was subsequently
validated through co-purification of each cDNA of interest (in frame with 6xHis in the
pCDFduet vector) with AID-FLAG (cloned in the second cassette of the pCDFduet
vector, in lieu of AID-CAT). We were not able to validate the interaction of 6/36
candidates, which corresponds to the 16% false positive rate. This information is
also included in the supplemental table in the column titled “Co-IP?”. Those that are
marked with a “Y” were able to be validated and those that are marked with an “N”
were not.
6.1.6 Bacterial Co-Expression and Co-purification
For co-expression and co-purification experiments, the coding sequence
for C- terminal FLAG-tagged AID was initially cloned into the second multiple
cloning site of pCDF-Duet (Novagen) with NdeI/XhoI (following the original
configuration of the screening setup). The first multiple cloning site was used for
cloning the cDNAs of candidate interactors in frame with the hexahistidine tag
using the SalI/NotI sites. For further co-purification experiments using AID and
RNF126, this configuration was used as well as the opposite (6xHisAID /
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RNF126-FLAG, to assuage fears of non-specific precipitation of AID onto FLAGagarose beads). In all cases, plasmids were transformed into BL21 DE3 cells
and protein expression was induced with 1mM IPTG for 12-16 hours at 23°C
after the OD600 reached 0.8. Bacterial pellets were collected by centrifugation and
directly resuspended in buffer A (20 mM HEPES [pH=7.0], 200 mM KCl, 1 mM
PMSF), frozen and stored at -80°C. Prior to protein purification, partially lysed
cells were thawed, treated with a non-specific nuclease (Benzonase; Novagen)
and then fully lysed using a cell disruptor (French press). The lysate was
centrifuged and the resulting supernatant was loaded either onto a Talon resin
charged with Co2+ ions (BD Biosciences) or on anti-FLAG beads (Sigma). Talon
resin purification was done as follows: The resin was first washed with buffer A
followed by buffer B (buffer A plus 30 mM Imidazole) and eluted with buffer A
containing 150mM or 250mM imidazole. The eluted proteins were immediately
dialyzed against buffer A to remove the imidazole. Alternatively, lysates were first
pre-cleared by incubation with agarose beads and subsequently incubated with
anti-FLAG beads for 2 hours at 4°C. Beads were then washed at least five times
with buffer A. The captured protein was eluted by incubating the beads with
buffer A containing FLAG peptide.
6.1.7 Mammalian Co-expression and Co-purification
293T cells that were plated at 60-75% confluence in a 6 well dish were
transfected with 1.5 µg of either pCDNA3.Flag-AID, pCDNA3.HA-RNF126 or
both. 48 hr post transfection cells were lysed with 300 µL of Cytosolic Lysis
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Buffer (50 mM HEPES, pH 7.2, 10% Glycerol, 1% NP-40, 10 mM KCl, 1 mM
MgCl2), sonicated for 10’ in 30’’ intervals and treated for 1hr with Benzonase
(Novagen). The nuclear pellet remaining after this treatment was resuspended
and lysed in high salt buffer (Cytosolic Lysis Buffer + 400 mM NaCl). Both lysates
were combined and the remaining cellular debris removed by centrifugation at
13.2K RPM. Protein concentrations were normalized between samples prior to
performing immunoblots and immunoprecipitations. Approximately 8% of the
lysate was loaded as “Input,” and the remainder immunoprecipitated with anti-HA
(specific for RNF126) or anti-Flag (specific for AID) beads overnight. Each IP was
washed 3X with Cytosolic lysis buffer followed by 3X washes with High Salt
buffer. Laemmli buffer was added to the beads, which were then boiled and
loaded on the gel.
6.1.8 B-Cell Purification and Activation
Naïve splenic B cells from 8-12 week old wildtype and aicda-/- C57BL/6
mice were purified by CD43 negative selection on a magnetic column (MACS,
Miltenyi Biotec). Purified B cells were plated at a concentration of 0.5 X 106
cells/mL and stimulated with 10 ng/mL IL-4 and 25 µg/mL LPS (Sigma).
6.1.9 Quantitative Real Time RT-PCR (Q-PCR)
Total RNA was isolated using TRIzol (Invitrogen) according to the
manufacture’s instruction. First strand cDNA was synthesized using Superscript
III Reverse Transcriptase (Invitrogen). Q-PCR was performed using the SYBR®
Green PCR Master Mix (Invitrogen). All samples were analyzed in triplicate and
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normalized to levels of CD19. Data shown represents an average of the results
from two different primer sets: 1, RNF126 Q1-F/R and 2, RNF126 Q2-F/R.
Primers for CD19 are called CD19-QPCR-F/R.
6.1.10 Preparation of mammalian cell extracts
Cells were harvested and the pellets washed with 1X PBS. Cells were
lysed with RIPA buffer (50 mM Tris (pH 8), 150 mM NaCl, .5% Na Deoxycholate,
.1% SDS, 1% NP-40, .5 mM EDTA, 1 mM DTT and protease inhibitor cocktail
(Roche)). Buffer used for the 293T ubiquitination assays was also supplemented
with the deubiquitinase inhibitor, N-Ethylmaleimide (NEM, 1 mg/mL, Sigma).
Lysates were normalized with the detergent compatible DC-Assay (Biorad).
When noted, quantification of protein levels was done using the ImageJ software.
Values shown represent the fold change of the protein of interest after
normalization to the loading control.
6.1.11 HEK 293T ubiquitination assay
HEK 293T cells were plated in a 6-well dish and transfected with 500 ng1µg of pCDNA3.AID/FLAG-AID, 500 ng -1µg of pCDNA3.HA-RNF126 and 1 µg
of pCDNA3.Flag-Ubiquitin, when indicated, using Lipofectamine 2000
(Invitrogen). 36-48hrs later, cells were lysed as described (Supplemental
Methods). AID immunoprecipitations were performed using either 2.5-3.5 µL of
anti-AID antibody (Cell Signaling) and protein G-Sepharose beads (Invitrogen) or
anti-Flag M2 agarose beads (Sigma). Beads were washed at least 3X with lysis
buffer and eluted with Laemmli buffer containing 200 mM DTT and boiling.
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Samples were loaded on a 12.5% Tris-HCl Criterion gel (BioRad) transferred and
blotted with the antibodies indicated.
6.1.12 In vitro ubiquitination assay
His-tagged RNF126 was purified as described. His-tagged Ube1 (E1),
His-tagged UbcH5b (E2) and ubiquitin were purchased from BioMol, Lysineless
Ubiquitin from Boston Biochem and hAID from Enzymax. All components were
resuspended in ubiquitination buffer (50mM Tris HCl (pH 7.5), 2.5 mM MgCl2,
1mM DTT) and incubated at 37°C for 30 minutes to 1 hour. An equal volume of
Laemmli buffer containing 200 mM DTT was added and the samples boiled prior
to gel loading. Concentrations of components used are as follows: Ube1-50 nM,
UbcH5b-500 nM, RNF126-300 ng, AID-300 ng, Ubiquitin-1-4 µg, ATP-1-2 mM, in
a total volume of 25 µL. Reactions were loaded on a 12.5% Tris-HCl Criterion gel
(Biorad) and membranes were blotted with an anti-AID antibody.
6.1.13 HEK 293T ubiquitination assay using alternate E3 ligases and
substrates
When alternate ligases and/or substrates were included in this assay, the
protocol remained as described; however, amounts of plasmid DNA transfected
in the cells varied depending on the expression level of the given construct.
750ng – 1 µg HA-BCA2 and HA-RNF8 and 200 ng of FLAG-PCNA were
transfected in these experiments.
6.1.14 RNF8/PCNA in vitro ubiquitination assay
RNF8 and PCNA were used as an alternate E3 Ligase/Substrate pair in
this assay. 100 ng of GST-RNF8 (Abnova) and 100 ng of GST-PCNA (Abnova)
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were incubated as described in Materials and Methods with 500 nM of either the
E2, UbcH5B or the E2, UbcH5C (BioMol). All other components and
concentrations remained the same.
6.2 Pertaining to all in vivo work: CHAPTER 4
6.2.1 Generation of an RNF126 conditional knockout mouse model
ES cells containing the targeted RNF126 allele were purchased from the
EUCOMM International Knockout Mouse Consortium. Targeting was done in the
JM8A3.N1 ES cell line, which is derived from a C57BL/6N background and
contain an agouti coat color.
ES cells were injected into a C57BL/6 blastocyst by the Rockefeller
University Gene Targeting Resource Center. Chimera mice of high chimerism
(brown/black in coat color) were selected and bred to C57BL/6 wildtype mice.
Offspring were screened for agouti (brown) coat color as an indication of whether
the targeted allele was transmitted to the offspring. Several rounds of breeding
produced a single brown mouse and southern blotting was used to verify the
presence of the RNF126 targeted allele.
Mice containing one copy of the targeted allele (RNF126ki/+) are
functionally heterozygous because the gene trap construct inserted in intron 1
disrupts translation. This gene trap cassette is flanked by Flipase recombinase
sites (FRT). RNF126ki/+ mice were bred to transgenic mice expressing the
Flipase recombinase (Jackson Labs # 005703) to reinstate complete translation
of the targeted allele. Mice containing a Flipped version of the targeted allele
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(RNF126Fl/+) were bred to C57BL/6 mice to cross out the Flipase transgene and
then to mb-1 Cre expressing mice (Hobeika et al., 2006) to generate the
conditional knockout. Through rounds of breeding, RNF126Fl/Flmb1Cre/+ mice were
generated and validated at the DNA, RNA and protein level as B cell-specific
RNF126 conditional knockout mice. RNF126FL/FL mb1+/+ were used as wildtype
littermate controls in experiments
6.2.2 Genotyping Primers
Table 6.1 presents the genotyping primers used during the generation of
the RNF126 conditional knockout mouse, as well as a brief description of where
the primers bind and the expected amplicons.
6.2.3 Southern Blot and PCR Analysis of RNF126 conditional knockout
mice
Initial confirmation of the correct integration of the construct into the rnf126
locus was completed by Southern blot analysis. When hybridized to SspIdigested genomic DNA, this probe could differentiate between wildtype (14.1 kb)
and targeted (8.5 kb) alleles.
Genomic DNA isolated from tail biopsies or pelleted splenic B cells were
used for PCR genotyping. Tails or B cells were incubated overnight at 56°C in
500 µL Tail Lysis Buffer (100 mM Tris-Cl pH 8.5, 5 mM EDTA, .2% SDS, 200 mM
NaCl). Samples were centrifuged at 9K RPM for 8 minutes to pellet any
remaining tail material and the supernatant was combined with an equal volume
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of isopropanol. Samples were centrifuged for 30 minutes at full speed (13.2K
RPM) to pellet the DNA, which was then dried and resuspended in water.
Primers used for genotyping and expected amplicon sizes for each
genotyping primer set are presented in 6.2.2. KOD Hot Start Polymerase (EMD
Millipore) was used for all PCR reactions. For the primer sets Endo-F/Endo-R
and Endo-F/RP-R, PCR conditions were 30 cycles of 95°C for 20sec, 54°C for
10sec, and 70°C for 4sec. All four primers for Cre genotyping were included in
one reaction. Conditions for this PCR were 30 cycles of 95°C for 20sec, 57°C for
10sec, 70°C for 5sec. Similarly, all four primers for Flipase genotyping were
included in one reaction. Conditions for this PCR were 30 cycles of 95°C for
20sec, 58°C for 10sec, 70°C for 10sec.
6.2.4 B Cell Culture Conditions
B Cells (primary and CH12) were cultured in RPMI-1640 + Glutamax
(Gibco Life Technologies) supplemented with 10% FBS (BenchMark), 1X Penn
Strep (Life Technologies), 55 µM β-mercaptoethanol (Life Technologies), 1mM
Sodium Pyruvate (Life Technologies), 5mM HEPES (Life Technologies), 1X MEM
Non Essential Amino Acids (Life Technologies). HEK 293T cells were cultured in
DMEM media (Gibco Life Technologies) supplemented with 10% FBS
(BenchMark), 1X Penn Strep (Life Technologies) and 2mM L-glutamine (Life
Technologies).
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6.2.5 Splenic B cell Purification and Activation
Naïve splenic B cells from 8-12 week old mice were purified by CD43
negative selection on a magnetic column (MACS, Miltenyi Biotec). Purified B
cells were plated at a concentration of 0.5 X 106 cells/mL and stimulated with
either (1) 10 ng/mL IL-4 (Sigma) and 1 mg/mL anti-CD40 (ebiosciences), (2) 10
ng/mL IL-4 and 25 µg/mL LPS (Sigma) or (3) 25 µg/mL LPS (Sigma).
6.2.6 In vitro Class Switch Recombination Assay
Naïve splenic B cells were purified and stimulated as described above. At
stated time points post-stimulation (e.g. 72hr, 96hr), cells were collected and
FACS analysis was used to determine the percentage of B cells, which have
undergone CSR.
6.2.7 B Cell Proliferation Analysis with CFSE
CFSE (Carboxyfluorescein diacetate succinimidyl ester, Invitrogen,
CellTrace) was dissolved in DMSO at a final concentration of 5 mM. B cells were
resuspended at 1X106/mL in PBS/5% FBS. 2 µL of CFSE was added for every 1
mL of cells to achieve a final CFSE concentration of 10 µM. Cells were labeled at
room temperature for 10 min. The tube was covered with aluminum foil to prevent
bleaching. The reaction was quenched by adding an equal volume of FBS and
placing the tube on ice for 5 min. The tube was filled with PBS/5%FBS and
centrifuged at 300xg for 5 min at room temperature. Cells were washed two more
times in PBS/5%FBS, resuspended in culturing medium supplemented with CSR
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stimuli and plated. Cells not loaded with CFSE were used as a negative control
for FACS analysis.
6.2.8 sqPCR of RNF126 levels
Splenic B cells were purified from mice stated in the given experiment and
stimulated to undergo CSR in vitro. RNA was prepared from 72hr activated B
cells using the RNeasy Mini Kit (Qiagen). First strand cDNA was synthesized
using Superscript III Reverse Transcriptase (Invitrogen) and semi-quantitative
PCR performed to assay levels of RNF126 mRNA. Primers for RPL32 were used
as a normalization control. Primers used were as follows: RNF126- F: 5’acggtacttctgccactgct-3’ (binds in exon 1) R: 5’-aactggctgtatccctgtgg-3’ (binds in
exon 4); RPL32- F: 5’-AAGCGAAACTGGCGGAAAC-3’ and R: 5’TAACCGATGTTGGGCATCAG-3’. PFU Turbo (Agilent) was used for PCR
amplification using an annealing temperature of 55°C and 30 cycles.
6.2.9 B Cell Development Assay
Bone marrow cells were flushed from the femurs and tibias of mice
indicated in the experiment. Flow cytometry was used to assay the relative
proportions of pro-, pre- and immature B cells in the bone marrow. Lymphocytes
were gated based on their FSC/SSC profiles and B cells were identified as
CD19+/IgM-. B cell subsets were determined by size (FSC) and surface CD43
levels. In addition, spleen cells were prepared and IgM/IgD double positive B
cells were assayed by Flow Cytometry. Antibodies used are stated below.
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6.2.10 Antibodies Used. Anti-RNF126 (Sigma, HPA043050), CD19-PE (Clone
ID3, BD Pharmingen 557399), CD19-APC (Clone ID3, BD Pharmingen 550992),
FAS-PE (BD Pharmingen 554258), GL7-FITC (BD Pharmingen 553666), GL7Alexa Fluor 647 (eBiosciences 51-5902-80), IgG1-PE (Clone A85-1, BD
Pharmingen 550083), IgG1-APC (BD Pharmingen 550874), CD43-PE (BD
Pharmingen 553271), IgM-PE (BD Pharmingen 553409), IgD FITC (BD
Pharmingen 553439), IgA-PE (eBiosciences 12-4204-82).
6.2.11 Preparation of mammalian cell extracts
Cells were harvested and the pellets washed with 1X PBS. Cells were
lysed with RIPA buffer (50mM Tris (pH 8), 150mM NaCl, .5% Na Deoxycholate,
.1% SDS, 1% NP-40, .5mM EDTA, 1mM DTT and protease inhibitor cocktail
(Roche)). Lysates were normalized with the detergent compatible DC-Assay
(Biorad).
6.2.12 Viral Transduction of CH12 Cells
HEK 293T cells were transfected with 1 µg of hairpin expressing pLKO.1
lentiviral vectors with 750 ng of psPAX2 and 250 ng of pMD2.G packaging
vectors with Lipofectamine 2000 reagent (Invitrogen). 24hr post-transfection,
media was changed to IMDM (Life Technologies) with 5% FBS (BenchMark).
72hr post-transfection, virus-containing supernatant was collected, filtered
through a .45µm filter, and supplemented with polybrene at 8µg/mL
concentration. 1X106 CH12 cells were resuspended in viral supernatant and spin-
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infected at 850xg for 2hr at 20°C. CH12 cells were removed from the centrifuge
and 1mL of culturing medium added.
6.2.13 shRNA Knockdown Experiments
CH12 cells were virally transduced with hairpin expressing vectors against GFP,
AID, and RNF126. 48hr post-infection, cells were selected in 1µg/mL of
puromycin. Cells were stimulated for CSR with 10 ng/mL IL-4 (Sigma), 1 µg/mL
anti-CD40 (eBiosciences) and 1 ng/mL TGFβ. CSR to IgA was analyzed by flow
cytometry at 48hr post stimulation. Hairpin sequences are as follows: shGFP:
GCAAGCTGACCCTGAAGTTCA, shAID:
CCGGGCGAGATGCATTTCGTATGTTCTCGAGAACATACGAAATGCATCTCGC
TTTTTG,
shRNF126-1:
CCGGGCTTTGAAATAAATGGACGTTCTCGAGAACGTCCATTTATTTCAAAGC
TTTTTG, shRNF126-2:
CCGGGCTCCTCAATCAGTTTGAGAACTCGAGTTCTCAAACTGATTGAGGAGC
TTTTTG, shRNF126-3:
CCGGCCCAGTGTGTAAAGAAGACTACTCGAGTAGTCTTCTTTACACACTGGG
TTTTTG.
6.2.14 Immunization of Mice
Mice were immunized intraperitoneally with 50µg of alum-precipitated
NP16/17-CGG (Biosearch Technologies). Precipitation was carried out at roomtemperature using 50mL of a 1 mg/mL solution of NP-CGG and 200µL of Alum.
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6.2.15 Mutation Analysis
Splenic germinal center B cells were FACS-sorted using the surface
markers CD19, FAS and GL7 and genomic DNA was prepared. The following
regions were amplified with a nested PCR reaction using PFUTurbo (Agilent) and
the stated primers: V186.2 Exon (351 bp) (5’TCTTTACAGTTACTGAGCACACAGGAC-3’ and 5’GGGTCTAGAGGTGTCCCTAGTCCTTCATGACC-3’ followed by 5’CAGTAGCAGGCTTGAGGTCTGGAC-3’ and 5’GGGTCTAGAGGTGTCCCTAGTCCTTCATGACC-3’), JH4 Intron (357 bp) (5’AGCCTGACATCTGAGGAC-3’ and 5’-TAGTGTGGAACATTCCTCAC-3’ followed
by 5’-CTGACATCTGAGGACTCTGC-3’ and 5’-GCTGTCACAGAGGTGGTCCTG3’) and V186.2 Upstream Region (295 bp) (5’GGCTCTAATGTTACATCCATAGCCTCAAC-3’ and 5’GGGTCTAGAGGTGTCCCTAGTCCTTCATGACC-3’ followed by 5’CAGACAAGATGAGGACTTGGGCTTCAGTATCC-3’ and 5’GTCCAGACCTCAAGCCTGCTACTG-3’). PCR products were blunt cloned into
the pSC-B vector provided with the StrataClone Blunt PCR Cloning Kit (Agilent)
and colonies sequenced with a T3 primer. Blat was run locally to align sequences
to a consensus and trim vector sequence information external to the PCR
product. For each region analyzed, all sequences from one mouse were
combined and mutation analysis was conducted with the aid of SHMTool
(Maccarthy et al., 2009).
166

6.2.16 NP Elisa
Serum from immunized mice was prepared from peripheral blood collected
from the facial vein using Serum Seperator Tubes (BD Biosciences). Serum
dilutions (prepared in blocking buffer) were incubated with either NP3-BSA or
NP30-BSA (5µg/mL) coated wells of a flat-bottom EIA/RIA plate (Costar). Serum
was incubated at 37°C for 1.5 hours after coated plates had been blocked in
blocking buffer at room temperature for 1 hour. Wells were washed 3X with
washing buffer after blocking and 5X after incubation with serum. A 1:1000
dilution of secondary antibody was prepared in blocking buffer, loaded in each
well and incubated for 1 hour at 37°C. Again, plates were washed 5X with
washing buffer. Plates were developed using a 1 mg/mL solution of 4-Nitrophenyl
phosphate disodium salt hexahydrate (PNPP, Sigma) resuspended in ELISA
buffer. Substrate was incubated for 30 minutes prior to measuring the OD at 405
nm. NP-specific serum IgG1 was detected using an alkaline phosphatase (AP)
conjugated secondary antibody (goat anti-mouse IgG1 antibody, Southern
Biotech, 1070-04). Total IgG1 levels for the purpose of normalization were
determined by coating plates with a Goat anti-mouse IgG antibody (Jackson
Labs, 115-006-071) and detection with the same secondary (anti-mouse IgG1)
antibody. Buffer conditions are as follows: Blocking Buffer (1% BSA, 1X Borate
Buffer), Washing Buffer (.05% Tween 20 in 1X PBS), 1X ELISA Buffer (.1M
Glycine (from a stock of 1M Glycine at pH 10.4), 1mM ZnCl2, 1mM MgCl2), 1X
Borate Buffer (100 mM Boric Acid, 25 mM Sodium Borate, 75 mM Sodium
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Chloride). Serum NP3 IgG1 and NP30 IgG1 levels are normalized to total IgG1
levels. Affinity Maturation is determined as the ratio of NP3/NP30.
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Table 6.1 Primers used to genotype the RNF126 conditional knockout
mouse. Primer sequences, descriptions and expected amplicon sizes
are presented.

mb-1 CRE

FLIPASE Transgene

Sequence

Description

R2-F

TCT ATA GTC GCA GTA GGC GG

Construct Specific Sequence,
5' of Targeted Region

Endo-F

CTG CCT GCT CTA CTC TTG TC

Binds Intron 1

Endo-R

GTA GGA CGT GGA CAG CTA GG

Binds Intron 1

RP-R

TGA ACT GAT GGC GAG CTC AGA CC

Construct Specific Sequence,
3' of Targeted Region

oIMR1348

CAC TGA TAT TGT AAG TAG TTT GC

oIMR1349

CTA GTG CGA AGT AGT GAT CAG G

oIMR7338

Amplicon
See Figure 4.2

RNF126 Locus

Primer Name

FLIPASE Transgene Detection

725 bp

CTA GGC CAC AGA ATT GAA AGA TCT

Internal Control-Forward

324 bp

oIMR7339

GTA GGT GGA AAT TCT AGC ATC ATC C

Internal Control-Reverse

hCRE-F

CCCTGTGGATGCCACCTC

Mb1 Cre Allele-Forward

hCRE-R

GTCCTGGCATCTGTCAGAG

Mb1 Cre Allele-Reverse

oIMR8744

CAAATGTTGCTTGTCTGGTG

Internal Control-Forward

oIMR8745

GTCAGTCGAGTGCACAGTTT

Internal Control-Reverse

169

450 bp

200 bp
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